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Abbreviations 
 
HKI: hexokinase I 
Glc-6-P: glucose 6-phosphate 
Glc: glucose 
Pi: phosphate 
1,5-anhydroGlc-6-P: 1,5-anhydroglucitol 6-phosphate 
2-deoxy Glc-6-P: 2-deoxy glucose-6-phosphate 
Man-6-P: mannose 6-phosphate 
Glc-1,6-P2: glucose 1,6-bisphosphate 
TNP-ADP: 2’-(or-3’)-O-(2,4,6-trinitrophenyl)-adenosine 5’-diphosphate 
To indicate amino acids in protein sequences or names of the mutant enzymes, one letter or 
three letters abbreviation was used. 
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Abstract 
Hexokinase I (HKI) is the pacemaker of glycolysis in brain and red bold cells, being subject 
to potent feedback inhibition by its product glucose 6-phosphate (Glc-6-P) and the relief of 
that inhibition by inorganic phosphate (Pi) and glucose (Glc). Presented here is a 
comprehensive model of inhibition and relief of inhibition for recombinant human HKI 
derived from crystal structures, molecular dynamics simulations, kinetics and directed 
mutations. Ligand interactions at each half of HKI are comparable in crystal structures, but in 
simulations, 2-deoxyglucose 6-phosphate (2-deoxyGlc-6-P) and mannose 6-phosphate (Man-
6-P) lose hydrogen bonds at the C-terminal half, consistent with early stages of ligand 
dissociation. 1,5-Anhydroglucose 6-phosphate (1,5-anhydroGlc-6-P), adopts an alternative 
binding mode, and stabilizes a slightly open C-terminal half. The kinetics of D413N and/or 
D861N enzymes (D413 and D861 interact with the 1-OH group of Glc-6-P) are consistent 
only with synergistic binding of two molecules of 1,5-anhydro-Glc-6-P to sites with unequal 
constants of dissociation. The crystal structure and simulation of HKI with glucose 1,6-
bisphosphate (Glc-1,6-P2) implicate Lys418 (N-terminal half) and Lys866 (C-terminal half) 
in stabilizing inhibited conformations of HKI, a finding support by directed mutations. Pi 
displaces 1,5-anhydroglucitol 6-phosphate from the N-terminal half, but not from the C-
terminal half. Glucose (Glc) up to concentration of 1 mM interacts synergistically with 1,5-
anhydroGlc-6-P, but at higher concentrations becomes an antagonist of inhibition. A site-
affinity model quantitatively accounts for these observed phenomena in wild-type and mutant 
forms of HKI. For wild-type HKI, inhibitor binds to sites of unequal affinity, coupled by 
negative coorperativity, with the site of highest affinity at the N-terminal half. Pi-displaces 
inhibitor from the N-terminal half, but does not prevent inhibition at the C-terminal half. 
Potent inhibition requires two molecules of bound glucose to HKI, and the binding of Glc to 
the active site seems primarily responsible for creating a state of HKI susceptible to potent 
inhibition. The mapping of mutations that affect allosteric mechanism in HKI clearly define 
the N-terminal inhibitor pocket and the flexible subdomain as key components of allostery in 
HKI. 
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Chapter I. General Introducation & Literature Review 
Hexokinase (ATP: D-hexose 6-phosphotransferase, EC2.7.1.1) catalyzes the initial and 
crucial step of glycolysis, the phosphorylation of 6-hydroxyl group of glucose (Glc) using 
[ATP-Mg]2– as the phosphoryl donor[1-3]. 
Glucose + [ATP•Mg]2–    Glc-6-P2– + [ADP•Mg]1– + H+ 
The focus of work here is human hexokinase Type I (HKI), and as the name implies, HKI 
can phosphorylate several six-carbon sugars (mannose, 2-deoxy glucose, and 2,5-anhydro-
glucitol, for example); however, only Glc binds to HKI with high affinity. As early as 1954, 
Crane demonstrated the importance of the 2-hydroxyl group in the binding of 6-
phosphorylated hexoses to an inhibitory site of HKI, whereas the 2-hydroxyl group was not 
important for substrate binding[4]. Only the 4-hydroxyl group is important for both hexose 
and hexose-6-phosphate binding[4]. Later studies showed that a doubly charged anionic group 
at the 6-position is necessary for effective inhibition[4-6]. A 5-thio group increases the binding 
affinities, both for the hexose and hexose-6-phosphate[6]. ATP is the best substrate for HKI 
(highest kcat, lowest Km). The Km values for other triphosphate nucleosides, such as ITP, GTP, 
CTP and UTP do not differ significantly from that of ATP, while the kcat values are 
significantly lower[7].  
 
Evolution of Hexokinase Family 
Four isozymes of hexokinase have been identified in mammalian tissues[8](Table I). The type 
I, II and III hexokinase isozymes, all with molecular weights of approximately 100 kDa, 
share 70% sequence identity[9]. N- and C- halves of isozymes I–III show extensive internal 
sequence similarity (~50% sequence identity) and structure similarity[9]. Hexokinase Type IV, 
commonly named glucokinase, is similar to yeast hexokinase isoforms A and B, having a 
molecular weight of 50 kDa, and exhibiting significant sequence similarity to both halves of 
isozymes I–III[9]. Presumably, all members in the hexokinase family derived from a common 
ancestor, a 30 kDa glucomannokinase-like enzyme which utilized poly(P) as substrate in 
primordial age before the appearance of ATP (Figure 1)[10]. One branch of the evolutionary 
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pathway led to poly(P)/ATP utilizing hexokinase, whereas the other led to a 50 kDa ATP-
specific hexokinase such as yeast hexokinase and hexokinase IV[10]. Whether the 50 kDa 
ATP-specific hexokinase, however, evolved independently from the 30 kDa 
glucomannokinase-like enzyme or from the poly(P)/ATP utilizing hexokinase is unclear. 
During evolution, the ATP-specific hexokinase acquired a new property of regulation, 
feedback inhibition by product, just like the isoforms in starfish and other marine 
organisms[9-10]. The 100 kDa hexokinase architecture appeared then through gene duplication 
and fusion[11-14]. The N-domain lost catalytic properties in becoming mammalian hexokinase 
types I and III[10]. The 100 kDa Glc-6-P insensitive hexokinase might have evolved directly 
from the 50 kDa Glc-6-P insensitive enzyme, or from the 50/100 kDa Glc-6-P sensitive 
enzyme, thereafter losing product inhibition. Some researchers suggest that the gene 
duplication and fusion occurred prior to the diversification of the hexokinase family, and that 
glucokinase evolved from the 100 kDa isozyme by losing its N-terminal regulatory 
domain[15]. 
 
General Kinetics Properties of Mammalian Hexokinases 
Besides sequence and structural similarities, isozymes I-III also share several properties, such 
as Km for glucose is in the sub-millimolar range and product inhibition is at physiologically 
relevant concentrations (micromolar level)[9]; however, they differ significantly in catalytic 
and regulatory properties. Both halves of hexokinase II possess catalytic activity[16], whereas 
the N-halves of hexokinase I and III are devoid of activity[9, 17-18]. Given the fact that both 
hexokinase I and II have special binding sites for Glc, Glc-6-P, Pi and ATP in both N- and C- 
domains, it is believed that during evolution, the N-terminal domain of hexokinase I lost its 
activity and evolved into a regulatory domain[9]. Inorganic phosphate (Pi) potently inhibits 
hexokinase II and III, and at high concentrations (millimolar) is an inhibitor of hexokinase I. 
At relatively low concentrations (100 µM), however, Pi antagonizes the inhibition of 
hexokinase I by Glc-6-P[9]. Among all four isozymes, only Hexokinase III is substrate-
inhibited by glucose at physiologically relevant concentrations (1 mM)[19-20]. In contrast, the 
Km for glucose is 100 times higher for glucokinase than the other mammalian hexokinase 
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isozymes. Glucokinase exhibits no substrate inhibition and is insensitive to physiologically 
relevant levels of Glc-6-P[9]. 
 
Tissue Distribution of Mammalian Hexokinases 
Given the different kinetics properties associated with each isozyme, it’s reasonable to expect 
the expression of different isozymes in different tissues. Hexokinase I, as a “housekeeping 
enzyme”, is found in all mammalian tissues and is highly or even exclusively expressed in 
brain and red blood cells[1-3]. Hexokinase II is mainly expressed in insulin-sensitive tissues 
such as skeletal muscle and adipose tissue[19]. Hexokinase III is expressed in very low levels, 
and is associated with the cell nucleus[19]. Hexokinase IV is mainly present in liver, but also 
found in neuoroendocrine cells[19].  
Both Hexokinase I and II are overexpressed in many cancer cells[21-22]. The 
overexpression leads to protection against apoptotic cell death[21-22]. Other studies show that 
mitochondrial hexokinase I and II binding increases with insulin treatment and ischemia in 
an isoform-specific way in heart[23]. HKI gene promoter mutation in humans causes 
hexokinase I deficiency and chronic hemolysis[24]. All these make hexokinase a good 
therapeutic target for a number of diseases. 
 
Physiological functions of hexokinase type I 
Hexokinase I is highly expressed in brain and red blood cells[1-3]. In brain, hexokinase I exists 
predominantly as mitochondrial bound form[9]. The bound enzyme preferentially uses ATP 
generated by oxidative phosphorylation, putatively allowing efficient cycling of adenine 
nucleotide to and from the inner matrix of the mitochondrion[9]. The first 15 residues of 
hexokinase I (HKI) are predicted to form a hydrophobic helix and are necessary and 
sufficient for targeting HKI to the mitochondrial outer membrane[25-27]. 
When bound to mitochondrial outer membrane, HKI is likely to interact with the 
cytosollic face of the voltage dependent anion channel (VDAC), while the other end of 
VDAC interacts directly with the adenylate nucleotide translocator (ANT) of mitochondrial 
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inner membrane. In turn, ANT interacts with cyclophilin D (Cph.D) inside the mitochondrial 
matrix[26]. The HKI-VDAC-ANT-Cph.D complex is the mitochondrial permeability 
transition pore, which opens putatively during cell apoptosis and necrosis. Recent studies 
show that glucose phosphorylation and mitochondrial binding are required for the anti-
apoptotic effect of hexokinase I and II[28]. 
HKI may form a tetramer when bound to mitochondria[26, 29]. Binding of human HKI 
to rat liver mitochondria is cooperative with a Hill coefficient of 3.1-3.3[30-32], but earlier 
investigations from at least three different groups provide no evidence for cooperativity in 
the binding of HKI to mitochondria[29, 33-34]. Glc-6-P can release ~60% HKI from 
mitochondria[33]. The presence of Mg2+ or Pi antagonizes Glc-6-P induced release effect[9]. 
The mechanism of Glc-6-P release of hexokinase I may be due to a conformational change 
induced by Glc-6-P binding to the N-terminal domain[9, 34]. The nucleoside triphosphates, 
ATP, CTP, GTP, UTP and ITP, are also capable of releasing 90% of the enzyme from the 
membrane[33]. The release mechanism due to nucleotides is probably distinct from that of 
Glc-6-P [33].  
In solution at physiological concentrations (1-10 µg/ml), HKI functions as a monomer, 
but dimerizes as protein concentration increases (>1 mg/ml)[9]. Small angle scattering 
experiments show that HKI exists exclusively as monomer up to a concentration of 3.6 
mg/ml when Pi present, though the enzyme dimerizes as protein concentration increases[35]. 
Unlike Pi, Glc-6-P helps HKI dimerize with 80% dimer at 0.9 mg/ml as shown in the small 
angle scattering experiment[35].  
 
X-ray Crystallography Structure of HKI 
The structure of recombinant HKI (Figure 2) has been solved by X-ray crystallography[32,35-
40]; however, compared to the functional monomeric enzyme in solution, HKI exists as a 
dimer in the crystal, with Glc·Glc-6-P or Glc·Pi binding in both N- and C-half[36-37]. Subunits 
in the HKI dimer align head-to-tail with twofold rotational symmetry. The N-terminal 
domain of one monomer interacts with the C-terminal domain of another monomer[32, 36-39]. 
Triple-mutant HKI (E280A/R283A/G284Y) eliminates subunit interactions of the crystalline 
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dimer, exhibits wild-type functional properties, and crystallizes as a monomer[40]. The 
structure of the monomeric HKI adopts a rod-like conformation, similar to subunits in the 
dimer[35, 40]. Furthermore, small angle x-ray scattering indicates HKI retains the conformation 
observed in crystallographic structures in solution in the presence and absence of ligands 
(Glc-6-P, glucose, Pi, and ADP) [35].  
The monomer of hexokinase I is composed of two structurally similar halves (N-
terminal and C-terminal) separated by a transition helix[35-41]. Each half is composed of large 
domain (residues 13-74, 210-447 in N-terminal half and residues 466-522, 658-895 in C-
terminal half) and the small domain (residues 75-209, 448-465 in N-terminal half and 
residues 523-657, 896-913 in C-terminal half)[40]. The relative position of the two domains in 
C-terminal half of HKI define two conformational states, open and closed states, differing by 
a 17° rotation of the small domain relative to the large domain[40]. In the Glc-6-P·Glc 
structure, both N-terminal and C-terminal halves are in the closed state, whereas in the Pi·Glc 
structure, the N-terminal half is closed and the C-terminal half is open[36-37]. HKI structures 
are consistent with that N-terminal half possessing a “tighter” conformation with respect to 
C-terminal half, and C-terminal half unfolding before the N-terminal half[41-42]. 
Although the N-terminal half of hexokinase I is catalytically inactive, it does contain 
a binding pocket for glucose and Glc-6-P which is nearly identical to that of C-terminal 
half[37]. The crystal structures reveal a high affinity binding site for Pi at the N-terminal half, 
overlapping the binding site of the 6-phosphoryl group of Glc-6-P[36-37]. The conformation of 
the N-terminal of hexokinase I in its Pi and Glc-6-P complexes differs slightly: the 
conformation of loop 445-450 is different and the N-terminal half pivots at the N-terminal 
end of the transition helix. The monomeric triple mutant HKI structure with ligands 
ADP·Pi·Glc reveals two ADP binding sites, one at the distant end of N-terminal half and one 
at the active site[40]. Although the phosphoryl groups of the ADP molecule at the C-terminal 
half do not bind as would be predicted for a productive substrate complex, the structures 
reveals the adenine ring binding pocket and conformational changes in the active site thought 
to be necessary for catalysis. The major difference between this structure and the previous 
structures is that the residue T784 is in an “up” position, providing space for the base of the 
adenine nucleotide. 
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The extremely limited interaction demonstrated in the structures between the two 
halves of the enzyme, as well as between two monomers, makes it very hard to imagine and 
understand how the N-terminal half delivers regulatory information to its catalytic C-terminal 
half (Figure 3). 
 
Glc-6-P Inhibition Mechanism Puzzle of HKI 
Crystal structures reveal two binding sites for Glc-6-P at high concentration in the presence 
of 1 mM glucose, whereas binding studies in solution indicate that only one molecule of Glc-
6-P binds to HKI with high affinity in the presence or absence of glucose[34, 43-45]. High 
affinity binding is thought to be responsible for potent Glc-6-P inhibition, but the kinetics 
mechanism of HKI inhibition is nonlinear compeptitive with ATP consistent with a second, 
weaker binding site for inhibitor[46]. Investigators have differed as to the site of high affinity 
binding (N-terminal half or C-terminal half) since the 1970s. Based on kinetics, Fromm 
suggested that Glc-6-P inhibits the enzyme by binding to the C-terminal half, the 6-
phosphoryl group competing with the γ-phosphate of ATP[44, 47]. Wilson assigned Glc-6-P 
inhibition to a site at the N-terminal half, on the basis of Glc-6-P protection against 
proteolysis[17, 41]. Both models have extensive supporting evidence[9, 17, 41, 44, 47]. The Fromm 
and Wilson models agree however that Pi antagonizes Glc-6-P inhibition by binding to a 
high-affinity site at the N-terminal half[9, 36]. Pi competes with Glc-6-P for the same 
phosphoryl binding site in the Wilson model, whereas Pi competes via an allosteric 
mechanism with Glc-6-P bound at the C-terminal half in the Fromm model. 
Results from numerous investigations from laboratories of Fromm and Wilson clearly 
indicate that each model individually cannot account for all observed phenomena. When HKI 
is cleaved proteolytically into two halves, the C-terminal half (mini-HKI) is active and 
inhibited potently by Glc-6-P without Pi-relief of inhibition[48]. On the other hand, the N-
terminal half binds Glc-6-P tightly[17,49]. Moreover, mutational studies have shown that Glc-
6-P is capable of inhibiting HKI when binding to either of the two binding sites on the 
enzyme[46, 50]. Only mutations at both Glc-6-P binding sites eliminate the inhibition[50]. 
Mutant forms of HKI exhibit reduced Pi-relief of Glc-6-P inhibition, which is inconsistent 
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with the Pi and Glc-6-P competing for the same phosphoryl binding site (Wilson model)[46]. 
The existence of a single high-affinity site for Glc-6-P in HKI can be reconciled with high 
affinity sites in each of the C- and N-terminal halves by a mechanism of anticooperativity in 
Glc-6-P binding[50] or by a conformational change in the N-terminal or C-terminal half when 
they become separated. 
The effect of Glc in the binding of Glc-6-P, while not entirely unrecognized, may be 
under-appreciated. The binding of Glc-6-P or Pi to HKI is synergistic with Glc[17]. 
Nonetheless, Glc-6-P still binds with high affinity in the absence of Glc[44], and Wilson has 
assigned this Glc-independent binding site to N-terminal half[49]. Synergistic interactions 
between the Glc and Glc-6-P are also observed with miniHKI but not the N-terminal half[17]. 
The observation of synergism between Pi and Glc in HKI is puzzling given the absence of 
synergism between Glc and Glc-6-P in the separate N-terminal half. 
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Table I. Mammalian Hexokinase Isozymes 
Isozyme M.W. (KDa) 
Glc-6-P 
Inhibition Pi-relief Tissue Distribution 
Mitochondrial 
Binding 
I 100   brain, 
red blood cells 
 
II 100   skeletal muscle, 
adipose tissue 
 
III 100   cell nucleus  
IV 50   liver, pancreas 
neuroendocrine cells 
 
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Figure 1. Putative ancestor and evolutionary process of hexokinase family[9-10]. 100 kDa HK formed 
through gene duplication. Consensus evolutionary transitions are shown by solid arrows, whereas possible 
transitions are indicated by dotted arrows. A: Putative ancestor of the HK family. B: HK from Gram+ bacteria, 
crenarchaeota. C: HK from yeast. D: HK from Gram– bacteria, cyanobacteria and amitochondriate protists. E: 
HK from mammalian HKI-III .F: HK from starfish and other marine organisms and S. mansoni. G: HK from 
tapeworm Hymenolepsis diminuta and lamprey (90 kDa). HK: hexokinase.  
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Figure 2. Crystal structures of HKI.  A, HKI with Pi·Glc bound (PDB:1HKC); B, HKI with Glc-6-P·Glc 
bound (PDB:1HKB); C, monomeric triple mutant of HKI with ADP·Pi·Glc bound (PDB:1DGK). The N-half 
and C-half is connected via a transition helix. Only the C-half of Pi·Glc bound structure is in open conformation, 
all others are in closed conformation. Color key: large domain, violet; small domain, yellow; Pi, red; Glc, green; 
Glc-6-P, pink; ADP, brown.  (The illustration was generated with PyMOL). 
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Figure.3. Dimer crystal structures of HKI (PDB:1HKB).  Residues in contact between subunits are in blue.  
(The illustration was generated with PyMOL). 
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Thesis Organization 
This thesis contains 6 chapters.  
Chapter I is the general introduction and literature review about hexokinase I.  
Chapter II is the study of a series of crystalline complexes and molecular dynamics 
simulations of recombinant human wild-type HKI and D413N with different phosphoryl 
ligands: Glc-6-P, 1,5-anhydro-Glc-6-P, 2-deoxy-Glc-6-P and Man-6-P. Studies here reveals 
an alternative binding mode for 1,5-anhydro-Glc-6-P. A positive binding synergism also 
appears for the mutant D413N and/or D861N. 
Chapter III is the study of crystalline complex and molecular dynamics simulations of 
D413N HKI with glc-1,6-P2. The new structure reveals two important residues K418 and 
K866 that are crucial for high affinity binding of 1,5-anhydro-Glc-6-P. A model of phosphate 
relief requires the present of EPI complex is derived and fitted. 
Chapter IV demonstrates the dual mechanism of Glc on Glc-6-P inhibition for recombinant 
human HKI. At low glucose concentration, the binding of Glc-6-P is synergistic with Glc. 
However at high concentrations, glucose is acting as an antagonist to 1,5-anhydro-Glc-6-P. 
Chapter V is the study of allosteric inhibition of Glc-6-P for HKI. The following residues 
which are not directly interact with Glc-6-P are found to be important for the allosteric 
inhibition : Gly448, Ser449, Ile781, Thr784, Leu795, Leu797 and L867. Results are 
consistent with a proposed mechanism in which the ligation of the N-terminal half by Glc-6-
P induces a rotation of the N-terminal half that alters nonbonded contacts with and within the 
flexible subdomain of the C-terminal half.  Conformational changes in the flexible 
subdomain, which involve the re-organization of hydrophobic residues within the core of that 
domain, stabilize an open binding pocket for ATP. 
Chapter VI presents general conclusions about the above studies. 
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Abstract 
Hexokinase I (HKI) is the pacemaker of glycolysis in the red bold cell, being subject to 
potent feedback inhibition by its product glucose 6-phosphate (Glc-6-P) and the relief of that 
inhibition by inorganic phosphate (Pi).  Mechanisms of inhibition and relief have been 
subjects of controversy, as no model adequately accounts for all observations.  Presented 
here are crystalline complexes and molecular dynamics simulations of recombinant human 
HKI with Glc-6-P, 1,5-anhydro-D-glucitol 6-phosphate (1,5-anhydroGlc-6-P), 
2-deoxy-β-D-glucose 6-phosphate (2-deoxyGlc-6-P) and β-D-mannose 6-phosphate 
(Man-6-P).  Ligand interactions at each half of HKI are comparable in crystal structures, but 
in simulations, 2-deoxyGlc-6-P and Man-6-P lose hydrogen bonds at the C-terminal half, 
consistent with early stages of ligand dissociation, and 1,5-anhydroGlc-6-P, relative to 
Glc-6-P, stabilizes slightly open conformations of N- and C-terminal halves.  The kinetics of 
D413N and/or D861N enzymes (D413 and D861 interact with 1-OH groups of Glc-6-P) are 
consistent only with synergistic binding of two molecules of 1,5-anhydroGlc-6-P to sites with 
unequal constants of dissociation.  A dynamics simulation of the D413N HKI demonstrates 
global conformational change that affects Glc-6-P recognition at N- and C-terminal halves.  
Studies here clarify the mechanism of action of 1,5-anhydroGlc-6-P, but also indicate a 
differential response of HKI to Glc-6-P and 1,5-anhydroGlc-6-P. 
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Introduction 
Hexokinase (ATP: D-hexose 6-phosphotransferase, EC2.7.1.1) catalyzes the initial step of 
glycolysis, the phosphorylation of 6-hydroxyl group of glucose (Glc) using [ATP-Mg]2– as 
the phosphoryl donor[1-3].  Four isozymes of hexokinase have been identified in mammalian 
tissues[4].  Type I, II and III hexokinase isozymes have molecular weights of 100 KDa, and 
share 70% sequence identity[5].  N- and C-terminal halves of isozymes I–III have ~50% 
sequence identity[5], putatively a result of the duplication and fusion of a gene of a primordial 
hexokinase[6-9].  Hexokinase IV (glucokinase) and yeast hexokinase isoforms A and B have 
molecular weights of 50 KDa, and exhibit significant sequence similarity to both halves of 
isozymes I–III[5]. 
Despite sequence and structural similarities, isozymes I-III differ significantly in 
functional properties.  Both halves of hexokinase II possess catalytic activity[10], whereas 
the N-terminal halves of hexokinase I and III are inactive[5, 11-12].  The reaction product 
glucose 6-phosphate (Glc-6-P) potently inhibits isozymes I-III (but not isoform IV) at 
physiological concentrations[5].  Inorganic phosphate (Pi) is a weak inhibitor of hexokinase 
II and III[5]; however, Pi antagonizes the inhibition of hexokinase I by 1,5-anhydroglucitol 
6-phosphate (1,5-anhydroGlc-6-P, an analog of Glc-6-P used in kinetics) at low (micromolar) 
concentrations, whereas, at millimolar concentrations it inhibits catalysis competitively with 
ATP[5]. 
In crystal structures, Glc-6-P binds to both halves of HKI[13-15].  Proteolytic cleavage 
of HKI produces an active C-terminal half (mini-HKI) that is inhibited potently by 
1,5-anhydroGlc-6-P with no Pi-relief[12, 16].  The N-terminal half of HKI is inactive, but it 
still binds Glc-6-P tightly[11-12].  Mutational studies have shown that 1,5-anhydroGlc-6-P 
inhibits HKI potently at either of two binding sites[17-18].  Only mutations at both Glc-6-P 
binding sites eliminate 1,5-anhydroGlc-6-P inhibition[18].  Data from equilibrium binding 
and kinetics experiments, however, indicate only one molecule of Glc-6-P binds to HKI with 
high-affinity, suggesting the dominance of one inhibitory mechanism or the possibility of 
negative cooperativity in Glc-6-P binding[18-22].  Crystal structures and experiments in 
directed mutations, kinetics and equilibrium binding have not identified the site of high 
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binding affinity for Glc-6-P. 
As early as 1954, Crane and Sols recognized the significance of the 2-hydroxyl group 
in the binding of 6-phosphorylated hexoses to an inhibitory site of HKI.  Millimolar levels 
of 2-deoxyGlc-6-P and Man-6-P are ineffective in inhibiting HKI activity[23].  Magnani et al. 
reported that the KIs for 2-deoxyGlc-6-P and Man-6-P are at least 20-fold higher than that of 
Glc-6-P[24].  In crystal structures, the 2-OH group of Glc-6-P hydrogen bonds with 
Ser449/897 and Asp84/532 (N-half/C-half) and the 1-OH group with Asp413/861[13].  Yet 
1,5-anhydroGlc-6-P has potent inhibition without a 1-OH group and 2-deoxyGlc-6-P is 
without potent inhibition.  The accepted conclusion from these observations: the 1-OH 
group is unimportant, but the 2-OH group is critical to inhibition. 
Structures of crystalline complexes of HKI with Glc-6-P, 1,5-anhydroGlc-6-P, 
2-deoxyGlc-6-P, and Man-6-P reported here indicate all phosphoryl ligands bind with lower 
thermal parameters to the C-terminal half relative to the N-terminal half.  Molecular 
dynamics simulations indicate stable binding of phosphoryl ligands to the N-terminal half 
(consistent with interactions observed in crystal structures); however, 1,5-anhydroGlc-6-P, 
2-deoxy-Glc-6-P, and Man-6-P exhibit binding modes to the C-terminal half which are not 
consistent with crystal structures.  In fact, a significant binding mode for 
1,5-anhydroGlc-6-P appears in a slightly open C-terminal half (a conformation not observed 
in crystal structures) in which its 2-OH group interacts with Asp861 (residue that interacts 
with the 1-OH of Glc-6-P in crystal structures).  Mutations of Asp861 and/or Asp413 result 
in stoichiometric dissociation constants that require binding synergism between two 
molecules of 1,5-anhydroGlc-6-P.  The behavior of  the mutant forms of HKI examined 
here cannot be reconciled with a model that couples two sites of nearly equal, high-binding 
affinity by a mechanism of negative cooperativity[18], but instead support the synergistic 
binding of two molecules of 1,5-anhydroGlc-6-P to sites of unequal affinity.  In such a 
model, the binding of Pi to the high-affinity site would elevate the dissociation constant of the 
low-affinity site, and hence eliminate inhibition. 
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Materials and methods 
Materials— A full-length cDNA of human hexokinase I, cloned into vector pET-11a was 
available from previous studies[16, 25-26].  Oligonucleotides came from IDT-DNA.  DNA 
sequencing was done by the Iowa State University DNA Sequncing and Synthesis Facility.  
Escherichia coli strain DH5a and BL21 were from Invitrogen.  DNaseI, 
phenylmethanesulfonyl fluoride (PMSF), leupeptin, bovine serum albumin (BSA), ATP, 
NADP, ampicillin, glucose 6-phosphate, mannose 6-phosphate and 2-deoxy-D-glucose 
6-phosphate were from Sigma.  1,5-Anhydro-D-sorbitol was from Toronto Research 
Chemicals.  Isopropyl-β-D-thiogalactopyranoside (IPTG) was from Bio-World.  DEAE 
sepharose CL-6B and CHT ceramic hydroxyapatite (HA) Type II were from Bio-Rad.  
DEAE-5PW HPLC media was from Tosohaas.  Glusoe-6-phosphate dehydrogenase 
(G6PDH) was from Roche.  2'-(or-3')-O-(2,4,6-Trinitrophenyl)-adenosine 5'-diphosphate 
(TNP-ADP) was from Invitrogen. 
Construction, Expression and Purification of Wild-type and Mutant Hexokinase I— The 
oligonucleotide primers for directed mutations are as follows: 
5’-CG-GTT-GGT-GTC-AAC-GGA-TCT-CTT-TAC-AAG-ACG-3’ for D413N and 
5’-CT-GTG-GGA-GTG-AAC-GGG-ACA-CTC-TAC-AAG-C-3’ for D861N, where the 
altered codon is underlined. 
A 200 ml culture of the transformed Escherichia coli BL21 was grown overnight at 
37 ºC in LB medium (33mg/L ampicillin) and then 1.5% cell were transferred to 9.6L LB 
medium (33mg/L ampicillin).  The culture was grown at 300 rpm and 37 ºC to A600=1.0.  
The temperature then was reduced to 16 ºC, isopropyl-β-D-thiogalactopyranoside (IPTG) was 
added to a final concentration of 0.5 mM and the culture was grown at 200 rpm for 20-22 hr. 
at 16 ºC.  The cells were re-suspended in 25 mM KPi (pH 7.5), 5 mM glucose, 3 mM MgCl2, 
1 mM dithiothreitol (DTT), 1 mM phenylmethanesulfonyl fluoride (PMSF), 50 µg/ml DNaseI 
and 5 µg/ml leupeptin.  The cells were broken by sonication and then centrifuged (33,000xg, 
1 hr.).  The supernatant fluid was adjusted to pH 7.5 and loaded onto a DEAE-anion 
exchange column, using 25 mM KPi, 5 mM glucose, 1 mM dithiothreitol DTT (pH 7.5), with 
a gradient of 0–400 mM NaCl.  The fractions containing HKI activity were pooled, 
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concentrated and dialyzed against 50 mM KPi (pH 7.0), 5 mM glucose, 1 mM dithiothreitol 
(DTT) and loaded onto a ceramics hydroxyapatite column with a gradient of 0.05–1 M KPi 
(pH 7.0).  HKI was collected and dialyzed against 25 mM KPi, 5 mM glucose, 1 mM 
dithiothreitol (DTT) (pH 7.5), and further purified by DEAE-5PW HPLC chromatography 
with a gradient of 0–500 mM NaCl.  The pure protein was identified by sodium 
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)[27].  Protein concentration 
was determined by the method of Bradford with BSA as a standard[28]. 
TNP-ADP Binding and Displacement— Wild-type HKI was prepared in a buffer of 50 mM 
Tris (pH 7.5) and 1mM Glc.  In all experiment involving TNP-ADP binding and 
displacement, the enzyme concentration is 2 µM.  In binding experiments, TNP-ADP 
concentrations range from 0–10 µM, whereas in displacement experiments, the TNP-ADP 
concentration is 3.66 µM.  Fluorescence measurements were made at room temperature 
using a 1-cm2 quartz cuvette on a SLM Amico 8000 fluorometer with entrance/exit slits of 4 
mm.  The excitation wavelength is 409 nm and emission scans are from 530 to 560 nm.  
Fluorescence intensity (average of three scans for each datum) was integrated over 530–560 
nm using 30 increments and an accumulation time of 1 sec per increment.  Fluorescence 
data were analyzed by the method described by Faller[29-30] with modifications as provided in 
the next paragraph. 
The observed fluorescence from a mixture of TNP-ADP and HKI comes from free 
TNP-ADP, TNP-ADP bound to HKI and HKI itself: 
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     Eqn.1 	 is an adjustable parameter (S) that accounts for background fluorescence due to the 
protein sample.  As HKI has no native fluorophore sensitive to an excitation wavelength of 
409 nm the parameter S should be a small value and nearly constant over the experiment 
presented here.    and   represent the total and free TNP-ADP concentrations, 
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respectively.    is a fluorescence enhancement factor of the bound fluorescent ligand 
relative to the free state.  Parameters a, b and c are determined by fitting fluorescence versus  in the absence of protein, the data for which comes from the addition of TNP-ADP to 
buffer.  The same buffer is used for the binding and displacement experiments. 
A single binding-site model adequately accounts for the  of the bound state as 
well as the displacement of TNP-ADP by phosphoryl ligand Glc-6-P, or 2-deoxyGlc-6-P or 
Man-6-P: 
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  $;  $ and $ are total and free phosphoryl ligand concentrations, respectively;   and   are total and free protein concentrations, respectively.  !" and !% are constants for the 
dissociation of TNP-ADP and phosphoryl ligand from protein, respectively.  The 
equilibrium and mass conservation relationships for [Lo] (total fluorophore concentration), 
[Ao] (total concentration of displacing ligand) and [Po] (total concentration of protein) lead to 
a third-order equation in the concentration of free protein [P].  Substitution of the 
equilibrium relationships into mass conservation relationships for protein leads to a 
third-order equation in the concentration of free protein [P].  For circumstances here, KA >> 
[P], allowing an approximation that reduces the third-order equation to one of second order: 
&1 
 $!( ) P 
 &!(    
 $!+!+ 
  ) P  P!+  0 
The physical root of this quadratic relationship is the concentration of free protein, and 
determines the concentration of free fluorophore [L]=[Lo]KL/(KL+[P]) at a given total 
concentration of fluorophore, [Lo].  GraFit software optimizes the fit of the observed 
fluorescence to the right-hand side of Eqn. 1 at fixed [Po] and varying [Lo] and [Ao] by 
adjusting parameters KA, KL, G and Fprotein[31]. 
Hexokinase Kinetics— Hexokinase activity was determined by the glucose-6-phosphate 
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dehydrogenase (G6PDH, E.C.1.1.1.49) coupled spectrometric assay[26].  Commercial 
G6PDH, as precipitate from ammonium sulfate, was dialyzed against 80 mM Tris (pH 8.0) 
extensively to remove sulfate, which at millimolar concentrations causes relief of 
1,5-anhydroGlc-6-P inhibition in the manner of Pi.  1,5-AnhydroGlc-6-P, which is not a 
substrate for G6PDH, is a surrogate for Glc-6-P in inhibition kinetics of HKI.  The 
dicyclohexylamine salt of 1,5-anhydroGlc-6-P was prepared as described by Ferrari and 
Crane[32] and its concentration determined by the method of Drueckes et al.[33].  The 
concentration of hexokinase in kinetics assays was 1.2–2.0 µg/ml and the assay volume was 
1 ml.  The assay buffer was 80 mM Tris (pH 8.0), 0.4 mM NADP, 3 mM MgCl2 and 2 mM 
Glc. 
Crystal Preparation— All the crystals were grown by the hanging drop method.  Wild-type 
or mutant forms of HKI stored in 25 mM KPi (pH 7.5), 1 mM glucose, 1mM dithiothreitol 
(DTT) was concentrated to 20–30 mg/ml in 50-kDa cut-off centrifugational filtration tube, 
then subject to 12–15 cycles of wash at 4 ºC with 2–3 volumes of a ligand buffer.  The 
ligand buffers are 40 mM 1,5-anhydroGlc-6-P, 40 mM 2-deoxyGlc-6-P, 40 mM Man-6-P or 
20 mM Glc-6-P, all pH 7.5 with 1 mM Glc.  3 µl of the resulting solutions, containing 
15–20 mg/ml protein and in the ligand buffer, was combined with an equal volume of 
precipitant solution containing 4.5-6.5% (w/v) polyethylene glycol 4000 or polyethylene 
glycol 8000, 0.1 M sodium acetate and 0.1 M sodium citrate, pH 6.0.  The drops 
equilibrated against 0.5 ml of the precipitant solution.  Prismatic needles of length 0.5–0.8 
mm and width 0.2–0.3 mm grew in two to three weeks at 4 ºC.  Crystals were transferred 
sequentially to a solution containing 1:1 ratio of the corresponding precipitant solution and 
20% glycerol, and then to 1:1 ratio of the corresponding precipitant solution and 40% 
glycerol before flash freezing in liquid nitrogen. 
X-ray Diffraction Data— X-ray diffraction data for Glc-6-P, 2-deoxyGlc-6-P and Man-6-P 
were collected at ALS beamline 4.2.2.  Diffraction data were processed with d*trek[34]. 
X-ray diffraction data for 1,5-anhydroGlc-6-P and D413N/Glc-6-P were collected at APS 
SBC-sec19.  Diffraction data were processed with HKL-3000[35]. 
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Structure Determination, Model Building and Refinement— All crystals has unit cell 
parameters isomorphous to those of the P21 crystal form published previously[13-15, 36].  In 
these crystal forms, HKI is a homodimer consistent with the results of ultracentrifugation 
studies[37], which reports the dimer prevails at concentrations of protein above 1 mg/ml in the 
presence of saturating concentrations of Glc and Glc-6-P.  Crystal structures were solved by 
molecular replacement using the HKI•Glc-6-P•Glc complex (PDB entry 1HKB)[13], less 
ligands and water molecules.  The program AMoRe or Molrep from CCP4 suite was used in 
calculation of rotation and translation functions, based on data to 3 Å resolution[38-39].  The 
program RefMac from CCP4 suite was used to refine the structures[40].  Further refinement 
employed CNS with hydrogen bond restraints[41].  Manual adjustments in the conformation 
of specific residues employed the program XTALVIEW[42]. 
Molecular Dynamics Simulations— NAMD package with the CHARMM 27 force field was 
used for molecular dynamics simulations on hexokinase I[43-44].  The initial coordinates 
came from chain A of each of the crystalline complexes.  TIP3P water molecules were 
added into a rectangular water box surrounding the single molecule of HKI with a buffering 
distance of 15 Å[45].  To balance the net charge of system, sodium and chloride ions were 
added.  Periodic boundary conditions were applied and the Particle mesh Ewald algorithm 
was used for the calculation of long-range electrostatic interactions[46].  Non-bonded Van 
der Waals interactions were applied with a cutoff of 12 Å.  The integration time step was 
2.0 fs.  All models were energy-minimized for 100 ps and gradually heated to 300 K to 
relax unfavorable contacts (if any), followed by another 100 ps simulation to equilibrate the 
system.  Finally, simulations of 10 ns were carried out at constant pressure and temperature 
(1.01325 bar and 300 K). 
Principal Component Analysis (PCA) Principal component analysis was applied to extract 
functionally important motions from simulations.  Rigid-body translations and rotations of 
the tetramer were removed before PCA by aligning trajectory structures onto the starting 
structure.  Principle components were calculated by decomposing the covariance matrix C 
which was calculated from the molecular dynamics trajectory as: 
( ) ( )jjiiij rrrrC −•−= ,   
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where i,j = 1,...3N, N is the total number of Cα atoms in the structure, r is the Cartesian 
coordinates of ith Cα atom, and the angle brackets denote an average over the entire trajectory.  
The Carma package was used in PCA analysis and VMD was used to visualize the principal 
motions[47,48]. 
 
Results 
TNP-ADP binding and displacement experiment— Two assays have been used in studies of 
kinetics of HKI.  One couples Glc-6-P formation through G6PDH to the formation of 
NADPH and the other couples ADP formation through pyruvate kinase (E.C.2.7.1.40) and 
lactate dehydrogenase (E.C.1.1.1.28)[26, 49].  The latter assay, because of the accumulation of 
Glc-6-P, would provide nonlinear progress curves, complicating the determination of initial 
velocities.  The assay which couples to Glc-6-P formation, however, limits the choice of 
inhibitors to 1,5-anhydroGlc-6-P; as 2-deoxyGlc-6-P and Man-6-P, are substrates of G6PDH, 
albeit poor ones.  Here we measure binding affinities of phosphoryl ligands through the 
displacement of TNP-ADP for HKI.  TNP-ADP is a linear competitive inhibitor with 
respect to [ATP-Mg]2–[30].  TNP-ADP binds with high-affinity to the single site at the 
C-terminal half of hexokinase I, and the binding of TNP-ADP and ATP are mutually 
exclusive[30].  The KL and G for TNP-ADP are 0.47 ± 0.04 µM and 5.51 ± 0.06, respectively 
(Figure 2).  Glc-6-P displaces TNP-ADP from wild-type HKI with a KA of 0.51 ± 0.02 µM, 
whereas KA values for 2-deoxyGlc-6-P and Man-6-P are at least 100 fold higher (Figure 2). 
All the fluorescence enhancement parameters (G) are similar.  Results here are consistent 
with those of Crane and Sols[23] and Magnani et al.[24], indicating weak inhibition of HKI due 
to 2-deoxy-Glc-6-P and Man-6-P. 
Kinetics of wild-type, D413N, D861N and D413/861N hexokinases— Asp413 and Asp861 
hydrogen bond with the 1-OH group of Glc-6-P at the N- and C-terminal halves, respectively.  
Mutations here were not expected to have a substantial effect on the inhibition of HKI by 
1,5-anhydroGlc-6-P, as this molecule lacks the 1-OH group.  The biggest effect is the 90% 
reduction in kcat due to the mutation of Asp861 to asparagines (Table I).  Conceivably 
Asp861 could play a role in the localization of Mg2+ in the active site for catalysis.  Of more 
26 
 
 
relevance to the study here, however, are effects on nonlinear competitive inhibition by 
1,5-anhydroGlc-6-P with respect to [ATP-Mg]2–.  The dissociation constant for the first 
inhibitor molecule from hexokinase KI increases slightly, whereas the dissociation constant 
for the second inhibitor molecule KII decreases (Table I).  Pi-relief of 1,5-anhydroGlc-6-P 
appears comparable for mutant and wild-type enzymes. 
Crystalline complexes of wild-type or D413N HKI with different phosphoryl ligands— For 
the most part, structures of wild-type HKI co-crystallized with Glc (1 mM) and Glc-6-P, 
1,5-anhydroGlc-6-P, 2-deoxyGlc-P or Man-6-P are isomorphous and are of comparable 
resolution, the exception being the complex of 1,5-anhydroGlc-6-P, which is of lower 
resolution and higher average thermal parameter (Table II).  The same crystal forms grew 
from buffers that contained only the 6-phosphoryl ligand (data not shown), but retained Glc 
and are in all respects identical to the structures reported in Table II.  HKI in crystallization 
experiments came from a storage buffer of 25 mM KPi (pH 7.5) and 1 mM Glc.  Evidently, 
multiple exchanges of HKI with buffers that contained 6-phosphoryl ligands without glucose 
failed to remove enzyme-bound glucose, as has been reported by other investigators[51]. 
Crystalline complexes of Table II are isomorphous to Glc/Glc-6-P complex 
previously reported[13].  Superimpositions of a single chains from each structure give 
root-mean-square deviations of less than 0.5 Å.  Each asymmetric unit contains a 
homodimer with observable electron density for residues 16–914.  The polypeptide chain 
crosses three times between large and small domains; residues 16–74 and 210–447 belong to 
the large domain and residues 75–209 and 448–466 to the small domain of the N-terminal 
half and residues 467–522 and 658–895 belong to the large domain and residues 523–657 
and 896–914 to the small domain of C-terminal half.  The two halves of each subunit 
contain molecules of Glc and 6-phosphoryl ligand bound to a crevice between large and 
small domains.  A common trend for all structures is a higher B-parameter for ligands 
bound to the N-terminal half relative to the C-terminal half.  The systematic difference in 
B-parameter is consistent with the appearance of systematically weaker electron density at 
the N- relative to the C-terminal half. 
Difference density maps generated from Fourier coefficients   -./-012342  
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indicate the presence of both α- and β-anomers of Glc (Figure 3).  If refinement employs 
the β-anomer or α-anomer of Glc, positive difference density appears at the α-anomer or 
β-anomer position of the 1-OH group, respectively.  The 1-OH group of β-D-Glc forms 
hydrogen bonds with Glu294 (N-terminal half) or Glu742 (C-terminal half) and the 1-OH 
group of α-D-Glc forms hydrogen bonds with Thr234 (N-terminal half) or Ser682 
(C-terminal half).  Indeed, both anomers are substrates for HKI with comparable values for 
Km and Vmax[5]. 
Difference electron difference density for the anomer alternative to the one used in 
refinement for Glc indicates the crystallographic data can distinguish 1,5-anhydroGlc-6-P, 
2-deoxyGlc-6-P and Man-6-P from Glc-6-P (Figure 4).  Refinement was repeated with 
Glc-6-P in place of the actual ligand used in co-crystallization experiments.  In each 
instance negative and/or positive difference density appeared at the expected locations, 
indicating the that the electron density at binding sites for the 1,5-anhydroGlc-6-P, 
2-deoxyGlc-6-P and Man-6-P was not due to Glc-6-P (as could happen if a small impurity of 
Glc-6-P were present in any of the samples). 
Differences in hydrogen bonding interactions between 6-phsophoryl ligands and the 
N-and C-terminal halves of HKI (Table III) are localized to the altered functional group of 
the ligand.  The absence of the 1-OH group in 1,5-anhydroGlc-6-P eliminates hydrogen 
bonds with Asp413 (N-terminal half) and Asp861 (C-terminal half) without noticeable effects 
on hydrogen bonds between protein and ligand involving the other hydroxyl groups or the 
6-phosphoryl group.  The absent 2-OH group in complexes 2-deoxyGlc-6-P eliminates 
hydrogen bonds with Asp84 and Ser447 (N-terminal half) and Asp532 and Ser897 
(C-terminal half).  The re-positioning of the 2-OH group in the Man-6-P complex eliminates 
hydrogen bonds with Asp84 (N-terminal half) and Asp532 (C-terminal half) without the loss 
of hydrogen bonds to Ser447 (N-terminal half) and Ser897 (C-terminal half).  In all ligated 
states, the subunits of HKI remain the same in crystal structures, giving no clear indication of 
the relative importance of hydroxyl groups in the inhibition of HKI. 
MD Simulations of Wild-type and D413N HKI— All simulations presented here begin with 
the equilibration of a crystallographic structure of a ligated complex of HKI.  
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Root-mean-square deviations (RMSD) of 6-phosphoryl ligands at the C-terminal half are 
higher than those at the N-terminal half (Figure 5), and for simulations of 
1,5-anhydroGlc-6-P, 2-deoxyGlc-6-P and Man-6-P, the differences are substantial.  
Difference in RMSD values are due primarily to a transition of the C-terminal half to a more 
open conformation relative to that present in crystal structures; however, for the Glc-6-P 
simulation, the N-terminal half moves toward a more closed conformation relative to that 
observed in crystal structures. 
Simulations of HKI with Glc-6-P reveal similar interactions at the N- and C-terminal 
halves except for the 6-phosphoryl group (Tables IV&V).  Thr536 forms hydrogen bonds 
with the 6-phosphoryl group of Glc-6-P in the crystal structure, but hydrogen bonds exist in 
only 4% of the frames over the simulation.  In contrast, hydrogen bonds between Ser88 and 
the 6-phosphoryl group of Glc-6-P are present at levels of 100%.  The simulation implies a 
less important role for the 6-phosphoryl group in Glc-6-P binding to the C- relative to the 
N-terminal half, whereas crystallographic results indicate no discernible difference (Table III).  
Interestingly, the C-terminal half in its open conformation binds phosphate through hydrogen 
bonds involving Thr680[50], a residue that in simulations plays a significant role in the 
binding of the 6-phosphoryl group of Glc-6-P. 
1,5-Anhydro-Glc-6-P has two binding modes to the C-terminal half in simulations 
(Figures 6&7).  Initially, 1,5-anhydroGlc-6-P binds like Glc-6-P save for one distinction: its 
6-phosphoryl group forms hydrogen bonds with Thr536 (Table IV, Figure 7).  At 
approximately the mid-point of the simulation the C-terminal half undergoes a transition, 
whereupon the 2-OH group of 1,5-anhydroGlc-6-P forms a hydrogen bond with Asp861 (a 
residue that interacts with the 1-OH group of Glc-6-P), while retaining hydrogen bonds with 
Thr536.  Principal component analysis (Figure 6) reveals two clusters of conformations for 
the C-terminal half in the 1,5-anhydroGlc-6-P simulation, each differing from that of the 
C-terminal half in the Glc-6-P simulation.  The two clusters in the 1,5-anhydroGlc-6-P 
simulation correlate with the two binding modes of the ligand.  The alternative 
(non-Glc-6-P) binding mode appears in a C-terminal half with a more open conformation 
relative to the conformation of C-terminal half in the Glc-6-P simulation (Figure 7).  In 
contrast, principal component analysis reveals single clusters for the N-terminal half ligated 
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by Glc-6-P or 1,5-anhydroGlc-6-P (Figure 6).  Although the two ligands have comparable 
sets of hydrogen bonds (Table IV), the N-terminal half with 1,5-anhydroGlc-6-P is more 
open than that of the N-terminal half with Glc-6-P (Figure 8). 
The effect of Glc-6-P on the N-terminal half (stabilization of a more closed 
conformation relative to the N-terminal half ligated with 1,5-anhydroGlc-6-P) is not observed 
in the simulation of D413N HKI ligated with Glc-6-P (Figure 8).  The conformation of the 
N-terminal half of D413N HKI ligated by Glc-6-P is similar to that of wild-type N-terminal 
half ligated by 1,5-anhydroGlc-6-P.  The D413N mutation could well have a global 
influence on the conformation of HKI (Figure 9).  Small movements in the N-terminal half 
due to mutation cause big changes in the relative position of the N- and C-terminal halves.  
Most significantly, the 6-phosphoryl group of Glc-6-P at the C-terminal half establishes a full 
set of hydrogen bonds with Thr536 which are absent in the simulation of Glc-6-P with the 
wild-type enzyme (Table IV).  The mutation D413N seemingly weakens Glc-6-P 
interactions at the N-terminal half, but strengthen interactions at the C-terminal half. 
Man-6-P and 2-deoxyGlc-6-P appear as though each is dissociating from the 
C-terminal half as simulations progress (Figure 10).  Initially, hydrogen bonds are present 
between the 6-phosphoryl group of each ligand and Thr536, but in simulations such 
interactions terminate due to the relative movement of small and large domains of the 
C-terminal half and the movement of the loop 533–588 (Figure 10).  In addition, the 
interactions of the 1-OH group of 2-deoxyGlc-6-P with Asp861 end abruptly (Figure 10).  
The stable hydrogen bond involving the 2-OH group of Man-6-P with Asp861 is not unlike 
that of the 2-OH group of 1,5-anhydroGlc-6-P, the primary difference being the loss of 
hydrogen bonds between the 6-phosphoryl group of Man-6-P and Thr536 not observed in the 
case of 1,5-anhydroGlc-6-P. 
The movements also result in the broken interactions between 3-OH group of 
Man-6-P and 2-deoxyGlc-6-P with Asp532 (Figure 10). In addition, the interactions between 
2-OH group of Man-6-P and Asp532 disappear (Figure 10).  Conceivably longer 
simulations might lead to further loss of ligand-protein hydrogen bonds at the C-terminal half.  
Man-6-P and 2-deoxyGlc-6-P retain stable interactions at the N-terminal half throughout 
30 
 
 
simulations (Tables IV, V & VI), with interactions dominated by 6-phosphoryl groups. 
 
Discussion 
Systematic differences in the thermal parameters and levels of electron density in the N- and 
C-terminal halves could be an artifact of packing contacts in the crystal.  Simulations which 
do little more than relax the subunit in the absence of inter-subunit contacts, lead to a more 
open C-terminal half in general, and in the specific case of Glc-6-P ligation, a more closed 
N-terminal half than in crystal structures.  The mildly acidic conditions of crystallization 
(pH 6.0) may also contribute to differences in crystal structures and simulations.  At pH 6, 
phosphoryl ligands are predominantly monoanions, whereas at pH 7.5 (simulations) and pH 
8.0 (conditions of assay) dianionic forms of phosphoryl ligands dominate.  The N-terminal 
half binds Pi (as a dianion) with high affinity relative to the C-terminal half[50], and hence the 
level of protonation of the phosphoryl moiety may be critical to a high affinity interaction of 
the 6-phosphoryl group at the N-terminal half.  Indeed, simulations clearly show favored 
binding of the 6-phosphoryl group of Glc-6-P to the N- relative to the C-terminal half (Table 
IV).  Protonation of the 6-phosphoryl group then may disproportionately weaken the 
binding of Glc-6-P to the N-terminal half relative to the C-terminal half, contributing to 
effects observed in crystal structures. 
Principal component analysis of simulations of wild-type HKI and D413N HKI 
reveal effects on Glc-6-P interactions distal and proximal to the site of mutation.  For 
instance, simulations of D413N HKI with bound Glc-6-P exhibit enhanced interactions at the 
C-terminal half along with weakened interactions at the N-terminal half (Figures 8&9).  
Moreover, values of stoichiometric dissociation constants KI and KII require interactions 
between inhibitor binding sites at the N- and C-terminal halves for D413N, D861N and 
D413/861N forms of HKI (Table I).  The requirement of interacting sites becomes clear 
when the stoichiometric model is recast as a site affinity model (Scheme I), recognizing four 
equilibriums and their constants of dissociation. 
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Scheme I 
The known values of KI and KII do not uniquely determine values for site affinity constants; 
however, the definition of a site interaction parameter α allows a systematic exploration of 
allowable values for site dissociation constants given experimentally determined values of KI 
and KII.  The relationships of Scheme I permit the determination of site affinity constants for 
an arbitrary value of α by way of Eqn. 2: 
5 6   7!88  97!88  47!8!88 2<    
5   7!88  5 6 and   
5 6  5 6 7=    
56   5  7=             Eqn. 2 
Values of α greater (less) than unity represent positive (negative) cooperativity, whereas a 
value of unity represents independent binding sites.  Values of KI and KII for the wild-type 
enzyme lead to physically acceptable site-dissociation constants for 0.35<α<∞.  At α = 0.35, 
32 
 
 
the site dissociation constants are nearly equal and of low value (high affinity), and become 
progressively different as α increases (Table VII).  The allowed range for D413N, D861N 
and D413/861N is 1.55<α<∞.  Site-dissociation constants must differ and ligand binding 
must be synergistic (α>1) in order to reproduce observed values of KI and KII.  In this model 
(synergistic binding to sites of unequal affinity), Pi-relief of 1,5-anhydroGlc-6-P occurs if Pi 
binds to the high-affinity site, which through the loss of synergism, causes the dissociation 
constant for the low affinity site to rise.  Although The mutant enzymes here require 
synergistic binding of 1,5-anhydroGlc-6-P, the wild-type enzyme, on the basis of KI and KII 
values, is consistent with any model (antagonistic, independent, or synergistic inhibitory 
sites).  The observation of a single high-affinity binding site for Glc-6-P[18-22] for wild-type 
HKI, however, is consistent only with a value of α less than unity. 
The foregoing analysis does not fix the site of high-affinity interaction (N- or 
C-terminal half) for 1,5-anhydroGlc-6-P, and indeed the site of tight binding may change 
with mutation.  Nonetheless results here favor tight-binding for 1,5-anhydroGlc-6-P at the 
N-terminal half.  This assignment stems from the low root-mean-square-deviation (RMSD) 
for inhibitors bound to the N- relative to the C-terminal half (Figure 5), better recognition of 
the phosphoryl moiety at the N- relative to the C-terminal half as measured by hydrogen 
bonding persistence (Tables IV, V&VI), and the unimodal binding of 6-phosphoryl molecules 
at the N-terminal half (Figure 6).  The C-terminal half in comparison has high 
root-mean-square-deviations for ligands (Figure 5), bimodal interactions involving 
1,5-anhydroGlc-6-P (Figure 6), and a tendency to transition from a closed to partially open 
conformation (Figure 7).  Binding synergism could arise from the tight-binding of a 
molecule of 1,5-anhydroGlc-6-P to the N-terminal half, forcing a partial opening of the 
C-terminal half, which in turn allows a second molecule of 1,5-anhydroGlc-6-P to bind in its 
alternative mode. 
The mechanism of nonlinear competitive inhibition with respect to ATP exhibited by 
1,5-anhydroGlc-6-P may also be a consequence of its alternative binding mode.  Glc-6-P is 
a linear competitive inhibitor and has not exhibited an alternative binding mode, although in 
longer simulations alternative interactions could arise.  Moreover, 1,5-anhydroGlc-6-P may 
not bind as tightly to the N-terminal half as Glc-6-P (Figure 8).  Simulations of D413N HKI 
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with Glc-6-P and wild-type HKI with 1,5-anhydroGlc-6-P have similar effects on the 
conformation of the N-terminal half.  The effects of mutation presumably weaken 
recognition of the 1-OH group of Glc-6-P, and cause KI to increase and KII to decrease.  
Arguably the proper recognition of the 1-OH group (as would be the case for wild-type HKI 
and Glc-6-P) should cause KI to decrease and KII to increase.  Although the effects of 
Glc-6-P are not easily assayable by kinetics, the Kd for Glc-6-P in equilibrium dialysis 
experiments is less than 1 µM[21, 52] and in fluorescence titrations is 0.5 µM (Figure 2).  Both 
values are significantly less than 20 µM (KI of 1,5-anhydroGlc-6-P). 
Simulations here also address potent inhibition of mini-HKI by 1,5-anhydroGlc-6-P 
and the effects due to mutations.  The 6-phosphoryl group of 1,5-anhydroGlc-6-P in each of 
its modes of interaction with the C-terminal half of HKI binds Thr536.  Regardless of 
binding mode, the mutation T536A will have an impact on 1,5-anhydroGlc-6-P inhibition.  
The mutation D861A also eliminates inhibition by 1,5-anhydroGlc-6-P[18], suggesting the 
possible significance of the alternative binding mode of 1,5-anhydroGlc-6-P in mini-HKI. 
Finally, we come to the 2-OH group of Glc-6-P and its importance to inhibition 
proposed by Crane and Sols[23].  Fluorescence titrations suggest 100-fold weaker binding of 
the 2-OH variants relative to Glc-6-P (Figure 2).  TNP-ADP is a competitive inhibitor with 
respect to [ATP-Mg]2–, so loss of fluorescence arises from the displacement of TNP-ADP 
from the C-terminal half of HKI by the binding of ligands.  The absence of the 2-OH group 
or the change in chirality of carbon-2 has a significant effect on ligand interactions at the 
C-terminal half in simulations.  In contrast, interactions of 2-deoxy-Glc-6-P and Man-6-P at 
the N-terminal half appear similar to those of Glc-6-P.  One possibility then has 
2-deoxy-Glc-6-P and Man-6-P binding to the N-terminal half with relatively high affinity, but 
with no influence on the C-terminal half due to the absence of interactions involving the 
2-position of the ligand.  Inhibition would come about by weak interactions of 
2-deoxy-Glc-6-P and Man-6-P with the C-terminal half.  Alternatively, one could have weak 
association with the N-terminal half due to the absent or repositioned 2-OH group, but retain 
allosteric inhibition triggered by interactions of the 1-OH group. 
Allosteric inhibition putatively stems from the nonbonded contacts between the loop 
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244–253 of the N-terminal half and the flexible subdomain of the C-terminal half[53] and in 
simulations an isosteric mutation (D413N) causes significant change to contacts between 
N-and C-terminal halves (Figure 9) that influence interactions of Thr536 at the active site.  
Moreover, ATP recognition by the C-terminal half of HKI correlates with the position and 
hydrogen bonding of Thr784 of the flexible subdomain[53], and even in a crystalline ATP 
complex of glucokinase[54], the corresponding threonine adopts the same ATP-favored 
conformation as observed in HKI. 
The mechanism of allosteric regulation of HKI by Glc-6-P and Pi has been obscured 
by packing interactions in crystals, differences in pH, assumptions of localized effects due to 
mutations, and the use of metabolite analogs that may not elicit a response comparable to the 
physiological effector.  Dynamics simulations offer a potential bridge from crystal 
structures, biased by packing interactions, to conformational states in solution that ultimately 
become the basis for a comprehensive of allostery in HKI. 
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Table I.  Kinetics parameters for wild-type and mutant forms of HKI.# 
 
HKI 
kcat KmGlc KmATP KI KII Pi-relief 
S-1 µM mM µM µM % 
Wild-type 92 ± 1 45 ± 3 1.03 ± 0.02 20 ± 3 240 ± 50 85 
D413N 82 ± 1 57 ± 2 0.98 ±0.06 23 ± 4 80 ± 20 80 
D861N 9.4 ± 0.1 37 ± 1 2.02 ± 0.09 30 ± 4 80 ± 20 86 
D413N/D861N 10.0 ± 0.1 32 ± 2 1.59 ± 0.06 35 ± 5 110 ± 40 78 
 
#Assays were in 80 mM Tris, pH 8.0, 1 mM DTT, 0.4 mM NADP, 3 mM MgCl2 along with varying amounts of 
[ATP-Mg]2–, Glc, Pi and/or 1,5-anhydroGlc-6-P.  In the determination of KmGlc, the concentration of Glc varied 
from 1/ 6 KmGlc to 10 KmGlc and that of [ATP-Mg]2– was fixed at 9 mM.  In the determination of KmATP, the 
concentration of [ATP-Mg]2– varied from 1/6 KmATP to 6 KmATP and that of Glc was fixed at 2 mM.  In the 
determination of KI and KII, the concentration of [ATP-Mg]2– varied from 1/2 KmATP to 4 KmATP, that of 
1,5-anhydroGlc-6-P from 20 to 100 µM and that of Glc was fixed at 2 mM.  Values for KI and KII for 
1,5-anhydroGlc-6-P were obtained by fitting data to a model of nonlinear competitive inhibition, the equation 
for which is as follows:  
V  V?@A
B1 
 K?(DE F 1 S= 
 HK?(DE KI< J F I S= 
 HK?(DE KI F KII< J F I S= LM
 
where S and I are concentrations of [ATP-Mg]2– and 1,5-anhydroGlc-6-P, respectively.  Pi-relief of inhibition 
is defined as 100 F (A-B)/A, where A is the slope from plots of reciprocal relative velocity versus 
1,5-anhydroGlc-6-P concentration in the absence of Pi, and B is the slope from plot of reciprocal relative 
velocity versus inhibitor concentration in the presence of 6 mM Pi.  Relative velocity is the ratio of velocity at 
a specific concentration of inhibitor to the velocity in the absence of inhibitor.  The [ATP-Mg]2– concentration 
is fixed at KmATP. 
 
 Table II.  Statistics for data collection and r
 
Protein Wild
Ligand a Glc
Space group P2(1)
Unit cell parameters 
a (Å) 82.63  
  b (Å) 121.53
  c (Å) 119.83
α (°) 
β (°) 92.82
γ (°) 
Resolution limits (Å) 37.90
No. of reflections 245322
No. of unique reflections 68327
% Completeness (overall) 99.22
% Completeness (last shell) 98.99
Rsyma 0.061
R-factorb 0.2421
Rfreec 0.2565
No. of atoms in refinement 14481
No. of water molecules 
Mean B parameters (Å2)  
   Main chain 
   Side chain 
  Glucose, N-half 
  Glucose, C-half 
  Sugar-phosphate, N-half 
  Sugar-phosphate, C-half 
Root mean square 
deviations  
   Bond lengths (Å) 0.004
Bond angles (°) 0.907
aRsys = j i|Iij- Ij |/ i jIij, where 
crystallographically unique intensities.
bR-factor = Fobs  Fcalc / |F
cRfree- is based upon 10% of the data randomly culled and not used in the refinement.
 
efinement of wild-type and mutant forms 
of HKI 
-type D413N Wild-type Wild-type
-6-P Glc-6-P 1,5-anhydroGlc-6-P 2-deoxyGlc-
 P2(1) P2(1) P2(1) 
    
 82.607 82.723 82.983 
 121.140 121.211 122.092 
 119.888 120.790 120.346 
90 90 90 90 
 92.69 93.12 92.975 
90 90 90 90 
-2.65 44.15-2.48 46.24-3.00 35.36-2.65
 3458364 665422 266419 
 83067 56036 69139 
 98.47 82.72 98.92 
 84.92 22.74 98.32 
 0.070 0.112 0.086 
 0.2391 0.2310 0.2397 
 0.2527 0.2537 0.2578 
 14394 14396 14508 
273 186 194 304 
    
55 61 78 55 
57 63 79 57 
45 52 81 45 
35 40 55 34 
51 78 80 51 
35 42 62 34 
    
 0.004 0.013 0.006 
 0.889 1.014 0.865 
i runs over multiple observations of the same intensity and 
 
obs|, Fobs > 0. 
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 Wild-type 
6-P Man-6-P 
P2(1) 
 
82.424 
123.090 
121.640 
90 
93.272 
90 
 45.78-2.70 
237474 
64558 
99.78 
99.85 
0.071 
0.2442 
0.2544 
14496 
288 
 
55 
56 
45 
37 
63 
37 
 
0.005 
0.887 
j runs over 
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Table III.  Donor-acceptor distances between ligand and protein from crystal structures. 
(Distances less than 3.2 Å for residues from the N- and C-terminal halves are listed for chains A and B.) 
Atom Residue 
Glc-6-P D413N/Glc-6-P 1,5-anhydroGlc-6-P 2-deoxyGlc-6-P Man-6-P 
NA NB CA CB NA NB CA CB NA NB CA CB NA NB CA CB NA NB CA CB 
O1 
D/N413/861#: OD1 2.9 3.1     3.5 3.2             3.1 3.1             
D/N413/861#: O/ND2 2.7 2.5 2.6 3.1 2.5 3.0 2.5 3.3         2.8 2.6 2.7 3.2 2.7 2.9 2.7 3.3 
O2 
D84/532:OD2 2.5 2.9 2.8 2.8 2.5 2.8 2.8 2.7 2.4 3.3 2.8 2.5                 
R91/539:NH1     
 
  2.7 4.9         
  
                
D/N413/861:O/ND2     
 
    
 
        
  
        2.5 2.9 2.9 3.0 
S449/897:N 3.7 3.1 2.9 2.8 3.3 3.2 2.8 3.0     2.8 2.8         3.6 2.9 3.1 3.0 
S449/897:OG     3.2 3.6   
 
        3.6 3.2         2.8 3.4 4.4 3.1 
O3 
D84/532:OD1 2.5 2.8 2.7 2.9 3.2 3.0 2.8 3.0 3.1 3.0 2.8 2.9 3.4 3.1 2.8 3.0 3.0 3.4 2.8 3.0 
D84/532:OD2 2.7 3.3   2.7 3.2     2.8 3.7 
  
2.4 3.4     2.4 2.9     
S449/897:OG 2.9 2.7 2.5 2.7 2.8 2.8 2.5 2.8 3.6 2.8 3.0 2.5 2.9 3.0 2.6 2.5 3.2 2.8 3.9 2.7 
O4 D209/657:OD2 2.8 2.7 2.9 2.6 2.7 2.7 2.9 2.5 3.0 2.5 3.3 2.6 2.8 2.8 3.0 2.6 3.1 2.6 3.0 2.6 
O1P 
S88/T536:N 3.1 3.6     3.1 3.6     3.2 3.2     3.0 3.0     2.7 3.8     
S88/T536:OG 
  
    
  
 
  
  
  
  
  
  
  
  
  3.2 4.0     
T232/680:N 3.1 2.9 2.8 2.9 3.4 2.8 2.9 2.9     3.1 3.2 3.2 2.8 2.9 3.0 3.6 2.7 2.8 2.9 
T232/680:OG 2.5 2.5 2.7 2.8 2.6 2.6 2.7 2.9 2.8 3.0 3.0 3.3 2.6 2.6 2.7 2.8 2.7 2.6 2.7 2.7 
O2P 
S88/T536:OG 2.7 4.2     3.2 3.5     2.7 4.4     2.9 4.2     3.2 3.8     
T232/680:N 3.3 3.2   3.1 3.8     2.9 3.0 3.0 3.4 3.2 3.4     2.7 3.9     
S415/T863:N 2.8 2.9 2.9 2.9 2.8 3.1 2.8 2.8 3.2 3.2 3.1 2.8 3.0 2.8 2.9 2.9 3.0 2.9 2.9 2.9 
S415/T863:OG 2.6 2.7 2.6 2.5 3.2 2.5 2.8 2.5 2.9 3.0 2.9 2.7 2.7 2.6 2.6 2.6 3.6 3.1 2.5 2.5 
O3P 
S88/T536:N 2.8 2.9 2.9 2.9 3.3 2.7 2.8 3.0 3.0 3.0 3.1 3.4 2.9 2.9 2.8 2.8 3.6 2.8 2.9 3.0 
S88/T536:OG 2.5 2.5 2.7 2.7 2.5 2.6 2.9 2.8 2.4 2.9 2.5 2.8 2.5 2.6 2.7 2.8 2.5 2.8 2.8 2.9 
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Table IV.  Fractional ratio for phosphoryl ligands of all MD simulation structures 
(distance N 3.2Å between phosphoryl ligand and corresponding residues) 
Atom Residue 
Glc-6-P D413N/ Glc-6-P 
1,5-anhydro 
Glc-6-P 
2-deoxy 
Glc-6-P Man-6-P 
N C N C N C N C N C 
O1 
D/N413/861:OD1 0.62 0.90 0.09 0.91 --- --- 0.74 0.31 0.81 0.52 
D/N413/861:O/ND2 0.52 0.69 0.68 0.62 --- --- 0.57 0.17 0.29 0.47 
K418/866:NZ 0.47 0.14 0.03 0.61 --- --- 0.09 0.02 0.11 0.04 
O2 
D84/532:OD1 0.22 0.91 0.41 0.12 0.13 0.24 --- --- --- --- 
D84/532:OD2 0.79 0.87 0.73 0.86 0.90 0.12 --- --- --- --- 
R91/539:NH1 0.04 --- 0.02 0.07 0.33 --- --- --- --- --- 
R91/539:NH2 0.08 0.06 --- --- 0.43 0.09 --- --- --- --- 
T213/661:OG1 --- --- --- --- --- --- --- --- --- 0.28 
D/N413/861:OD1 --- --- --- --- 0.04 --- --- --- 0.52 0.35 
D/N413/861:O/ND2 --- --- --- --- --- 0.73 --- --- 0.15 0.40 
S449/897:N 0.45 0.15 0.26 0.56 0.13 0.13 --- --- 0.23 --- 
S449/897:OG 0.01 --- 0.01 0.03 0.26 0.22 --- --- 0.76 0.17 
O3 
D84/532:OD1 0.85 0.98 0.81 0.81 0.85 0.72 0.52 0.14 0.72 0.11 
D84/532:OD2 0.70 --- 0.64 0.33 0.69 0.10 0.39 --- 0.84 --- 
D209/657:OD2 --- --- --- 0.05 0.01 --- 0.21 0.67 --- 0.76 
S449/897:OG 0.90 0.96 0.86 0.98 0.49 0.79 0.26 0.33 0.65 0.17 
O4 
G87/535:N --- 0.54 --- 0.06 0.07 0.11 --- 0.05 --- 0.18 
D209/657:OD2 1.00 1.00 1.00 0.99 0.92 0.40 1.00 0.99 1.00 0.95 
Glc:O6 --- --- --- --- --- --- 0.07 0.30 --- 0.03 
O1P 
S88/T536:N 0.48 --- 0.08 0.07 0.07 0.02 0.53 0.02 0.12 --- 
S88/T536:OG(1) 0.45 --- 0.20 --- 0.32 --- 0.57 --- --- --- 
T232/680:N 0.25 0.42 0.46 0.98 0.30 0.98 0.51 1.00 0.87 0.68 
T232/680:OG1 0.25 0.43 0.44 1.00 0.30 0.97 0.53 1.00 0.98 0.98 
S415/T863:N 0.20 --- 0.48 --- 0.46 ---- --- --- --- --- 
S415/T863:OG(1) 0.30 --- 0.58 --- 0.66 --- 0.02 --- --- --- 
O2P 
S88/T536:N 0.33 --- 0.56 --- 0.57 --- 0.10 --- --- --- 
S88/T536:OG(1) 0.46 --- 0.70 --- 0.53 --- 0.24 --- 0.02 --- 
T232/680:N 0.45 0.54 0.00 0.05 0.04 0.03 0.46 --- 0.27 0.42 
T232/680:OG1 0.47 0.57 0.00 --- 0.14 0.02 0.47 --- 0.04 0.15 
S415/T863:N 0.19 0.39 0.37 0.86 0.25 0.64 0.42 0.73 0.75 0.46 
S415/T863:OG(1) 0.25 0.43 0.43 1.00 0.31 1.00 0.53 1.00 1.00 1.00 
O3P 
S88/T536:N 0.27 0.04 0.42 0.99 0.33 0.44 0.47 0.39 0.99 0.04 
S88/T536:OG(1) 0.27 0.04 0.29 1.00 0.28 0.45 0.35 0.45 1.00 0.03 
T232/680:N 0.27 0.05 0.56 --- 0.62 --- 0.01 --- --- --- 
T232/680:OG1 0.29 --- 0.57 --- 0.65 0.02 --- --- --- 0.03 
S415/T863:N 0.38 0.50 0.00 --- 0.03 --- 0.37 --- --- --- 
S415/T863:OG(1) 0.48 0.57 0.00 --- 0.06 --- 0.47 --- --- --- 
--: value less than 0.01 or not exist.  
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Table V.  Fraction of frames from molecular dynamics simulations with hydrogen 
bonds between protein residues and the 6-phosphoryl groups of ligands$. 
 
Residue 
Glc-6-P D413N/ Glc-6-P 
1,5-anhydro 
Glc-6-P 
2-deoxy 
Glc-6-P Man-6-P 
N C N C N C N C N C 
S88/T536:N$ 0.99 0.04 0.98 0.99 0.93 0.99 0.88 0.44 0.97 0.39 
S88/T536:OG(1)$ 0.92 0.04 0.96 1.00 0.58 0.90 0.91 0.44 0.91 0.45 
S88/T536# 1.00 0.04 1.00 1.00 0.96 1.00 0.98 0.45 1.00 0.47 
T232/680:N$ 0.96 0.97 0.99 0.98 0.97 0.69 0.95 0.98 0.97 1.00 
T232/680:OG1$ 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.98 1.00 1.00 
T232/680# 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
S415/T863:N$ 0.76 0.89 0.85 0.86 0.24 0.50 0.74 0.64 0.78 0.73 
S415/T863:OG(1)$ 1.00 1.00 1.00 1.00 1.00 0.64 1.00 1.00 1.00 1.00 
S415/T863# 1.00 1.00 1.00 1.00 1.00 0.64 1.00 1.00 1.00 1.00 
 
$A pair of polar atoms define a hydrogen bond if the corresponding donor-acceptor distance is less than or equal 
to 3.2 Å. 
#Represents the fraction of frames with hydrogen bonds between any polar atom of the indicated protein residue 
and any atom of the 6-phosphoryl group. 
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Table VI.  Fraction of frames from molecular dynamics simulations with hydrogen 
bonds between oxygen atoms of the 6-phosphoryl group and any polar atom from the 
protein$. 
6-Pi 
Glc-6-P D413N/ Glc-6-P 
1,5-anhydro 
Glc-6-P 
2-deoxy 
Glc-6-P Man-6-P 
N C N C N C N C N C 
O1P 0.99 0.44 1.00 1.00 0.88 0.83 1.00 0.99 0.98 1.00 
O2P 0.99 1.00 1.00 1.00 0.98 0.97 0.98 1.00 1.00 1.00 
O3P 1.00 0.61 0.99 1.00 0.81 0.92 0.98 0.47 0.97 0.48 
 
$A pair of polar atoms define a hydrogen bond if the corresponding donor-acceptor distance is less than or equal 
to 3.2 Å. 
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Table VII.  Values (µM) for site dissociation constants OP Q and OP R of Scheme I 
for selected values of α for wild-type and mutant forms of HKI. 
 
α 
0M1/0M2 
wt-HKI D413N D861N D413/861N 
0.35 33/51 --a --a --a 
1.0 22/220 --a --a --a 
1.5 21/340 31/89 --a 50/120 
2.0 21/460 28/130 42/120 44/180 
 
aNo physical solution. 
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Figure 1.  Overview of the wild-type HKI•Glc-6-P•Glc complex.  Large domains are blue and small 
domains yellow.  The flexible subdomain (residues 766–812) and corresponding residues of the N-terminal 
half (residues 318–364) are purple.  Ligands Glc-6-P and Glc are sticks.  The illustration was generated with 
PyMOL. 
43 
 
 
Figure 2.  TNP-ADP binding and displacement curves for wild-type hexokinase I.  A, Titration of 2 µM 
wild-type hexokinase I (binding curve) or buffer only (baseline) with TNP-ADP.  B, Displacement of 
TNP-ADP from wild-type hexokinase I with different ligands.  The fitted parameters are shown below. 
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Figure 3.  Electron density for glucose in structures of HKI.  A, β-D-glucose and α-D-glucose.  B, 
Electron density (2Fo-Fc) for β-D-glucose, contoured at 2σ (blue) in combination with Fo-Fc positive electron 
density (green) contoured at 3σ.  (Fo-Fc negative electron density is not observed at levels above 2σ).  C, 
Hydrogen bonds between the 1-hydroxyl group of β- and α-D-glucose and protein.  Illustration generated with 
Chemdraw (panel A) and PyMOL (panels B and C). 
.  
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Figure 4.  6-Phosphoryl ligands and associated electron densities.  A. Phosphoryl ligands. B. Electron 
density for each complex with Glc-6-P as the modeled ligand.  Density levels are for 2Fo-Fc (blue), positive 
Fo-Fc (green) )and negative Fo-Fc (red) at contour levels indicated for data collected from complexes of 
enzyme with Glc-6-P, 1,5-anhydroGlc-6-P, 2-deoxyGlc-6-P and Man-6-P.  Illustration generated with 
Chemdraw (panel A) and PyMOL (panel B). 
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Figure 5.  RMSD of phosphoryl ligand from MD simulations for N- and C-terminal halves of each 
complex. 
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Figure 6.  Principal component analysis of HKI.  First two components of PCA based on all N-terminal 
half (A) or C-terminal half (B) structures from wild-type•Glc-6-P, wild-type•1,5-anhydroGlc-6-P and 
D413N•Glc-6-P MD simulations.  Mode 1 and mode 2 for the C-terminal half of the 
wild-type•1,5-anhydroGlc-6-P simulation are marked by arrows. 
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Figure 7.  Representative structures from PCA distributions of C-terminal half HKI.  Panels A and B 
are C-terminal halves from simulations of Glc-6-P with wild-type HKI (blue), mode 1 of 1,5-anhydroGlc-6-P 
and wild-type HKI (magenta) and mode 2 of 1,5-anhydroGlc-6-P and wild-type HKI (pink).  Mode 1 and 2 are 
defined in Figure 6.  The large domain of the C-terminal half, excluding residues 766–812 (flexible 
subdomain), is the basis of superpositions.  The C-terminal half in mode 2 is more open relative to that of the 
C-terminal half with Glc-6-P.  Panels C and D show hydrogen bond networks for 1,5-anhydroGlc-6-P in mode 
1 (magenta) and mode 2 (pink), respectively. 
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Figure 8.  Representative structures from PCA distributions for the N-terminal half of HKI.  The 
N-terminal half large domain, excluding residues 318–364 (residues corresponding to the flexible subdomain of 
the C-terminal half), is the basis of superposition.  Panels A and C are views of the N-terminal half and its 
inhibitor binding pocket, respectively, of wild-type•Glc-6-P (blue) and D413N•Glc-6-P (green) complexes.  
The wild-type•Glc-6-P complex is more closed relative to the D413N•Glc-6-P complex (panel A), and the 
inhibitor occupies different locations within the pocket (panel C).  Panels B and D are views of the N-terminal 
half and its inhibitor binding pocket, respectively, of wild-type•Glc-6-P (blue) and 
wild-type•1,5-anhydroGlc-6-P (magenta) complexes.  The wild-type•1,5-anhydroGlc-6-P complex (magenta) 
is similar to the D413N•Glc-6-P complex (green), but different from the wild-type•Glc-6-P complex (blue). 
  
50 
 
 
 
Figure 9.  Superposition of 
representative HKI structures from 
PCA distributions for the N-terminal 
half.  N-terminal half large domains, 
excluding residues 318–364 (residues 
corresponding to the flexible subdomain 
of the C-terminal half) are the basis of 
superposition of wild-type (blue) and 
D413N (green) complexes with Glc-6-P 
(panel A).  The transition helix 
leverages the slight opening of the 
N-terminal half of D413N HKI into 
large rigid-body movements in the C- 
relative to the N-terminal half.  These 
movements ultimately enhance 
interactions involving the 6-phosphoryl 
group of Glc-6-P and Thr536 of the 
C-terminal half (panel B). 
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Figure 10.  Distance between selected polar atoms from ligand and protein over time.  The lines are 
smoothed by taking averaging five successive frames.  OXP and OD represent the closest pair of oxygen 
atoms between the 6-phosphoryl group and indicated residue. 
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Chapter III. Determination of Site Affinity Constants for Product Inhibition Wild-type 
and Mutant forms of Recombinant Human Hexokinase Type I 
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Abstract 
Hexokinase I (HKI) is the pacemaker of glycolysis in the red blood cell, being subject to 
potent feedback inhibition by its product glucose 6-phosphate (Glc-6-P) and the relief of that 
inhibition by inorganic phosphate (Pi).  Presented here are investigations of glucose 
1,6-bisphosphate (Glc-1,6-P2) as an inhibitor of HKI, using kinetics, directed mutation, 
crystallography and molecular dynamics.  The data support the hypothesis of an alternative 
binding mode for 1,5-anhydroglucitol 6-phosphate (1,5-anhydroGlc-6-P) as the basis for its 
nonlinear competitive inhibition of HKI.  In addition, the investigations identify Lys418 
(N-terminal half) and Lys866 (C-terminal half) as critical elements of networks of hydrogen 
bonds that support potent inhibition of HKI by 1,5-anhydroGlc-6-P.  A new approach to the 
analysis of data from kinetics for the first time provides site dissociation constants for 
wild-type and mutant forms of HKI.  Wild-type and many mutant forms of HKI exhibit 
binding antagonism between sites of inhibition at the N- and C-terminal halves, with the 
N-terminal half having the site of high binding affinity.  Specific mutations, however, can 
result in binding synergism and/or change the site of high binding affinity to the C-terminal 
half.  The analysis here is broadly applicable to any form of HKI that exhibits Pi-relief of 
inhibition. 
 
Introduction 
Hexokinase (ATP: D-hexose 6-phosphotransferase, EC2.7.1.1) catalyzes the initial step of 
glycolysis, the phosphorylation of 6-hydroxyl group of glucose (Glc) using [ATP-Mg]2– as 
the phosphoryl donor [1-3].  Four isozymes of hexokinase have been identified in mammalian 
tissues[4].  Type I, II and III hexokinase isozymes have molecular weights of 100 kDa, and 
share 70% sequence identity[5].  N- and C-terminal halves of isozymes I–III have ~50% 
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sequence identity[5], putatively a result of the duplication and fusion of the gene for a 
primordial hexokinase[6-9].  Hexokinase IV (glucokinase) and yeast hexokinase isoforms A 
and B have molecular weights of 50 kDa, and exhibit significant sequence similarity to both 
halves of isozymes I–III[5]. 
Despite sequence and structural similarities, isozymes I-III differ significantly in 
functional properties.  Both halves of hexokinase II possess catalytic activity[10], whereas 
the N-terminal halves of hexokinase I and III are inactive[5, 11-12].  The reaction product 
glucose-6-phosphate (Glc-6-P) potently inhibits isozymes I-III (but not isoform IV) at 
physiological concentrations[5].  Inorganic phosphate (Pi) is a weak inhibitor of hexokinase 
II and III[5]; however, Pi antagonizes the inhibition of hexokinase I by 1,5-anhydroglucose 
6-phosphate (1,5-anhydroGlc-6-P, an analog of Glc-6-P used in kinetics) at low (micromolar) 
concentrations, whereas, at millimolar concentrations Pi inhibits catalysis competitively with 
ATP[5]. 
Substantial evidence supports a single high-affinity binding site for Glc-6-P.  
Equilibrium dialysis experiments indicate sub-micromolar dissociation constants for Glc-6-P 
from HKI, with a binding stoichiometry of one mole of inhibitor per mole of enzyme[13-14].  
Fluorescence binding studies are consistent with a single binding site for Glc-6-P with a 
sub-micromolar dissociation constant (Chapter 2, this thesis).  Glc-6-P up to concentrations 
of 1 mM is a linear competitive inhibitor with respect to ATP[20].  Other observations, 
however, point to multiple sites of inhibitor action and the possibility of two high-affinity 
sites.  Glc-6-P binds to both halves of HKI in crystal structures, and exhibits essentially 
identical hydrogen bonding interactions[15-17].  Proteolytic cleavage of HKI produces an 
active C-terminal half (mini-HKI), inhibited potently by 1,5-anhydroglucose 6-phosphate 
(1,5-anhydroGlc-6-P, an analog of Glc-6-P used in kinetics) with no Pi-relief of inhibition[12, 
18]
.  The N-terminal half of HKI is inactive, but still binds Glc-6-P tightly[11-12].  
1,5-AnhydroGlc-6-P remains a potent inhibitor of mutant forms of HKI that eliminate 
inhibitor binding at either the N- or C-terminal half[19-20].  Only mutations at both Glc-6-P 
binding sites eliminate inhibition[20].  Finally, 1,5-anhydroGlc-6-P is a nonlinear competitive 
inhibitor with respect to ATP of wild-type HKI[19]. 
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These observations have been the basis for numerous models to explain the functional 
properties of HKI.  Fromm and colleagues favor a single, high-affinity binding site at the 
C-terminal half that physically overlaps the ATP pocket, but allows glucose to bind to the 
active site[14, 21-22].  Alternatively, Wilson and colleagues assign the site of high-affinity 
association of Glc-6-P to the N-terminal half (allosteric mechanism of inhibition)[11, 23].  Pi 
relieves Glc-6-P inhibition in the Fromm model by binding to the N-terminal half (allosteric 
mechanism for Pi-relief), and in the Wilson model Pi binds to the 6-phosphoryl site of 
Glc-6-P[5, 24].  These models have undergone revision over time.  The discovery of potent 
inhibition of mini HKI necessitated an adjustment to the Wilson model, acknowledging the 
existence of a latent high-affinity site for inhibition at the C-terminal half unmasked by the 
removal of the N-terminal half[5].  Similarly, the persistence of high-affinity inhibition by 
1,5-anhydroGlc-6-P exhibited by T536A HKI is consistent with a mechanism of allosteric 
inhibition[20].  To reconcile one high-affinity site in equilibrium binding studies and two 
high affinity sites implied by crystal structures and mutant forms of HKI, Liu et al.[20] 
proposed a model of equal high-affinity sites coupled by negative cooperativity. 
Evidence presented in Chapter 2 of this thesis, however, cannot be reconciled with a 
model of two high-affinity inhibitory sites coupled by negative cooperativity.  D413N 
and/or D861N forms of HKI exhibit nonlinear competitive inhibition by 1,5-anhydroGlc-6-P 
such that the N- and C-terminal half binding sites must have unequal affinities and be 
coupled by binding synergism.  In this model Pi binds to the N-terminal half, blocking the 
high-affinity site and elevating the dissociation constant at the C-terminal site through loss of 
binding synergism.  Data from wild-type HKI is consistent with this model as well, further 
adding to the list of possible mechanisms of inhibition.  The mechanism of inhibition is 
completely determined, however, by assigning values to site dissociation constants and an 
interaction or coupling parameter, and presented here is a method that accomplishes this goal 
and quantitatively establishes the mechanism of inhibition of HKI. 
Binding synergism of 1,5-anhydroGlc-6-P is ascribed to an alternative binding mode 
to the C-terminal half of HKI observed in molecular dynamics simulations.  Glucose 
1,6-bisphosphate (Glc-1,6-P2) is also an inhibitor of HKI[25-26], but it cannot adopt the 
alternative binding mode of 1,5-anhydroGlc-6-P because of unfavorable steric interactions 
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between its 1-phosphoryl group and the enzyme.  Glc-1,6-P2 is a linear competitive 
inhibitor with respect to ATP (up to 400 µM). At millimolar concentrations, a second 
molecule of Glc-1,6-P2 binds to HKI with a dissociation constant of approximately 3 mM, 
relative to 240 µM for 1,5-anhydroGlc-6-P.  Mutations of D413N and/or D861N enhance 
the binding affinity of Glc-1,6-P2 to levels near those of 1,5-anhydroGlc-6-P, and still the 
inhibition mechanism remains linear competitive with respect to ATP.  A crystal structure of 
D413N HKI with Glc-1,6-P2 and molecular dynamics simulations implicate Lys418 and 
Lys866 in hydrogen bonding networks that support the recognition of the 1-OH of Glc-6-P.  
Mutations of K418A and/or K866A increase dissociation constants for 1,5-anhydroGlc-6-P, 
and K418A (but not K866A) significantly reduces Pi-relief of inhibition.  These mutations, 
along with those in Chapter 2 of this thesis, cover a spectrum of inhibition mechanisms, from 
binding antagonism to synergism and from N-terminal to C-terminal dominant. 
 
Materials and methods 
Materials— A full-length cDNA of human hexokinase I, cloned into vector pET-11a was 
available from previous studies[18, 27-28].  Oligonucleotides came from IDT-DNA.  DNA 
sequencing was done by the Iowa State University DNA Sequencing and Synthesis Facility.  
Escherichia coli strain DH5a and BL21 were from Invitrogen.  DNaseI, 
phenylmethanesulfonyl fluoride (PMSF), leupeptin, bovine serum albumin (BSA), ATP, 
NADP, ampicillin, glucose 6-phosphate, and glucose 1,6-bisphosphate were from Sigma.  
1,5-Anhydro-D-sorbitol was from Toronto Research Chemicals.  
Isopropyl-β-D-thiogalactopyranoside (IPTG) was from Bio-World.  DEAE sepharose 
CL-6B and CHT ceramic hydroxyapatite (HA) Type II were from Bio-Rad.  DEAE-5PW 
HPLC media was from Tosohaas.  Glusoe-6-phosphate dehydrogenase (G6PDH) was from 
Roche. 
Construction, Expression and Purification of Wild-type and Mutant Hexokinase I— The 
oligonucleotide primers for directed mutations are as follows: 
5’-GAC-GGA-TCT-CTT-TAC-GCG-ACG-CAC-CCA-CAG-3’ for K418A and 
5’-GG-ACA-CTC-TAC-GCG-CTT-CAT-CCA-CAC-3’ for K866A, where the altered codon 
is underlined. 
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A 200 ml culture of the transformed Escherichia coli BL21 was grown overnight at 
37 ºC in LB medium (33mg/L ampicillin) and then 1.5% cell were transferred to 9.6L LB 
medium (33mg/L ampicillin).  The culture was grown at 300 rpm and 37 ºC to A600=1.0.  
The temperature then was reduced to 16 ºC, isopropyl-β-D-thiogalactopyranoside (IPTG) was 
added to a final concentration of 0.5 mM and the culture was grown at 200 rpm for 20-22 hr. 
at 16 ºC.  The cells were re-suspended in 25 mM KPi (pH 7.5), 5 mM glucose, 3 mM MgCl2, 
1 mM dithiothreitol (DTT), 1 mM phenylmethanesulfonyl fluoride (PMSF), 50 µg/ml DNaseI 
and 5 µg/ml leupeptin.  The cells were broken by sonication and then centrifuged (33,000xg, 
1 hr.).  The supernatant fluid was adjusted to pH 7.5 and loaded onto a DEAE-anion 
exchange column, using 25 mM KPi, 5 mM glucose, 1 mM dithiothreitol DTT (pH 7.5), with 
a gradient of 0–400 mM NaCl.  The fractions containing HKI activity were pooled, 
concentrated and dialyzed against 50 mM KPi (pH 7.0), 5 mM glucose, 1 mM dithiothreitol 
(DTT) and loaded onto a ceramics hydroxyapatite column with a gradient of 0.05–1 M KPi 
(pH 7.0).  HKI was collected and dialyzed against 25 mM KPi, 5 mM glucose, 1 mM 
dithiothreitol (DTT) (pH 7.5), and further purified by DEAE-5PW HPLC chromatography 
with a gradient of 0–500 mM NaCl.  The pure protein was identified by sodium 
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)[29].  Protein concentration 
was determined by the method of Bradford with BSA as a standard[30]. 
Hexokinase Kinetics— Hexokinase activity was determined by the glucose-6-phosphate 
dehydrogenase (G6PDH, E.C.1.1.1.49) coupled spectrometric assay[28].  Commercial 
G6PDH, as precipitate from ammonium sulfate, was dialyzed against 80 mM Tris (pH 8.0) 
extensively to remove sulfate, which at millimolar concentrations causes relief of 
1,5-anhydroGlc-6-P inhibition in the manner of Pi.  1,5-AnhydroGlc-6-P, which is not a 
substrate for G6PDH, is a surrogate for Glc-6-P in inhibition kinetics of HKI.  The 
dicyclohexylamine salt of 1,5-anhydroGlc-6-P was prepared as described by Ferrari and 
Crane[31] and its concentration determined by the method of Drueckes et al.[32].  The 
concentration of hexokinase in kinetics assays was 1.2–2.0 µg/ml and the assay volume was 
1 ml.  The assay buffer was 80 mM Tris (pH 8.0), 0.4 mM NADP, 3 mM MgCl2 and 2 mM 
Glc. 
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Crystal Preparation— All the crystals were grown by the hanging drop method.  Wild-type 
or mutant forms of HKI stored in 25 mM KPi (pH 7.5), 1 mM glucose, 1mM dithiothreitol 
(DTT) was concentrated to 20–30 mg/ml in 50-kDa cut-off centrifugational filtration tube, 
then subject to 12–15 cycles of wash at 4 ºC with 2–3 volumes of a ligand buffer.  The 
ligand buffers are 40 mM α-Glc-1,6-P2 or 20 mM Glc-6-P, all pH 7.5, with 1 mM Glc.  3 µl 
of the resulting solutions, containing 15–20 mg/ml protein in the ligand buffer, was combined 
with an equal volume of precipitant solution containing 4.5-6.5% (w/v) polyethylene glycol 
4000 or polyethylene glycol 8000, 0.1 M sodium acetate and 0.1 M sodium citrate, pH 6.0.  
The drops equilibrated against 0.5 ml of the precipitant solution.  Prismatic needles of 
length 0.5–0.8 mm and width 0.2–0.3 mm grew in two to three weeks at 4 ºC.  Crystals 
were transferred sequentially to a solution containing 1:1 ratio of the corresponding 
precipitant solution and 20% glycerol, and then to 1:1 ratio of the corresponding precipitant 
solution and 40% glycerol before flash freezing in liquid nitrogen. 
X-ray Diffraction Data— X-ray diffraction data for D413N•Glc-6-P and D413N•Glc-1,6-P2 
were collected at APS SBC-sec19.  Diffraction data were processed with HKL-3000[33]. 
Structure Determination, Model Building and Refinement— All crystals has unit cell 
parameters isomorphous to those of the P21 crystal form published previously[15-17, 34].  In 
these crystal forms, HKI is a homodimer consistent with the results of ultracentrifugation 
studies[37], which reports the dimer prevails at concentrations of protein above 1 mg/ml in the 
presence of saturating concentrations of Glc and Glc-6-P.  Crystal structures were solved by 
molecular replacement using the HKI•Glc-6-P•Glc complex (PDB entry 1HKB)[15], less 
ligands and water molecules.  The program AMoRe or Molrep from CCP4 suite was used in 
calculation of rotation and translation functions, based on data to 3 Å resolution[35, 36].  The 
program RefMac from CCP4 suite was used to refine the structures[37].  Further refinement 
employed CNS with hydrogen bond restraints[38].  Manual adjustments in the conformation 
of specific residues employed the program XTALVIEW[39]. 
Molecular Dynamics Simulations— NAMD package with the CHARMM 27 force field was 
used for molecular dynamics simulations on hexokinase I[40, 41].  The initial coordinates 
came from chain A of each of the crystalline complexes.  TIP3P water molecules were 
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added into a rectangular water box surrounding the single molecule of HKI with a buffering 
distance of 15 Å[42].  To balance the net charge of system, sodium and chloride ions were 
added.  Periodic boundary conditions were applied and the Particle mesh Ewald algorithm 
was used for the calculation of long-range electrostatic interactions[43].  Non-bonded Van 
der Waals interactions were applied with a cutoff of 12 Å.  The integration time step was 
2.0 fs.  All models were energy-minimized for 100 ps and gradually heated to 300 K to 
relax unfavorable contacts (if any), followed by another 100 ps simulation to equilibrate the 
system.  Finally, simulations of 10 ns were carried out at constant pressure and temperature 
(1.01325 bar and 300 K). 
Principal Component Analysis (PCA) Principal component analysis was applied to extract 
functionally important motions from simulations.  Rigid-body translations and rotations of 
the tetramer were removed before PCA by aligning trajectory structures onto the starting 
structure.  Principle components were calculated by decomposing the covariance matrix C 
which was calculated from the molecular dynamics trajectory as: 
( ) ( )jjiiij rrrrC −•−= ,   
where i,j = 1,...3N, N is the total number of Cα atoms in the structure, r is the Cartesian 
coordinates of ith Cα atom, and the angle brackets denote an average over the entire trajectory.  
The Carma package was used in PCA analysis and VMD was used to visualize the principal 
motions[47,48]. 
 
Results 
Kinetics of wild-type and mutant hexokinases— Asp413 and Asp861 hydrogen bond with the 
1-OH group of Glc-6-P (bound as the β-anomer in crystal structures), so mutations here were 
not expected to have a substantial effect on inhibition of HKI by 1,5-anhydroGlc-6-P or 
Glc-1,6-P2 as the former lacks the 1-OH group altogether and the latter is a 
phosphoryl-linked α-anomer.  Parameters (Table I) for 1,5-anhydroGlc-6-P are reproduced 
from Chapter 2 to facilitate the comparison to those for Glc-1,6-P2.  The effects of the same 
series of mutations as probed by the two inhibitors differ significantly.  1,5-AnhydroGlc-6-P 
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is a nonlinear competitive inhibitor of all four enzymes, whereas Glc-1,6-P2 is a linear 
competitive inhibitor at concentrations up to 400 µM.  A second molecule of Glc-1,6-P2 
binds to HKI with a dissociation constant of approximately 3 mM, approximately 10-fold 
higher than KII (240 µM) reported for 1,5-anhydroGlc-6-P (Figure 1).  The effect of single 
mutations at position 413 and 861 is a uniform decrease in the KI of Glc-1,6-P2, whether the 
mutation is at the N-terminal or C-terminal half.  The effect of the double mutation 
(D413/861N) appears additive, its KI approaching that of 1,5-anhydroGlc-6-P for the 
wild-type enzyme.  Same mutations cause KI of 1,5-anhydroGlc-6-P to increase and KII to 
decrease. 
Motivation for the mutation of Lys418 and Lys866 come from crystallographic 
structures and molecular dynamics simulations (details of which follow in the results section) 
which indicate an important role for the side chains at positions 418 and 866 in stabilizing 
hydrogen bonds between inhibitor and protein.  Parameters from kinetics of K418A and/or 
K866A verify the significance of lysines at positions 418 and/or 866 (Table II).  Inhibition 
by 1,5-anhydroGlc-6-P is 2- to 8-fold weaker for mutant enzymes relative to wild-type or 
mini HKI.  Pi-relief of 1,5-anhydroGlc-6-P inhibition is greatly reduced in constructs that 
include K418A, even though position 418 is relatively far from the binding site for Pi at the 
N-terminal half. 
Crystalline Complex of D413N HKI with Glc-1,6-P2— Wild-type HKI did not form quality 
crystals in the presence of Glc-1,6-P2, even though control crystallization experiments 
produced good crystals with Glc-6-P.  Glc-1,6-P2, however, binds with higher affinity to 
D413N HKI than to wild-type enzyme, and this mutant enzyme produced crystals (Table III) 
isomorphous to those of the Glc/Glc-6-P complex of the wild-type enzyme[15] (Figure 2).  
Superpositions of single chains from the Glc/Glc-1,6-P2 complex with D413N HKI give 
root-mean-square deviations of less than 0.5 Å.  Each asymmetric unit contains a 
homodimer with observable electron density for residues 16–914.  The polypeptide chain 
crosses three times between large and small domains; residues 16–74 and 210–447 belong to 
the large domain and residues 75–209 and 448–466 to the small domain of the N-terminal 
half and residues 467–522 and 658–895 belong to the large domain and residues 523–657 
and 896–914 to the small domain of C-terminal half.  The two halves of each subunit 
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contain molecules of Glc and Glc-1,6-P2 bound to a crevice between large and small 
domains. 
Glc-1,6-P2 is associated with strong electron density in the C-terminal half and 
relatively weak density at the N-terminal half, as has been recognized in previously reported 
crystal structures of 6-phosphoryl ligand complexes of wild-type HKI.  Nonetheless, 
hydrogen bonds between Glc-1,6-P2 and the N- and C-terminal halves are comparable, and 
aside from differences due to the α-1-phosphoryl group, are similar to those of Glc-6-P 
(Table IV).  Hydrogen bonds evidently peculiar to the Glc-1,6-P2 complex involve R91/539 
and 1-phosphoryl group (Figure 3).  In addition, the structure reveals a hydrogen bond 
between Lys866 and the backbone carbonyl of Ser893 that draws residues 893-897 closer to 
the ligand and stabilizes the interaction between 2-hydroxyl group of the inhibitor and 
Ser897 (Figure 4). 
Molecular Dynamics Simulation of the D413N HKI with Glc-1,6-P2— All simulations 
presented here begin with the equilibration of a crystallographic structure of the ligated 
complex of HKI.  Root-mean-square deviations (RMSD) of Glc-1,6-P2 at the C-terminal 
half are higher than those at the N-terminal half (Figure 5), and comparable to the difference 
observed for Glc-6-P in previous work (Chapter 2, this thesis).  The systematic difference in 
RMSD values is due primarily to the movement of loop 533–538 away from the 
6-phosphoryl group of the ligand (Figure 3), allowing additional space in the binding pocket.  
Elevated movement of Glc-1,6-P2 at the C-terminal half, however, does not lead to ligand 
dissociation or a bimodal distribution in principal component analysis.  The distribution of 
conformational states as represent by the two principal components in the simulation of 
D413N HKI with Glc-1,6-P2 is unimodal and much like that observed for Glc-6-P (Figure 6). 
Thr536 forms hydrogen bonds with the 6-phosphoryl group of the Glc-1,6-P2 in the 
crystal structure, but hydrogen bonds are virtually nonexistent over the simulation (Tables V 
& VI).  In contrast, hydrogen bonds between Ser88 and the 6-phosphoryl group of 
Glc-1,6-P2 are present at levels of 100%.  The simulation of Glc-6-P in the D413N HKI 
reveals a different outcome: hydrogen bonds are established between Thr536 (as well as 
Ser88) and the 6-phosphoryl group (Table VI).  The 1-phosphoryl group of Glc-1,6-P2 
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group makes hydrogen bonds with Arg91 (N-terminal half) and Arg539 (C-terminal half) 
over the entire simulation, as observed in the crystal structure (Figure 3).  Furthermore, the 
1-phosphoryl group of Glc-1,6-P2 group makes hydrogen bonds with Lys418 (N-terminal 
half) and Lys866 (C-terminal half) over the entire simulation; and this is not seen in the 
crystal structures (Figure 3). 
The simulation of D413N or wild-type enzyme with Glc-6-P reveals a stable 
hydrogen bond between Asn413 or Asp413 (N-terminal half) and Asp 861 (C-terminal half) 
with 1-hydroxyl group of Glc-6-P.  In the simulation of D413N HKI with Glc-1,6-P2, 
however, no such hydrogen bonds exist because of the substitution of 1-α-phosphoryl for the 
1-β-hydroxyl group.  Instead, Asn413 forms a hydrogen bond with the backbone carbonyl 
of Gly448 (in 25% of frames), and Asp861 forms a hydrogen bond with side chain of Ser893 
(in 61% of frames).  A stable hydrogen bond exists between Asp861 and Lys866 (90% of 
frames) during the simulation of D413N HKI with Glc-1,6-P2, but its counterpart (hydrogen 
bond between Asn413 and Lys418) at the N-terminal half is nearly absent (present in 5% of 
frames).  By comparison, Asn413 and Lys418 from a hydrogen bond (52% of frames), and 
so too do Asp861 and Ly866 (99% of frames), in the simulation of D413N HKI with Glc-6-P.  
The simulation of wild type enzyme with Glc-6-P exhibited stable hydrogen bonds at both 
halves (99% of frames). 
 
Discussion 
Wild-type, D413N and/or D861N forms of HKI exhibit nonlinear competitive inhibition by 
1,5-anhydroGlc-6-P with respect to ATP[19].  Moreover, the stoichiometric constants for the 
dissociation of 1,5-anhydroGlc-6-P from singly-ligated HKI and doubly-ligated HKI, were so 
close in value as to require a model of synergistic binding to sites of unequal affinity 
(Chapter 2, this thesis).  Synergism in binding hypothetically comes from an alternative 
binding mode for 1,5-anhydroGlc-6-P to the C-terminal half as revealed by a molecular 
dynamics simulation.  Glc-1,6-P2, however, should not favor this alternative binding mode 
because of unfavorable steric effects between its α-1-phosphoryl group and the protein.  
Hence, wild-type, D413N and/or D861N should exhibit only linear competitive inhibition 
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with respect to ATP, as is indeed the case (Table I) and principal component analysis should 
exhibit a unimodal distribution indicative of a single binding mode, which is evident from 
Figure 6. 
Asp413 and Asp861 in the wild-type enzyme would have unfavorable electrostatic 
interactions with the 1-phosphoryl group of Glc-1,6-P2, and hence mutations of these 
residues to asparagines could enhance binding affinity by the reduction of negative charge.  
On the other hand, the loss of charge at positions 413 and 861 could destabilize hydrogen 
bonding networks involving Lys418 and Lys866 (Asp413 and Asp861 interact directly with 
Lys418 and Lys866, respectively), and as a consequence weaken interactions with the 2-OH 
group of the inhibitor.  1,5-AnhydroGlc-6-P derives no benefit in the reduction of negative 
electrostatic charge, hence its KI rises due to mutations at 418 and 861 (Table I).  Evidently, 
the reduction of negative charge more than compensates for the weakening of hydrogen 
bonds causing KI values of Glc-1,6-P2 to decrease. 
Simulations with 1,5-anhydroGlc-6-P and Glc-6-P put the high affinity site at the 
N-terminal half (Chapter 2, this thesis), and here a simulation of the Glc-1,6-P2 complex with 
D413N HKI indicates a loss of interaction with Thr536 (C-terminal half) while hydrogen 
bonds persist between protein and ligand at the N-terminal half (Table VI).  Again, as for 
Glc-6-P and 1,5-anhydroGlc-6-P, RMSD values for Glc-1,6-P2 are consistent with tighter 
interactions at the N-terminal half relative to the C-terminal half.  These observations favor 
the model of inhibition proposed by Wilson. 
Partial relief of inhibition exhibited by K418A is not consistent with the Wilson 
model in which Pi and inhibitor are mutually exclusive in binding to a single site.  Indeed, 
although Lys418 is in the N-terminal half, its location is removed from the binding site for Pi, 
and more likely to weaken interactions with inhibitor without loss of binding affinity for Pi.  
Although Pi-relief of 85% is not 100%, the prevailing belief has been one of mutually 
exclusive binding of Pi and inhibitor[5].  The existence of K418A HKI with 50% Pi-relief 
forces reexamination of existing models of allosteric regulation, leading directly to Scheme I: 
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Scheme I 
As glucose is saturating in Scheme I, all enzyme states have bound glucose, [A] 
represents the concentration of [ATP-Mg]2–, [P] the concentration of Pi, and [I] the 
concentration of 1,5-anhydroGlc-6-P.  Scheme I differs from past models in allowing 
1,5-anhydroGlc-6-P (I) and Pi (P) to form an EPI complex.  This complex has Pi bound to 
the N-terminal half, eliminating the high-affinity site for inhibitor (by direct displacement or 
allostery), and in addition a molecule of inhibitor bound to the C-terminal half with relative 
low affinity.  The relationship of reciprocal velocity to [A], [I], [P] and Vmax (maximum 
velocity) is given by Eqn. 1 as follows: 
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Eqn. 1 can be simplified by letting [P] to go to infinity, and having 	   (conditions of 
assay) and    (Michaelis constants for ATP are independent of Pi levels).  The 
resulting equation is as follows: 
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A plot of 1/V versus [I] at saturating concentrations of Pi is linear (as observed), and KPI is 
one-half of the intercept divided by the slope. 
KPI values run from 45–100 µM for 1,5-anhydroGlc-6-P and 210–520 µM for 
Glc-1,6-P2 (Table VIII).  In the presence of saturating Pi, inhibition by Glc-1,6-P2 is weaker 
(KPI higher) than that caused by 1,5-anhydroGlc-6-P, and yet Pi-relief is consistently greater 
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for 1,5-anhydroGlc-6-P than Glc-1,6-P2.  Moreover, K418A has 50% Pi-relief, but its KPI 
with respect to 1,5-anhydroGlc-6-P is identical to that of wild-type enzyme which exhibits 85% 
Pi-relief (Table VI).  These apparent discrepancies stem from the dependence of Pi-relief on 
KI.  In fact if KII is large, then Pi relief  100  (1KI/KPI).  In the case of K418A, KI 
increases twofold, but KPI remains unchanged.  Hence, the decrease in Pi-relief due to the 
K418A mutation results from an increase in KI with no change in KPI.  For the mutation 
K866A, KPI increases 6-fold, but KI also increases so that Pi-relief is unchanged from that of 
the wild-type enzyme. 
The KPI parameter here offers several advantages and potential insights heretofore not 
appreciated.  Firstly, KPI is a more reliable parameter than KI or KII.  KI (and hence KII) is 
sensitive to uncontrolled levels of Pi (contaminants of substrates and/or inhibitors) or sulfate 
(incomplete dialysis of coupling enzymes), whereas the determination of KPI occurs in the 
presence of saturating Pi.  Secondly, KPI is a direct measure of a site affinity constant, the 
dissociation of inhibitor from a Pi-HKI complex that has only a single binding site for 
inhibitor.  That binding site, given the overwhelming evidence for the binding of Pi to the 
N-terminal half, must be at the C-terminal half.  Indeed, mutations in the C-terminal half 
cause significant changes in KPI (Table VIII), whereas most mutations to the N-terminal half 
have little effect.  Thirdly, a mutation in the N-terminal half that changes KPI could result 
from a perturbation to the allosteric machinery linking the N- and C-terminal halves of HKI. 
The second attribute of KPI listed in the foregoing is of particular interest.  KPI as a 
site-dissociation constant for inhibitor at the C-terminal half is a possible measure of the 
site-affinity constant  ! " introduced in Chapter 2 of this thesis.  Given numerical values 
for KI, KII and  ! ", one can calculate a value for α and  !  for any HKI construct as 
follows: 
#  $  ! "%" &$  ! "  %'(   and  !   #   ! "    Eqn. 3 
Values of α,  ! " and  !  for each HKI construct studied here are in Table VIII.  Values 
for α vary over a relatively narrow range.  The addition of ± 2σ to values of KII change α, 
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but values for  !  are not altered.  (As α is proportional to 1/KII in Eqn. 3, fixed values of 
KI and  ! " require the product α to be constant.  Hence,  !   α   ! " must 
also be constant).  We see from Table VIII that the mutation of Lys418 to alanine causes a 
5-fold increase in  !  and redefines the high-affinity binding site as  ! " (which remains 
unchanged from that of the wild-type enzyme), that is the C-terminal half has now the site of 
high-affinity, and not surprisingly, Pi-relief has fallen to 44% (Table II).  The mutation of 
Lys866 to alanine on the other hand, increases  ! " by 6-fold, but causes only a twofold 
increase in  ! .  Hence, the site of high affinity remains at the N-terminal half.  Finally 
K418/866A causes a 7.6-fold increase in  ! " (C-terminal half) and a 9-fold increase in 
 !  (N-terminal half) relative to the wild-type enzyme.  By teasing out site-dissociation 
constants from the data, the effects of single and double mutations are consistent and clear.  
Values for KI and KII alone, however, do not reveal the impact of a specific mutation on 
inhibitor binding to a specific site. 
The mechanism of inhibition due to Glc-1,6-P2 stands in contrast to that 
1,5-anhydroGlc-6-P for all but the wild-type enzyme.  Two inhibitor molecules bind with 
antagonism to the wild-type enzyme (α significantly below unity); however, for the D413N 
and/or D861N mutant enzymes, two molecules of 1,5-anhydroGlc-6-P bind with synergism, 
whereas two molecules of Glc-1,6-P2 bind with antagonism.  Although the value of KII for 
Glc-1,6-P2 is uncertain, values as low as 500 µM (clearly not observed from the kinetics data) 
would still require α less than unity.  Hence, the mechanism of inhibition of HKI is not only 
sensitive to single mutations, but also dependent on the molecular structure of the inhibitor.  
In fact, Glc-1,6-P2 might better approximate the properties of Glc-6-P than does 
1,5-anhydroGlc-6-P on the basis of molecular dynamics simulation presented here and in 
Chapter 2 of this thesis. 
In the brain cell, intracellular concentrations of Glc are close to 5 µM, hence the 
concentration of Glc-6-P may never rise to a level that directly inhibits the C-terminal half.  
Pi-relief then is adequate by itself in countering product inhibition.  The situation in the red 
blood cell, however, may be different as serum levels of Glc are millimolar, and Glc-6-P 
concentrations are substantial relative to KPI.  Logically one would anticipate an additional 
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mechanism to relieve product inhibition, and indeed the effect of Glc on product inhibition 
seems a likely place to look for such a mechanism[46].  In the next Chapter of this thesis we 
show that the weak inhibition of HKI by 1,5-anhydroGlc-6-P is sensitive to the concentration 
of Glc. 
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Table I.  Kinetics parameters for wild-type and mutant forms of HKI.# 
 
 
#Assays were in 80mM Tris, pH8.0, 1mM DTT, 0.4mM NADP, 3 mM MgCl2 along with varying amounts of 
[ATP-Mg]2–, Glc, Pi and/or 1,5-anhydroGlc-6-P.  In the determination of KmGlc, the concentration of Glc varied 
from 1/ 6 KmGlc to 10 KmGlc and that of [ATP-Mg]2– was fixed at 9mM.  In the determination of KmATP, the 
concentration of [ATP-Mg]2– varied from 1/6 KmATP to 6 KmATP and that of Glc was fixed at 2 mM.  In the 
determination of inhibition constants KI and KII for 1,5-anhydroGlc-6-P, the concentration of [ATP-Mg]2– varied 
from 1/2 KmATP to 4 KmATP, that of 1,5-anhydroGlc-6-P from 20 to 100 µM and that of Glc was fixed at 2 mM.  
Values for KI and KII were obtained by fitting data to a model of nonlinear competitive inhibition, the equation 
for which is as follows:  
*  *+,- .1  0+12  1 34  +1 4   5 34  +1   4   5" 34 6(
 
where S and I are concentrations of [ATP-Mg]2– and 1,5-anhydroGlc-6-P, respectively.  In the determination of 
inhibition constant Ki for Glc-1,6-P2, the concentration of [ATP-Mg]2– varied from 1/2 KmATP to 6 KmATP, that of 
Glc was fixed at 2 mM, and that of Glc-1,6-P2 from 40 to 400 µM for wild-type HKI, 40 to 240 µM for D413N, 
40 to 160 µM for D861N and D413N/D861N.  Values for Ki were obtained by fitting data to a model of linear 
competitive inhibition, the equation for which is as follows:   
*  *+,- .1  0+12  1 34  +1 4   5 34 6(
 
Pi-relief of inhibition is defined as 100(A-B)/A, where A is the slope from plots of reciprocal relative velocity 
versus the concentration of 1,5-anhydroGlc-6-P or Glc-1,6-P2 in the absence of Pi, and B is the slope from plot 
of reciprocal relative velocity versus inhibitor concentration in the presence of 3 or 6 mM Pi.  Relative velocity 
is the ratio of velocity at a specific concentration of inhibitor to the velocity in the absence of inhibitor.  The 
[ATP-Mg]2– concentration is fixed at KmATP.   
aInhibition constants with respect to 1,5-anhydroGlc-6-P. 
bInhibition constants with respect to Glc-1,6-P2. 
 
HKI kcat 
s-1 
KmGlc 
µM 
KmATP 
mM 
KIa 
µM 
KIIa 
µM 
Pi-Relief/ 
1,5-anhydr
oGlc-6-P 
% 
Kib 
µM 
Pi-Relief/
Glc-1,6-P2 
% 
WT 92 ± 1 45 ± 3 1.03 ± 0.02 20 ± 3 240 ± 50 85 169 ± 4 65 
D413N 82 ± 1 57 ± 2 0.98 ± 0.06 23 ± 4 80 ± 20 80 106 ± 6 78 
D861N 9.4 ± 0.1 37 ± 1 2.02 ± 0.09 30 ± 4 80 ± 20 86 67 ± 2 71 
D413N/D861N 10.0 ± 0.1 32 ± 2 1.59 ± 0.06 35 ± 5 110 ± 40 78 44 ± 2 72 
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Table II.  Kinetics parameters for wild-type and mutant forms of HKI.# 
 
HKI kat 
s-1 
KmGlc 
µM 
KmATP 
mM 
KI 
µM 
KII 
µM 
Pi-Relief 
% 
Wild-type 92 ± 1 45 ± 3 1.03 ± 0.02 20 ± 3 a 240 ± 50 85 
Mini-HKI 40 ± 1 30 ± 3 0.95 ± 0.05 12.5 ± 0.6 b NAc NRc 
K418A 63 ± 1 88 ± 4 0.93 ± 0.05 44 ± 4 1100 ± 500 44 
K866A 66 ± 2 63 ± 4 1.48 ± 0.09 70 ± 10 400 ± 300 89 
K418A/K866A 71 ± 1 56 ± 2 1.1 ± 0.1 170 ± 20 1500 ± 700 52 
mini-K866A 41 ± 1 43 ± 3 2.9 ± 0.2 60 ± 3 b NAc NRc 
#Assays were in 80mM Tris, pH8.0, 1mM DTT, 0.4mM NADP, 3 mM MgCl2 along with varying amounts of 
[ATP-Mg]2–, Glc, Pi and/or 1,5-anhydroGlc-6-P.  In the determination of KmGlc, the concentration of Glc varied 
from 1/ 6 KmGlc to 10 KmGlc and that of [ATP-Mg]2– was fixed at 9 mM.  In the determination of KmATP, the 
concentration of [ATP-Mg]2– varied from 1/6 KmATP to 6 KmATP and that of Glc was fixed at 2 mM.   
aIn the determination of KI and KII for 1,5-anhydroGlc-6-P the concentration of Glc was fixed at 2 mM, that of 
[ATP-Mg]2– varied from 1/2 KmATP to 4 KmATP, that of 1,5-anhydroGlc-6-P from 12 to 200 µM for wild-type, 
K418A and K866A, from 25 to 400 µM for K418A/K866A double mutant.  Values for KI and KII were 
obtained by fitting data to a model of nonlinear competitive inhibition, the equation for which is as follows:  
*  *+,- .1  0+12  1 34  +1 4   5 34  +1   4   5" 34 6(
 
where S and I are concentrations of [ATP-Mg]2– and 1,5-anhydroGlc-6-P, respectively.  Pi-relief of inhibition 
is defined as 100(A-B)/A, where A is the slope from plots of reciprocal relative velocity versus the 
concentration of 1,5-anhydroGlc-6-P or Glc-1,6-P2 in the absence of Pi, and B is the slope from plot of 
reciprocal relative velocity versus inhibitor concentration in the presence of 3 or 6 mM Pi.  Relative velocity is 
the ratio of velocity at a specific concentration of inhibitor to the velocity in the absence of inhibitor.  The 
[ATP-Mg]2– concentration is fixed at KmATP.   
bIn the determination of KI for 1,5-anhydroGlc-6-P, the concentration of [ATP-Mg]2– varied from 1/2 KmATP to 6 
KmATP, that of Glc was fixed at 2 mM, that of 1,5-anhydroGlc-6-P from 20 to 100 µM for mini-HKI, 30 to 160 
µM for mini-K866A. Values for KI were obtained by fitting data to a model of linear competitive inhibition, the 
equation for which is as follows:   
*  *+,- .1  0+12  1 34  +1 4   5 34 6(
 
cN.A.: Not Applicable;  N.R.: No Relief. 
 
 
 
 
 
 
 Table III. Statistics of data collection and refinement Statistics for HKI complex with 
Protein 
Ligand 
Space group 
Unit cell parameters
a (Å) 
  b (Å) 
  c (Å) 
α (°) 
β (°) 
γ (°) 
Resolution limits (Å)
No. of reflections
No. of unique reflections
% Completeness (overall)
% Completeness (last shell)
Rsym a 
R-factor b 
Rfree c 
No. of atoms in refinement
No. of water molecules
Mean B parameters (Å
   Main chain 
   Side chain 
  Glucose, N-half
  Glucose, C-half
  Phosphoryl ligand, N
  Phosphoryl ligand, C
Root mean square deviations 
   Bond lengths (Å)
Bond angles (°)
#Data reproduced from Chapter 2 to facilitate the comparison to those for
aRsys = j i|Iij- Ij |/ i jIij, where 
crystallographically unique intensities.
bR-factor = Fobs  Fcalc / |F
cRfree- is based upon 10% of the data 
 
Glc-6-P or Glc-1,6-P2. 
Wild-type# D413N# D413N 
Glc-6-P Glc-6-P Glc-1,6-P
P2(1) P2(1) P2(1) 
    
82.63   82.607 82.255 
121.53 121.140 120.748
119.83 119.888 120.556
90 90 90 
92.82 92.69 92.62 
90 90 90 
 37.90-2.65 44.15-2.48 35.41-2.40
 245322 3458364 1901444
 68327 83067 92019 
 99.22 98.47 98.52 
 98.99 84.92 95.11 
0.061 0.070 0.046 
0.2421 0.2391 0.2472 
0.2565 0.2527 0.2729 
 14481 14394 14497 
 273 186 275 
2)     
55 61 53 
57 63 55 
 45 52 45 
 35 40 36 
-half 51 78 52 
-half 35 42 32 
    
 0.004 0.004 0.004 
 0.907 0.889 1.070 
 Glc-1,6-P2. 
i runs over multiple observations of the same intensity and 
 
obs|, Fobs > 0. 
randomly culled and not used in the refinement. 
73 
2 
 
 
 
 
j runs over 
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Table IV. Donor-acceptor distances between phosphoryl ligand and protein in crystal 
structures# 
(Two chains are listed separately with at least one donor-acceptor distance 7 3.2 Å.) 
Phosphoryl 
Ligand Residue 
Wild-type/Glc-6-P D413N/Glc-6-P D413N/Glc-1,6-P2 
NA NB CA CB NA NB CA CB NA NB CA CB 
O1 
D/N413/861$:OD1 2.9 3.1 
  
3.5 3.2 
  
    
D/N413/861$:O/ND2 2.7 2.5 2.6 3.1 2.5 3.0 2.5 3.3     
O2 
D84/532:OD2 2.5 2.9 2.8 2.8 2.5 2.8 2.8 2.7 2.9 3.1 2.9 3.0 
R91/539:NH1 
    
2.7 4.9 
  
    
S449/897:N 3.7 3.1 2.9 2.8 3.3 3.2 2.8 3.0 3.5 3.2 3.0 3.1 
S449/897:OG 
  
3.2 3.6 
    
    
O3 
D84/532:OD1 2.5 2.8 2.7 2.9 3.2 3.0 2.8 3.0 2.9 3.1 2.7 2.8 
D84/532:OD2 2.7 3.3 
  
2.7 3.2 
  
2.5 3.1   
S449/897:OG 2.9 2.7 2.5 2.7 2.8 2.8 2.5 2.8 3.5 2.9 2.6 3.1 
O4 D209/657:OD2 2.8 2.7 2.9 2.6 2.7 2.7 2.9 2.5 2.8 2.9 3.0 2.6 
O1P 
S88/T536:N 3.1 3.6 
  
3.1 3.6 
  
    
S88/T536:OG(1) 
        
    
T232/680:N 3.1 2.9 2.8 2.9 3.4 2.8 2.9 2.9 2.9 3.0 2.7 2.9 
T232/680:OG 2.5 2.5 2.7 2.8 2.6 2.6 2.7 2.9 2.5 2.6 2.8 2.8 
O2P 
S88/T536:OG(1) 2.7 4.2 
  
3.2 3.5 
  
    
T232/680:N 3.3 3.2 
  
3.1 3.8 
  
    
S415/T863:N 2.8 2.9 2.9 2.9 2.8 3.1 2.8 2.8 2.8 3.0 2.9 3.0 
S415/T863:OG(1) 2.6 2.7 2.6 2.5 3.2 2.5 2.8 2.5 2.8 2.7 2.6 2.5 
O3P 
S88/T536:N 2.8 2.9 2.9 2.9 3.3 2.7 2.8 3.0 2.9 3.1 3.1 3.1 
S88/T536:OG(1) 2.5 2.5 2.7 2.7 2.5 2.6 2.9 2.8 2.7 2.8 2.9 2.9 
O1P* 
N537:OD2 
        
  3.1 3.4 
R91/539:NH1 
        
3.7 2.9 3.0 5.2 
R91/539:NH2 
        
3.2 3.3 3.3 2.9 
#O1P, O2P and O3P are the oxygen atoms from 6-phosphoryl group.  O1P* is an oxygen atom from 
1-phosphoryl group of Glc-1,6-P2. 
$D/N413/861 means either D or N 413 from N-terminal half and D861 from C-terminal half. 
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Table V.  Fraction of frames from molecular dynamics simulations with hydrogen 
bonds between protein residues and 6-phosphoryl ligands$. 
Phosphoryl 
Ligand Residue 
Wild-type/Glc-6-P D413N/Glc-6-P D413N/Glc-1,6-P2 
N C N C N C 
O1 
D/N413/861:OD1 0.62 0.90 0.09 0.91 --- --- 
D/N413/861:O/ND2 0.52 0.69 0.68 0.62 --- --- 
K418/866:NZ 0.47 0.14 0.03 0.61 --- --- 
R91/539:NH2 --- --- --- --- 0.07 0.29 
O2 
D84/532:OD1 0.22 0.91 0.41 0.12 --- --- 
D84/532:OD2 0.79 0.87 0.73 0.86 --- --- 
R91/539:NH1 0.04 --- 0.02 0.07 0.06 --- 
R91/539:NH2 0.08 0.06 --- --- 0.07 0.33 
S449/897:N 0.45 0.15 0.26 0.56 0.26 0.13 
S449/897:OG 0.01 --- 0.01 0.03 0.02 0.02 
O3 
D84/532:OD1 0.85 0.98 0.81 0.81 0.33 0.10 
D84/532:OD2 0.70 --- 0.64 0.33 0.43 0.83 
D209/657:OD2 --- --- --- 0.05 --- --- 
S449/897:OG 0.90 0.96 0.86 0.98 0.89 0.79 
O4 
G87/535:N --- 0.54 --- 0.06 0.10 0.13 
D209/657:OD2 1.00 1.00 1.00 0.99 0.98 0.93 
Glc:O6 --- --- --- --- --- --- 
O1P 
S88/T536:N 0.48 --- 0.08 0.07 0.12 --- 
S88/T536:OG(1) 0.45 --- 0.20 --- --- --- 
T232/680:N 0.25 0.42 0.46 0.98 0.87 0.68 
T232/680:OG1 0.25 0.43 0.44 1.00 0.98 0.98 
S415/T863:N 0.20 --- 0.48 --- --- --- 
S415/T863:OG(1) 0.30 --- 0.58 --- --- --- 
O2P 
S88/T536:N 0.33 --- 0.56 --- --- --- 
S88/T536:OG(1) 0.46 --- 0.70 --- 0.02 --- 
T232/680:N 0.45 0.54 0.00 0.05 0.27 0.43 
T232/680:OG1 0.47 0.57 0.00 --- 0.05 0.15 
S415/T863:N 0.19 0.39 0.37 0.86 0.75 0.46 
S415/T863:OG(1) 0.25 0.43 0.43 1.00 1.00 1.00 
O3P 
S88/T536:N 0.27 0.04 0.42 0.99 0.99 0.04 
S88/T536:OG(1) 0.27 0.04 0.29 1.00 1.00 0.03 
T232/680:N 0.27 0.05 0.56 --- --- --- 
T232/680:OG1 0.29 --- 0.57 --- --- 0.03 
S415/T863:N 0.38 0.50 0.00 --- --- --- 
S415/T863:OG(1) 0.48 0.57 0.00 --- --- --- 
O1P* 
R91/539:NH1 --- --- --- --- 0.46 0.49 
R91/539:NH2 --- --- --- --- 0.39 0.32 
O2P* 
R91/539:NH1 --- --- --- --- --- 0.16 
K418/866:NZ --- --- --- --- 0.92 0.44 
O3P* 
R91/539:NH1 --- --- --- --- 0.72 0.46 
R91/539:NH2 --- --- --- --- 0.24 0.30 
K418/866:NZ --- --- --- --- 0.43 0.45 
$Donor-acceptor distance 7 3.2 Å between pairs of polar atoms infers the presence of a hydrogen bond.  The 
absence of a value indicates less than 0.01 of frames exhibited a hydrogen bond.  O1P, O2P and O3P are 
oxygen atoms of 6-phosphoryl group and O1P*, O2P*, O3P* are those of the 1-phosphoryl group of Glc-1,6-P2 
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Table VI. Fraction of frames from molecular dynamics simulations with hydrogen 
bonds between protein residues and the 6-phosphoryl groups of ligands$. 
 
Residue 
Wild-type/Glc-6-P D413N/Glc-6-P D413N/Glc-1,6-P2 
N C N C N C 
S88/T536:N$ 0.99 0.04 0.98 0.99 0.99 0.04 
S88/T536:OG(1)$ 0.92 0.04 0.96 1.00 1.00 0.03 
S88/T536# 1.00 0.04 1.00 1.00 1.00 0.04 
T232/680:N$ 0.96 0.97 0.99 0.98 0.95 0.90 
T232/680:OG1$ 1.00 1.00 1.00 1.00 1.00 1.00 
T232/680# 1.00 1.00 1.00 1.00 1.00 1.00 
S415/T863:N$ 0.76 0.89 0.85 0.86 0.75 0.46 
S415/T863:OG(1)$ 1.00 1.00 1.00 1.00 1.00 1.00 
S415/T863# 1.00 1.00 1.00 1.00 1.00 1.00 
 
$A pair of polar atoms define a hydrogen bond if the corresponding donor-acceptor distance is less than or equal 
to 3.2 Å. 
#Represents the fraction of frames with hydrogen bonds between any polar atom of the indicated protein residue 
and any atom of the 6-phosphoryl group. 
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Table VII. Fraction of frames from molecular dynamics simulations with hydrogen 
bonds between oxygen atoms of the 6-phosphoryl group and any polar atom from the 
protein$. 
 
 
Wild-type/Glc-6-P D413N/Glc-6-P D413N/Glc-1,6-P2 
N C N C N C 
O1P$ 0.99 0.44 1.00 1.00 0.99 0.99 
O2P$ 0.99 1.00 1.00 1.00 1.00 1.00 
O3P$ 1.00 0.61 0.99 1.00 1.00 0.06 
O1P*# 
--- --- --- --- 
0.67 0.56 
O2P*# 
--- --- --- --- 
0.94 0.63 
O3P*# 
--- --- --- --- 
0.97 0.91 
 
$A pair of polar atoms define a hydrogen bond if the corresponding donor-acceptor distance is less than or equal 
to 3.2 Å. 
 
 
 
  
78 
 
 
 
Table VIII. Kinetics parameters and site affinity constants with respect to 
1,5-anhydroGlc-6-P for wild-type HKI and mutants#  
(α unitless, others in µM) 
 
Inhibitor &construct KI KII α  !   ! "(KPI)  "    " 
1,5-AnhydroGlc-6-P: 
       
WT 20 ± 3 240 ± 50 0.38 30 62 ± 2 77 163 
D413N 23 ± 4 80 ± 20 1.15 47 45 ± 2 41 39 
D861N 30 ± 4 80 ± 20 1.77 43 98 ± 3 24 56 
D413/861N 35 ± 5 110 ± 40 1.37 55 95 ± 4 41 69 
K418A 44 ± 4 1100 ± 500 0.19 146 63 ± 7 768 332 
K866A 70 ± 10 400 ± 300 1.14 86 369 ± 34 76 324 
K418/866A 170 ± 20 1500 ± 700 0.49 270 460 ± 14 554 946 
Glc-1,6-P2:        
WT 169 ± 4 2900 ± 400 0.24 313 368 ± 15 1324 1560 
D413N 106 ± 6 2900 ± 400 0.23 133 518 ± 19 590 2294 
D861N 67 ± 2 2900 ± 400 0.11 98 211 ± 19 916 1968 
D413/861N 44 ± 2 2900 ± 400 0.10 54 233 ± 3 545 2339 
#KI, and KII are reproduce from Tables I & II.   0 2(KPI) is determined experimentally as described in the 
discussion section.  The following equations determine the coupling parameter α and the remaining site 
dissociation constants: 
#  02" 0  2( ;  0 1  #55   :5;  0 2  :5;  2 1   
0 1 #4 ;  1 2   
0 2 #4  
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Figure 1. Inhibition of wild-type HKI by 1,5-anhydroGlc-6-P (panel A) and Glc-1,6-P2 (panel B).  In the 
determination of KI and KII, the concentration of Glc was fixed at 2 mM, that of [ATP-Mg]2– varied from 1/2 
KmATP to 4 KmATP, that of 1,5-anhydroGlc-6-P from 12 to 200 µM, and that of Glc-1,6-P2 from 40 to 1000 µM.  
Values for KI and KII were obtained by fitting data to a model of nonlinear competitive inhibition, the equation 
for which is as follows: 
*  *+,- .1  0+12  1 34  +1 4   5 34  +1   4   5" 34 6(
 
 
where S and I are concentrations of [ATP-Mg]2– and 1,5-anhydroGlc-6-P or Glc-1,6-P2, respectively.  Values 
for the stoichiometric dissociation constants KI and KII for 1,5-anhydroGlc-6-P are 20±3 and 240±50 µM, 
respectively, and for G1c-1,6-P2 195 ± 10 and 2900±400 µM, respectively. 
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Figure 2.  Overview of the D413N/Glc-1,6-P2/Glc complex.  Large domains are gray and small domains 
white.  Glc-1,6-P2 and Glc are black as sticks.  (The illustration was generated with PyMOL). 
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Figure 3. The binding pocket of ligands from crystal structures (A, B, C) and MD simulations structures 
(D, E, F).  A, D, wild-type/Glc-6-P structures; B, E, D413N/Glc-6-P structures; C, F, D413N/Glc-1,6-P2 
structures.  (The illustration was generated with PyMOL). 
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Figure 4.  Loop 893–897 with related residues in D413N Glc-1,6-P2 crystal complex.  Donor-acceptor 
distances are in unit of Å.  (The illustration was generated with PyMOL). 
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Figure 5.  Root-mean-square deviation (RMSD) of atoms of phosphoryl ligands.  Deviations are 
calculated from superimposed N- or C-terminal halves taken over 10 nsec simulations of a single molecule of 
HKI, ligated at the N and C-terminal halves. 
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Figure 6.  Principal component analysis of HKI.  First two components of PCA based on all N-terminal 
half (A) or C-terminal half (B) structures from wild-type•Glc-6-P, D413N•Glc-6-P and D413N•Glc-1,6-P2  
molecular dynamics simulations.   
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Chapter IV.  Glucose as a Modulator of Inhibition in Recombinant 
Human Hexokinase Type I 
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Abstract 
Hexokinase I (HKI) catalyzes the initial step of glycolysis in brain and red blood cells. 
1,5-Anhydroglucitol 6-phosphate (1,5-anhydroGlc-6-P), an analog of the product glucose 
6-phosphate (Glc-6-P), inhibits by binding antagonistically to sites of unequal affinity at the 
N- and C-terminal halves of HKI.  Pi displaces 1,5-anhydroglucitol 6-phosphate from the 
N-terminal half, but is unable to displace inhibitor from the C-terminal half.  Presented here 
are the effects of glucose (Glc) on the inhibition of HKI.  Consistent with findings of 
multiple binding sites for Glc and Glc-6-P in crystal structures, the kinetics of HKI are 
nonlinear as a function of Glc and 1,5-anhydroGlc-6-P concentrations.  For wild-type HKI 
and mutant forms of HKI that eliminate the binding of inhibitor to either the N- or C-terminal 
half, two molecules of Glc must bind before the occurrence of potent inhibition.  High 
concentrations of Glc eliminate inhibition due to the binding of a second molecule of 
inhibitor to the wild-type enzyme, but mutant forms of HKI that have but one inhibitor 
binding site exhibit no Glc-relief of inhibition.  The relevance of these findings to the 
physiological function of HKI are as follows: at low concentrations of Glc typically found in 
brain cells, HKI may not be subject to strong product inhibition.  At normal levels of 
glucose in red blood cells, HKI can be potently inhibited by product.  At elevated levels of 
glucose common in hyperglycemia, product inhibition is potent but partial. 
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Introduction 
Glucose (Glc) is the main energy source for all mammalian cells and the sole energy source 
for brain[1].  In fact, approximately 40-50% of all circulating glucose in humans supports 
energy metabolism of the brain[2].  Only a short period of hypoglycemia causes permanent 
damage to brain[3].  Hexokinase (ATP: D-hexose 6-phosphotransferase, EC2.7.1.1) is the 
crucial enzyme in regulation of glucose metabolism and catalyzes the initial step of glucose 
phosphorylation using [ATP-Mg]2– as the phosphoryl donor[4-6].  In mammalian tissues, four 
isozymes of hexokinase have been identified[7].  Types I, II and III hexokinases, all with 
molecular weights of approximately 100 kDa, share 70% sequence identity[8].  N- and C- 
terminal halves of isozymes I–III show ~50% sequence identity, putatively a consequence of 
duplication and fusion of a primordial hexokinase gene[9-12].  Hexokinase IV (glucokinase) 
and yeast hexokinase isoforms A and B have molecular weights of 50 kDa, and exhibit 
significant sequence similarity to both halves of isozymes I–III[8]. 
Different isozyme of hexokinase has different tissue distributions and kinetic 
properties.  Hexokinase I is found in all mammalian tissues and is highly or even 
exclusively expressed in brain and red blood cells[4-6].  Hexokinase II is mainly expressed in 
insulin-sensitive tissues such as skeletal muscle and adipose tissue[13].  Hexokinase III is 
expressed at very low levels, and is associated with the cell nucleus[13].  Hexokinase IV is 
mainly present in liver, but also found in nuoroendocrine cells[13].  Both hexokinase I and II 
are overexpressed in many cancer cells[14-15].  The overexpression leads to protection against 
apoptotic cell death[14-15]. 
Both halves of hexokinase II possess catalytic activity, whereas the N-halves of 
hexokinase I and III are devoid of activity [8, 16-18].  The reaction product, 
glucose-6-phosphate (Glc-6-P), potently inhibits isozymes I-III (but not isoform IV) at 
physiologically concentrations[8].  Inorganic phosphate (Pi) is an inhibitor for hexokinase II 
and III[8].  However, Pi specifically antagonizes the inhibition of hexokinase I by 
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1,5-anhydroglucitol 6-phosphate (1,5-anhydroGlc-6-P, an analog of Glc-6-P used in kinetics) 
at relatively low concentrations, whereas at higher concentrations it acts as an inhibitor 
competitive with ATP[8]. 
Substantial evidence supports a single high-affinity binding site for Glc-6-P.  Both 
equilibrium dialysis experiments and fluorescence binding studies (Chapter 2, this thesis) 
indicate a single binding site for Glc-6-P with a submicromolar dissociation constant[19-20].  
Glc-6-P up to concentrations of 1 mM is a linear competitive inhibitor with respect to ATP[20].  
Other observations, however, point to multiple sites of inhibitor action and even two 
high-affinity sites.  Glc-6-P binds to both halves of HKI in crystal structures (Figure 1), and 
exhibit essentially identical hydrogen bonding interactions[2, 21-22].  Proteolytic cleavage of 
HKI produces an active C-terminal half (mini-HKI) and inactive N-terminal half[17, 23].  A 
high-affinity site for Glc-6-P exists in the N-terminal half and in mini-HKI, and inhibition of 
mini-HKI by 1,5-anhydroGlc-6-P is comparable to that of the intact enzyme, save for the loss 
of Pi-relief[17, 23-24].  1,5-anhydroGlc-6-P is a nonlinear competitive inhibitor with respect to 
ATP of wild-type HKI[25].  Separate mutations of the binding pocket for Glc-6-P at each half 
does not abolish 1,5-anhydroGlc-6-P inhibition, only the combined mutations at both N- and 
C-terminal halves eliminate inhibition[25-26]. 
These observations historically provide the basis for two models for HKI inhibition.  
Fromm and colleagues suggest that Glc-6-P inhibits the enzyme by binding to the C-terminal 
half, with the 6-phosphoryl group overlapping the γ-phosphate site for ATP and the 
glucopyranose moiety binding to a site distinct from the glucose pocket[20, 27-28].  Wilson and 
colleagues assigned Glc-6-P inhibition to an allosteric site at the N-terminal half[17, 23].  Both 
models have Pi as an antagonist of Glc-6-P inhibition, binding to a high-affinity site at the 
N-terminal half[8, 29].  These models have undergone revision over time.  The discovery of 
potent inhibition of mini-HKI necessitated an adjustment to the Wilson model, 
acknowledging the existence of a latent high-affinity site for inhibition at the C-terminal half 
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unmasked by the removal of the N-terminal half[8].  Similarly, the persistence of 
high-affinity inhibition by 1,5-anhydroGlc-6-P exhibited by T536A HKI is consistent only 
with a mechanism of allosteric inhibition[26].  To reconcile one high-affinity site in 
equilibrium binding studies and two sites indicate by crystal structures and mutant forms of 
HKI, Liu et al. proposed a model of equal high-affinity sites coupled by negative 
cooperativity[26].  Results of Chapters 2 and 3 of this thesis, however, clearly show binding 
sites for 1,5-anhydroGlc-6-P must have unequal affinity for inhibitor, with antagonistic 
coupling of inhibitor binding sites for the wild-type enzyme.  Moreover, Pi only displaces 
1,5-anhydroGlc-6-P from the N-terminal high-affinity site, leaving unchanged the residual 
inhibition due to the binding of inhibitor to the C-terminal half. 
Glucose binds tightly to both halves of HKI[2] (to the active site of the C-terminal half 
and to the vestigial active site of the N-terminal half) interacting with residues of identical or 
comparable type.  The effect of glucose on HKI is not entirely clear.  The binding of 
Glc-6-P or Pi to HKI is synergistic with glucose[17].  Nonetheless, Glc-6-P still binds with 
high affinity to HKI in the absence of glucose[19-20], and Wilson has assigned this 
glucose-independent binding site to the N-terminal half[23].  Synergistic interactions between 
glucose and Glc-6-P are also observed with mini-HKI but not the N-terminal half[17].  The 
observation of synergism between Pi and glucose in HKI is puzzling given the absence of 
synergism between glucose and Glc-6-P in the separate N-terminal half.  Even more 
perplexing is the partial relief of Glc-6-P inhibition due to high concentrations of Glc[30]. 
These results suggest important roles for glucose in Glc-6-P inhibition.  Presented 
here are studies of the effect of Glc and Glc-6-P on the fluorescence emission of TNP-ADP, a 
competitive inhibitor of HKI with respect to ATP.  In addition, the nonlinear response of the 
wild-type enzyme to the concentration of Glc divides into zones of low, moderate and high 
Glc concentrations.  The results are consistent with synergistic interactions between Glc 
binding to the active site and inhibitor binding to the C-terminal or N-terminal half of the 
93 
enzyme, that in fact the binding of Glc to the active site is necessary for potent inhibition.  
Glc concentrations in excess of 1 mM, however, antagonize inhibitor binding at the 
C-terminal half.  A kinetic mechanism is proposed here that accounts for 
1,5-anhydroGlc-6-P inhibition of HKI at the extraordinarily broad range of Glc 
concentrations observed in brain tissue and the red blood cell. 
 
Materials and methods 
Materials – The plasmids in vector pET11a for wild-type HKI and T232A, G896A and 
mini-HKI were available from previous studies (chapter 2, this thesis).  Escherichia coli 
strain DH5a and BL21 were from Invitrogen.  DNaseI, PMSF, leupeptin, bovine serum 
albumin (BSA), ATP, NADP, Glc-6-P, ampicillin were from Sigma.  1,5-anhydro-D-sorbitol 
was from Toronto Research Chemicals.  isopropyl-D-thiogalactopyranoside (IPTG) was 
from Bio-World.  DEAE sepharose CL-6B and CHT ceramic hydroxyapatite (HA) Type II 
media were from Bio-Rad.  DEAE-5PW HPLC media was from Tosohaas.  
Glusoe-6-phosphate dehydrogenase (G6PDH) was from Roche.  
2’-(or-3’)-O-(2,4,6-trinitrophenyl)-adenosine 5’- diphosphate (TNP-ADP) was from 
Invitrogen. 
Expression and Purification of Wild-type and Mutant Hexokinases— Plasmids for wild-type, 
T232A and G896A enzymes were developed as indicated in Chapters 2 and 5 of this thesis.  
A 200 ml culture of the transformed Escherichia coli BL21 was grown overnight at 37 ºC in 
LB medium (33 mg/L ampicillin) and then 1.5% cell were transferred to 9.6 L LB medium 
(33 mg/L ampicillin).  The culture was grown at 300 rpm and 37 ºC to A600=1.0.  The 
temperature then was reduced to 16 ºC, isopropyl-β-D-thiogalactopyranoside (IPTG) was 
added to a final concentration of 0.5 mM and the culture was grown at 200 rpm for 20-22 hr. 
at 16 ºC.  The cells were re-suspended in 25 mM KPi (pH 7.5), 5 mM glucose, 3 mM MgCl2, 
1 mM dithiothreitol (DTT), 1 mM phenylmethanesulfonyl fluoride (PMSF), 50 µg/ml 
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DNaseI and 5 µg/ml leupeptin.  The cells were broken by sonication and then centrifuged 
(33,000xg, 1 hr.).  The supernatant fluid was adjusted to pH 7.5 and loaded onto a 
DEAE-anion exchange column, using 25 mM KPi, 5 mM glucose, 1 mM dithiothreitol DTT 
(pH 7.5), with a gradient of 0–400 mM NaCl.  The fractions containing HKI activity were 
pooled, concentrated and dialyzed against 50 mM KPi (pH 7.0), 5 mM glucose, 1 mM 
dithiothreitol (DTT) and loaded onto a ceramics hydroxyapatite column with a gradient of 
0.05–1 M KPi (pH 7.0).  HKI was collected and dialyzed against 25 mM KPi, 5 mM glucose, 
1 mM dithiothreitol (DTT) (pH 7.5), and further purified by DEAE-5PW HPLC 
chromatography with a gradient of 0–500 mM NaCl.  The pure protein was identified by 
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)[31].  Protein 
concentration was determined by the method of Bradford with BSA as a standard[32]. 
TNP-ADP Binding and Displacement— Wild-type and mutant enzymes were prepared to a 
concentration of 40 mg/ml in 50 mM Hepes (pH 7.8) and 1 mM Glc, then diluted to a final 
concentration of 0.2 mg/ml (2 µM) in 50 mM Hepes (pH7.8) containing 5 µM Glc, 25 µM 
Glc, 75 µM Glc and 1 mM Glc, respectively before each experiment.  In binding 
experiments, TNP-ADP concentrations range from 0–10 µM, whereas in displacement 
experiments, the TNP-ADP concentration is 3.66 µM.  Fluorescence measurements were 
made at room temperature using a 1-cm2 quartz cuvette on a SLM Amico 8000 fluorometer 
with entrance/exit slits of 4 mm.  The excitation wavelength is 409 nm and emission scans 
are from 530 to 560 nm.  Fluorescence intensity (average of three scans for each datum) 
was integrated over 530–560 nm using 30 increments and an accumulation time of 1 sec per 
increment.  Fluorescence data were analyzed by the method described by Faller[33], as 
modified by Nimer et al.[34]. 
The observed fluorescence from a mixture of TNP-ADP and HKI comes from free 
TNP-ADP, TNP-ADP bound to HKI and HKI itself: 
   		 
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	 is an adjustable parameter (S) that accounts for background fluorescence due to the 
protein sample.  As HKI has no native fluorophore sensitive to an excitation wavelength of 
409 nm the parameter S should be a small value and nearly constant over the experiment 
presented here.    and   represent the total and free TNP-ADP concentrations, 
respectively.    is a fluorescence enhancement factor of the bound fluorescent ligand 
relative to the free state.  Parameters a, b and c are determined by fitting fluorescence versus 
 in the absence of protein, the data for which comes from the addition of TNP-ADP to 
buffer.  The same buffer is used for the binding and displacement experiments. 
A single binding-site model adequately accounts for the  of the bound state as 
well as the displacement of TNP-ADP by phosphoryl ligand Glc-6-P, or 2-deoxyGlc-6-P or 
Man-6-P: 
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$ and $ are total and free phosphoryl ligand concentrations, respectively;   and 
  are total and free protein concentrations, respectively.  !" and !% are constants for the 
dissociation of TNP-ADP and phosphoryl ligand from protein, respectively.  The 
equilibrium and mass conservation relationships for [Lo] (total fluorophore concentration), 
[Ao] (total concentration of displacing ligand) and [Po] (total concentration of protein) lead to 
a third-order equation in the concentration of free protein [P].  Substitution of the 
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equilibrium relationships into mass conservation relationships for protein leads to a 
third-order equation in the concentration of free protein [P].  For circumstances here, KA >> 
[P], allowing an approximation that reduces the third-order equation to one of second order: 
&1 
 $!( ) P 
 &
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The physical root of this quadratic relationship is the concentration of free protein, and 
determines the concentration of free fluorophore [L]=[Lo]KL/(KL+[P]) at a given total 
concentration of fluorophore, [Lo].  GraFit software optimizes the fit of the observed 
fluorescence to the right-hand side of Eqn. 1 at fixed [Po] and varying [Lo] and [Ao] by 
adjusting parameters KA, KL, G and Fprotein[35]. 
Hexokinase Kinetics Studies -- Hexokinase activity was determined by the 
glucose-6-phosphate dehydrogenase (G6PDH, E.C.1.1.1.49) - coupled fluorometric or 
spectrometric assay [36].  Commercial G6PDH in ammonium sulfate precipitate form was 
dialyzed extensively against 50mM Hepes (pH7.8) buffer (for fluorometric assay) and 50mM 
Tris (pH7.8) buffer (for spectrometric assay), repectively, to remove sulfate and eliminate the 
relief effect on Glc-6-P inhibition by mimicking Pi.  1,5-anhydroGlc-6-P is a surrogate for 
Glc-6-P to study Glc-6-P inhibition and the dicyclohexylamine salt of AnGlc-6-P was 
prepared as described by Ferrari R.[37].  The concentration was determined by the method 
described by Drueckes P.[38].  The concentration of hexokinase was 0.03-0.05 µg/ml for 
fluorometric assay and 1.2-2.0 µg/ml for spectrometric assay.  The Kinetic analysis was 
done with the computer program GraFit 7.0[35].   
 
Results 
Rationale for the Selection of Mutants— Besides the wild-type enzyme, three mutations were 
employed in this report to study the glucose-dependency of Glc-6-P binding and 
1,5-anhydroGlc-6-P inhibition.  Mini-HKI is the truncated C-terminal half of full-length 
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HKI[24, 26, 39-40].  The mutations T232A and G896A eliminate 1,5-anhydroGlc-6-P inhibition 
originating at the N-terminal half[26] and C-terminal half, respectively (Chapter 5, this thesis).  
All the above mutants have specific activity no worse than 50% of the wild-type enzyme.  
Although all the mechanisms of inhibition by 1,5-anhydroGlc-6-P are competitive with 
respect to ATP, the kinetic mechanisms of inhibition with respect to Glc have not been 
reported.  Preliminary work indicated a complex kinetic mechanism for the wild-type 
enzyme.  In principle, the investigation of mutants with only a single inhibitory mechanism 
could clarify phenomena exhibited by the wild-type system.  Wild-type and mutant 
hexokinases investigated here are at least 95% pure as determined by SDS-polyacrylamide 
gel electrophoresis (data not shown). 
TNP-ADP Binding and Displacement— As shown in Table I, and Figure 2.A, the parameters 
for baseline fitting were unaffected by changes in glucose concentrations.  TNP-ADP binds 
to wild-type HKI and all mutants with high affinity (KL < 0.6 µM).  Whereas dissociation 
constants for wild-type HKI, mini-HKI and T232A are nearly the same within experimental 
uncertainty, KL values for G896A are 3–4-fold higher than that of the other HKI forms.  All 
the forms of HKI exhibit 1.2–1.5-fold increase in KL (dissociation constant for TNP-ADP 
from the enzyme) and 1.05–1.15 fold increase in G (fluorescence enhancement factor) as 
glucose concentration increase from 5–1000 µM (Table I & Figure 4.A).  	 () 
values are close for each protein, indicating no unexpected fluorescence from any of the 
protein preparations.  The displacement of TNP-ADP by Glc-6-P becomes more effective as 
glucose concentrations increase; however, the Glc-dependency of Glc-6-P differs for each 
enzyme.  Relative to KA at 1 mM Glc, KA values at 5 µM Glc increase 1.1-, 1.4-, 3.3- and 
4.1-fold for G896A, wild-type HKI, T232A and mini-HKI, respectively (Table II, Figure 3 
and 4.B).  Evidently, wild-type HKI behaves more like G896A, whereas T232A behaves 
more like mini-HKI. 
Kinetics at High Glc Concentrations— Scheme I is a rapid-equilibrium model governing the 
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kinetics of wild-type HKI for Glc concentrations up to 10 mM, and is relevant to results of 
Figure 5. 
 
Scheme I 
In Scheme I, the association/dissociation of ligands are not shown explicitly, but can 
be deduced from the different ligation levels of the enzyme.  All equilibrium constants are 
stoichiometric constants of dissociation, with B, A, I, P and E representing Glc, [ATP-Mg]2–, 
1,5-anhydroGlc-6-P, Pi and wild-type HKI, respectively.  Scheme I leads to Eqn. 1: 
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Assumptions well-grounded in experimental data constrain some of the parameters of Eqn 1.  
On the basis of fluorescence binding data (Table I) the dissociation constant for TNP-ADP is 
not sensitive to the concentration of Glc.  Hence the dissociation of A from EA, EBA, EBBA 
and EBBBA is governed by the same constant Ka = KmATP.  As a consequence of 
thermodynamic cycles in Scheme I, Kb is the constant of dissociation of B from EB and EBA, 
Kbb is the constant of dissociation of B from EBB and EBBA, and Kbbb is the constant of 
dissociation of B from EBBB and EBBBA.  Glc is not a substrate inhibitor and kcat values for 
the conversion of EBBA and EBBBA into products must equal to within experimental error 
(linear behavior of reciprocal velocity at high concentrations of Glc in the absence of 
inhibitor).  The EBA species is a mixture of ATP-bound C-terminal half with a Glc-bound 
N-terminal half and ATP-bound C-terminal half with a Glc-bound C-terminal half, of which 
only the latter is active.  The assumption of kcat = 0 for the EBA species is equivalent to 
having most of it with Glc bound to the N-terminal half.  Indeed several observations 
support high-affinity binding of Glc to the N-terminal half of HKI[8, 17, 23].  EB then must 
represent Glc bound primarily to the N-terminal half, and the constant for dissociation of Glc 
from EBB, represented by Kbb, is the Km for Glc. 
In fitting Eqn.1 to data, values for KmATP, KmGlc and kcat were determined 
independently by separate experiments in which either Glc or ATP varied over a 
concentration range from 1/59Km to 59Km.  Refinement employed these experimentally 
determined values for KmATP, KmGlc and kcat as constants in the refinement of initial values for 
Kbi, Kbbi, Kbbbi, Kbbii, Kbbbii, Kb and Kbbb using Eqn. 1.  Optimization followed the protocol of 
Table III and resulted in reasonable values for parameters with uncertainties no greater than 
30%, except for Kb, which refined to a value of 1 µM with substantial relative uncertainty 
(Table IV). 
Fits of data for T232A and G896A HKI employ Scheme II and Eqn. 2, the 
fundamental difference being the elimination of complexes with two bound inhibitors. 
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Scheme II 
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Species in Scheme II are defined as in Scheme I, and the results of optimization are in Table 
IV. 
Finally fits of data for mini-HKI use Scheme III and Eqn. 3, which eliminates species 
with three bound molecules of Glc and/or two bound molecules of inhibitor. 
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Scheme III 
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Species in Scheme III are defined as in Scheme I, and the results of optimization are in Table 
IV. 
 
Discussion 
Past efforts to account for observed functional behavior of HKI relied on simple models 
proscribed by Occam’s razor.  Models had but one binding site for Glc, Glc-6-P, ATP and 
Pi[8].  Crystal structures of HKI provided the first concrete basis for more complex 
interactions between ligands and HKI, defining two sites for Glc, Glc-6-P, and ATP, and one 
site for Pi[2, 22, 29, 39].  Here we provide evidence for a third binding site for Glc that probably 
overlaps one of the binding sites for Glc-6-P.  Except for the ATP site at the N-terminal 
half[39], all other sites have well-defined roles in modulating the activity of HKI. 
The refined value for Kb (approximately 1 µM) is consistent with the tight binding of 
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Glc to HKI observed by Kenkare and coworkers[19].  If values of Kb rise significantly above 
10 µM, the model-based curves of Figure 5 become convex upward at low concentrations of 
Glc rather than the observed set of near-parallel lines.  In fact, all constructs of HKI 
presented in Figure 5 approximate a set of parallel lines which is the hallmark of a 
mechanism of uncompetitive inhibition with respect to Glc.  Although the EB complex in 
Scheme I represents a mixture of ligated states have one bound molecule of Glc, the 
dominant component of this mixture should have the N-terminal half with Glc. 
Kbi has high values for wild-type, T232A and G896A hexokinases, which indicates 
weak binding of 1,5-anhydroGlc-6-P to enzyme with one bound molecule of Glc, presumably 
to the N-terminal half.  This outcome is a surprise, but to have tight binding of inhibitor to 
say the N-terminal half would be fundamentally inconsistent with the sets of parallel lines in 
Figure 5.  Binding of the first inhibitor molecule becomes tight only after a second molecule 
of glucose binds, presumably at the active site.  Substantial synergism exists in all 
constructs, as measured by the quotient Kbi/Kbbi (Ki/Kbi for mini-HKI), but synergism is 
extraordinary for the wild-type and G896A enzymes (10- and 40-fold, respectively).  
Binding of the second molecule of 1,5-anhydrGlc-6-P to the wild-type enzyme is 
approximately 20-fold weaker than the first molecule of inhibitor.  The effect of binding a 
third molecule of Glc is negligible on the first-bound inhibitor molecule, but decidedly 
antagonistic toward the second bound molecule of inhibitor. 
Of the observations made in the foregoing paragraph, the requirement for two bound 
molecules of Glc for potent inhibition by 1,5-anhydrolGlc-6-P is most intriguing.  The 
inhibitor has two possible binding sites (N- and C-terminal halves), but the high-affinity 
binding of inhibitor must be synergistic with the binding of Glc to the C-terminal half.  The 
easiest explanation for such synergism puts the high-affinity binding site at the C-terminal 
half, where Glc and 1,5-anhydroGlc-6-P can together leverage a conformational change from 
an open to a closed half.  The kinetics of the wild-type enzyme however, indicate that 
103 
inhibitor binds with higher affinity to the N-terminal half (Chapter 3, this thesis).  For latter 
to be consistent with Scheme I and observations here, inhibitor binding to the N-terminal half 
must be synergistically with Glc binding to the C-terminal half.  Indeed, the G896A enzyme 
(C-terminal inhibitor site impaired) exhibits a higher level of synergism than the T232A 
enzyme (N-terminal inhibitor site impaired).  Hence, conformational change in HKI in 
response to the binding of Glc at the active site (C-terminal half) greatly enhances the 
binding of inhibitor to the N-terminal half of the protein.  The conformational changes in 
HKI that leverage this effect are unclear.  In essence, Glc is a substrate and a modulator of 
an allosteric inhibition. 
Neither T232A HKI nor G896A HKI, enzymes that have impaired inhibitor binding 
sites at the N- and C-terminal half, respectively, exhibit Glc-relief of inhibition (Figure 5).  
High concentrations of Glc also have no effect on the truncated C-terminal half of HKI (mini 
HKI) (Figure 5).  Evidently, the mechanism of Glc-relief of inhibition by 
1,5-anhydroGlc-6-P affects the binding of the second inhibitor molecule.  Given the 
property of binding antagonism for 1,5-anhydroGlc-6-P to the wild-type enzyme (Chapter 3, 
this thesis) the second inhibitor molecule binds to either the N- or C-terminal half with 
elevated site affinity constants relative to the first molecule of bound inhibitor.  At sufficient 
concentrations, Glc can compete at either the N- or C-terminal half to remove the second 
molecule of bound inhibitor, but concentrations of Glc never rise sufficiently to compete with 
the first molecule of bound inhibitor.  The Glc-relieved state of inhibition most likely puts a 
molecule of Glc (the third to bind to HKI) at the glucopyranose locus of the inhibitor pocket 
(Figure 6).  Hence, the EBBBI complex is a mixture of two states of ligation: One state has 
one inhibitor and one Glc molecule bound to the N-terminal half with two Glc molecules 
bound to the C-terminal half and the other has two Glc molecules bound to the N-terminal 
half with one inhibitor and one Glc molecule bound to the C-terminal half.  The two states 
may not be equally populated, but in the absence of dissociation constants for Glc from the 
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inhibitor sites, the dominant state (if any) cannot be determined. 
The question also remains as to whether Glc-relief and Pi-relief of inhibition are 
additive.  From the model presented in Chapter 3 of this thesis, one would predict no 
Glc-relief of inhibition in the presence of Pi.  Pi would displace inhibitor from the 
N-terminal half, causing the site affinity constant for inhibitor at the C-terminal half to 
decrease from 163 to 62 µM (Chapter 3, Table VIII, this thesis).  The effect would be 
equivalent to the mutation of Thr232 to alanine, which eliminates 1,5-anhydroGlc-6-P  
inhibition at the N-terminal half.  T232A HKI does not exhibit Glc-relief of inhibition, and 
one would not expect Glc-relief in the presence of millimolar levels of Pi.  Given these 
observations one might anticipate Glc- and Pi-relief mechanisms to overlap, and as a 
consequence be non-additive. 
Tris and Hepes buffers result in significant differences in the kinetics of wild-type 
HKI.  For instance, Kbbii almost doubles in Hepes relative to Tris.  The doubling effect is 
consistent with results of Liu[26], which indicate elevated Kii values in the presence of Hepes 
for the wild-type and engineered monomeric forms of HKI.  One cannot rule out the 
possibility of Hepes at 100 mM competing with the binding of the second molecule of 
1,5-anhydroGlc-6-P, but notably such competition is not evidenced by lower Kbbi values for 
potent inhibition.  Other differences due to buffer and/or pH seem plausible.  The KL 
reported here (Hepes, pH 7.8) for the dissociation of TNP-ADP from wild-type HKI at 1 mM 
Glc is 0.18 ± 0.02 µM, a 3-fold difference from that reported in Chapter 2 (Tris, pH 7.5).  
KA (dissociation constant for Glc-6-P) is 0.21 ± 0.01 µM in Hepes versus 0.51 ± 0.02 µM in 
Tris at 1 mM Glc (Table II).  Tris has been the buffer of choice historically for 
investigations of hexokinase, but at low protein concentrations, the enzyme retains specific 
activity longer and has lower Km values for Glc and ATP in Hepes than in Tris. 
Fromm and colleagues reported a dissociation constant of 0.124 µM in Tris, pH 7.6, 
with 0.6 mM Glc and a dissociation constant of 0.50 µM putatively free of glucose[20]; 
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however, complete removal of Glc from HKI is difficult even by means of extensive washing 
and dialysis[19, 29].  Kenkare and colleagues reported a dissociation constant of 0.9 ± 0.05 
µM in NEM acetate buffer, pH 8.0, 0.1 M KCl and 2.5 mM Glc; and a constant of 2.8 ± 0.48 
µM in the same buffer with 0.5 µM glucose.  Results are consistent with previous reports 
indicating a decreased dissociation constant for Glc-6-P from HKI as concentrations of Glc 
increase[17, 19, 20].  This phenomenon reflects synergism between the binding of glucose to 
the C-terminal half, which in turn enhances inhibitor association at either the C- or 
N-terminal halves. 
Under normal respiration, glycolysis is limited to 3% of capacity in the brain by the 
supply of glucose.  Pi may play only a small role in regulation of HKI under these 
conditions[42].  Moreover, results here would indicate an absence of potent product 
inhibition (compare Kbi and Kbbi).  During oxygen deprivation or heightened activity in 
localized regions of the brain, intracellular Glc concentrations can rise sharply as plasma 
glucose (at a level of 5 mM) floods into the brain cell through glucose transporters.  Under 
these conditions, HKI is susceptible to potent feedback inhibition by product, and relief of 
that inhibition by possibly the combined actions of Glc and Pi.  In erythrocytes, glucose 
concentrations are normally 5 mM and blood glucose homeostasis is tightly regulated[1].  
Blood glucose levels in the blood cell is slightly elevated relative to the serum glucose 
concentration[45].  Hence, glucose concentrations inside the red blood cell are high enough 
to induce Glc-relief of Glc-6-P inhibition of HKI.  In the erythrocytes of diabetic patients, 
Glc-6-P concentrations are elevated[30].  In normal erythrocytes, however, HKI is saturated 
with glucose.  Thus the increase of Glc-6-P concentration under hyperglycemic conditions 
cannot be due to increased availability of glucose.  In fact, high concentrations of Glc-6-P 
levels of diabetic patients may be evidence of Glc-relief of Glc-6-P inhibition of HKI, 
enhancing flux through glycolysis as a mechanism to reduce serum glucose levels.  Further 
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relief of HKI from product inhibition in the red blood cell then could offer a means of 
treatment of the hyperglycemic condition. 
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Table I.  Parameters for TNP-ADP titration experiments at different Glc 
concentrations # 
 
 parameter [Glc] = 5 µM [Glc] = 25 µM [Glc] = 75 µM [Glc] = 1 mM 
Buffer/ 
Baseline 
a 0.27 ± 0.02 0.27 ± 0.01 0.244 ± 0.005 0.240 ± 0.006 
b 4.54 ± 0.09 4.57 ± 0.06 4.66 ± 0.03 4.65 ± 0.04 
c 0.12 ± 0.01 0.132 ± 0.008 0.141 ± 0.004 0.143 ± 0.005 
Wild-type 
KL 0.118 ± 0.008 0.13 ± 0.01 0.15 ± 0.01 0.18 ± 0.02 
G 3.65 ± 0.02 3.80 ± 0.02 3.94 ± 0.02 4.09 ± 0.03 
S 1.3 ± 0.1 1.3 ± 0.2 1.2 ± 0.2 1.2 ± 0.2 
T232A 
KL 0.095 ± 0.008 0.101 ± 0.009 0.12 ± 0.01 0.128 ± 0.009 
G 4.76 ± 0.03 4.79 ± 0.03 5.03 ± 0.04 5.32 ± 0.03 
S 1.0 ± 0.2 1.1 ± 0.2 0.7 ± 0.3 1.0 ± 0.2 
G896A 
KL 0.46 ± 0.07 0.48 ± 0.06 0.53 ± 0.07 0.55 ± 0.06 
G 5.7 ± 0.1 5.8 ± 0.1 5.8 ± 0.1 6.02 ± 0.09 
S 2.0 ± 0.8 2.0 ± 0.6 2.6 ± 0.7 2.2 ± 0.6 
Mini-HKI 
KL 0.11 ± 0.03 0.12 ± 0.03 0.13 ± 0.03 0.14 ± 0.02 
G 3.35 ± 0.06 3.41 ± 0.06 3.55 ± 0.06 4.03 ± 0.05 
S 2.2 ± 0.4 2.1 ± 0.4 1.9 ± 0.5 1.8 ± 0.4 
 
#Experiments employ 2 µM enzyme in 50 mM Hepes, pH7.8, at indicted Glc concentrations. 
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Table II.  Parameters for displacement of TNP-ADP by Glc-6-P at different Glc 
concentrations# 
 
HKI Parameter [Glc] = 5 µM [Glc] = 25 µM [Glc] = 75 µM [Glc] = 1 mM 
Wild-type 
KA 0.29 ± 0.01 0.22 ± 0.01 0.21 ± 0.01 0.21 ± 0.01 
G 3.85 ± 0.02 3.99 ± 0.04 4.23 ± 0.04 4.55 ± 0.05 
S 2.6 ± 0.1 2.4 ± 0.2 1.9 ± 0.2 2.2 ± 0.2 
T232A 
KA 2.14 ± 0.08 1.14 ± 0.04 0.97 ± 0.05 0.65 ± 0.03 
G 4.41 ± 0.03 4.48 ± 0.03 4.84 ± 0.04 5.11 ± 0.04 
S 3.0 ± 0.2 2.8 ± 0.2 3.3 ± 0.3 4.2 ± 0.3 
G896A 
KA 1.07 ± 0.07 1.07 ± 0.05 1.09 ± 0.04 0.96 ± 0.05 
G 4.75 ± 0.06 5.08 ± 0.05 5.17 ± 0.04 5.34 ± 0.05 
S 8.6 ± 0.3 7.6 ± 0.2 7.6 ± 0.2 7.7 ± 0.2 
Mini-HKI 
KA 0.60 ± 0.03 0.27 ± 0.02 0.16 ± 0.01 0.15 ± 0.01 
G 2.84 ± 0.02 3.11 ± 0.04 3.38 ± 0.06 3.98 ± 0.05 
S 8.4 ± 0.2 10.1 ± 0.2 9.7 ± 0.3 8.6 ± 0.2 
 
#Experiments employ 3.36 µM TNP-ADP and 2 µM enzyme in 50 mM Hepes, pH7.8, at indicated Glc 
concentrations. 
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Table III. Fitting process for wild-type HKI in Tris buffer$. 
 
  Round 1 Round 2 Round 3 Round 4 
kcat (s-1) 83 ± 1# 83 83 83 
Kb (µM) 1 ± 3 1 ± 3 1 ± 3 1 ± 3 
Kbb (µM) 110 ± 5# 110 110 110 
Kbbb (µM) 1000 1000 1000 1200 ± 400 
Ka (µM) 1300 ± 20#  13000 1300  1300 
Kbi (µM) 100  160 ± 70 160 ± 70 160 ± 70  
Kbbi (µM) 15 15 15.1 ± 0.3 15.1 ± 0.3 
Kbbbi (µM) 15 15 15.2 ± 0.4 15.2 ± 0.4 
Kbbii (µM) 300 280 ± 20 280 ± 20 280 ± 20 
Kbbbii (µM) 600 600 600 580 ± 60 
 
#Determined independently. 
$For each round, the bold font represents parameters already determined and fixed in the refinement of other 
parameters.  The italic font represents the initial estimated for the parameters input prior to fitting, determined 
by trial-and-error spection.  The underlined font represents parameters determined by Grafit for that round. 
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Table IV.  Inhibition of 1,5-anhydroGlc-6-P with respect to Glc at fixed ATP 
concentrations# 
HKI Wild-type Wild-type T232A G896A  Mini-HKI 
Buffer  Hepes, pH7.8 Tris, pH8.0 Tris, pH8.0 Tris, pH8.0 Buffer Tris, pH8.0 
ATP (µM)  6000 6000 9000 600 ATP  9000 
kcat (s-1) 91 83 60 88 kcat (s-1) 50 
Kb (µM) 1 ± 3 1 ± 3 2 ± 1 4 ± 2   
Kbb$ (µM) 57 110 81 45 Kb* (µM) 37.7 
Kbbb (µM) 424 ± 113 1200 ± 400 900 ± 500 700 ± 200 Kbb (µM) 670 ± 130 
Ka $ (µM) 817 1300 1400 566 Ka* (µM) 1001 
Kbi (µM) 516 ± 963 160 ± 70  220 ± 70 6000 ± 7000 Ki (µM) 43 ± 9 
Kbbi (µM) 12.6 ± 0.7 15.1 ± 0.3 39 ± 5 152 ± 4 Kbi (µM) 5.6 ± 0.1 
Kbbbi (µM) 11.4 ± 0.4 15.2 ± 0.4 52 ± 9 162 ± 2 Kbbi (µM) 4.9 ± 0.1 
Kbbii (µM) 150 ± 10 280 ± 20 N.A. N.A.   
Kbbbii(µM) 230 ± 10 580 ± 60 N.A. N.A.   
#Data for wild-type enzyme is fitted according to Scheme I and Eqn. 1, T232A and G896A are fitted according 
to Scheme II and Eqn. 2 and mini-HKI are fitted according to Scheme III and Eqn. 3. 
$Kbb is KmGlc and Ka is KmATP for wild-type HKI, T232A and G896A. 
*Kb is KmGlc and Ka is KmATP for mini-HKI. 
N.A.: not applicable 
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Figure 1.  Overview of HKI·Glc-6-P·Glc complex (PDB: 1HKB).  The large domains are colored dark grey 
and small domains colored light grey.  Ligands Glc-6-P and Glc are colored black as sticks.  (The illustration 
was generated with PyMOL.) 
 
  
112 
 
 
Figure 2.  TNP-ADP baseline and binding to wild-type HKI at different concentrations of Glc.  A, 
Addition of TNP-ADP to 50 mM Hepes buffer, pH 7.8.  B, Addition of TNP-ADP to 2 µM HKI in 50 mM 
Hepes, pH 7.8.  Glc concentrations are as indicated. 
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Figure 3.  Displacement of TNP-ADP by Glc-6-P at different concentrations of Glc for wild-type and mutant 
HKI.  A, wild-type HKI.  B, T232A.  C, G896A.  D, mini-HKI.  Glc concentrations are as indicated  ---- 
Raw data is as following (without vertical axis normalized):  
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Figure 4.  Dissociation constants for TNP-ADP (KL. panel A) and Glc-6-P (KA, panel B) for wild-type and 
mutant HKI at different concentrations of Glc. 
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Figure 5.  Inhibition of HKI enzymes by 1,5-anhydroGlc-6-P with respect to Glc at fixed ATP 
concentrations.  Assays are in 50 mM Hepes, pH 7.8, 0.2 mM NADP, and 3 mM MgCl2 (panel A) or in 80 
mM Tris, pH 8.0, 0.4 mM NADP, and 3 mM MgCl2 (panels B–E).  A. wild-type HKI with [Glc] = 35 µM–10 
mM, [1,5-anhydroGlc-6-P] = 50–385µM, and [ATP] = 4.5 mM.  The data were fit to Scheme I and Eqn. 1.  B. 
wild-type HKI with [Glc] = 55µM–10mM, [1,5-anhydroGlc-6-P] = 50-385 µM, [ATP] = 6 mM.  The data 
were fit Scheme I and Eqn. 1.  C. T232A HKI with [Glc] = 33µM–1mM, [1,5-anhydroGlc-6-P] = 10–600 µM, 
[ATP] = 9mM.  The data were fit to Scheme II and Eqn. 2.  D. G896A HKI with [Glc] = 25 µM–10 mM, 
[1,5-anhydroGlc-6-P] = 200–800 µM, [ATP] = 0.6 mM.  The data were fit to Scheme II and Eqn. 2. E. 
mini-HKI with [Glc] = 25 µM–5 mM, [1,5-anhydroGlc-6-P] = 20-160 µM, [ATP] = 9 mM  The data were fit 
to Scheme III and Eqn. 3. 
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Figure 6.  Glucose binding sites observed and implied.  A. Glc-6-P and Glc molecules sit in the ligand 
pocket (from crystal structure of the HKI•Glc-6-P•Glc complex, Chapter 1, this thesis).  B. Model for two 
bound Glc molecules in the ligand pocket.  (This illustration was generated with PyMOL). 
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Chapter V.  Tracking Allosteric Pathways in Human Hexokinase Type I by Directed 
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Abstract 
Hexokinase I (HKI) catalyzes the first step in glycolysis, the formation of glucose 
6-phosphate (Glc-6-P) from glucose (Glc).  HKI is subject to potent product inhibition and 
relief of product inhibition by phosphate Pi.  Crystallographic studies reveal paired binding 
sites for Glc-6-P and Glc at each half of HKI, and a high-affinity binding site for Pi at the 
N-terminal half.  Glc-6-P can inhibit catalysis by binding to the N-terminal half or 
C-terminal half.  Pi partially relieves inhibition by displacing Glc-6-P from the N-terminal 
half.  Here we explore the effect of mutations at putative structural elements of the 
regulatory machinery of HKI, the ends of the transition helix connecting N- and C-terminal 
halves and the flexible subdomain of C-terminal half including the contact region between 
two halves of HKI.  Mutations at both the N-terminal end of the transition helix and the 
flexible subdomain severely disrupt 1,5-anhydroGlc-6-P inhibition and Pi-relief of inhibition.  
HKI activity and inhibition kinetics with alternative nucleoside triphosphates indicate 
different functional states for the C-terminal half of HKI relative to truncated HKI lacking 
the N-terminal half.  Results from directed mutation are consistent with a proposed 
mechanism in which the ligation of the N-terminal half by Glc-6-P induces a rotation of the 
N-terminal half that alters nonbonded contacts with and within the flexible subdomain of the 
C-terminal half.  Conformational changes in the flexible subdomain, which involve the 
re-organization of hydrophobic residues within the core of that domain, stabilize an open 
binding pocket for ATP. 
Introduction 
Hexokinase (ATP: D-hexose 6-phosphotransferase, EC2.7.1.1) catalyzes the first step of 
glycolysis, the phosphorylation of 6-hydroxyl group of glucose (Glc) using [ATP-Mg]2– as 
122 
the phosphoryl donor [1-3].  Four isozymes of hexokinase have been identified in mammalian 
tissues [4].  Type I, II and III hexokinases, all with molecular weights of approximately 100 
kDa, share 70% sequence identity[5], whereas isozyme IV (glucokinase) has molecular 
weights of 50 kDa[5].  N- and C- terminal halves of isozymes I–III, as well as isozyme IV, 
show extensive sequence and structure similarity but different functional properties [5].  Both 
halves of hexokinase II possess catalytic activity, whereas the N-halves of hexokinase I and 
III are inactive [5-8].  The reaction product, glucose-6-phosphate (Glc-6-P), potently inhibits 
isozymes I-III (but not isoform IV, 50kDa) at physiologically relevant concentrations [5].  
Inorganic phosphate (Pi) itself is an inhibitor of hexokinase II and III[5].   However, Pi 
specifically antagonizes the inhibition of hexokinase I by Glc-6-P at relatively low 
concentrations; whereas, at higher concentrations it acts as an inhibitor competitive with 
ATP[5]. 
Presumably, all members in the hexokinase family derive from a common ancestor, a 
30 kDa glucomannokinase-like enzyme which utilized poly(P) as substrate in an age before 
the appearance of ATP[9].  During evolution, this ancient hexokinase acquired additional 
attributes, such as flexible subdomain (residues 766–812 in hexokinase I) and became 
ATP-specific at the cost of losing poly(P) as a substrate[9].  Through gene duplication and 
fusion, the 100 kDa hexokinase architecture appeared[10-13].  However, whether the product 
inhibition evolved before or after gene duplication and fusion remains unclear. 
Wild-type HKI exists as a head-to-tail dimer in crystals[14-16].  Mutations that disrupt 
dimerization retain properties in Glc-6-P inhibition and Pi-relief, indicating the allosteric 
communication must come from crosstalk between the N- and C- terminal halves of a single 
subunit[17].  The N- and C-terminal halves are connected by a long transition helix which 
starts from Glc-6-P binding site at the N-terminal half.  C-terminal half of HKI is in an open 
state and the N-terminal half closed when Glc and Pi are present[18].  Glc-6-P induces the 
closure of C-terminal half as well as a rotation of the N-teminal half relative to the 
C-terminal half.  That rotation alters contacts between segment 241–253 from the 
N-terminal half and the flexible subdomain from C-terminal half[17].  ADP-bound HKI is in 
a conformation similar to Glc-6-P-bound HKI, with N- and C- terminal halves closed; 
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however, the flexible subdomain from C-terminal half is substantially different in two 
structures[18].  A pocket for the base moiety of ADP is closed when Glc-6-P is bound, and 
Thr784 exists in different locations and networks of hydrogen bonds in the presence of the 
adenine nucleotide or Glc-6-P. 
In crystal structures, Glc-6-P binds to both halves of hexokinase I (HKI)[14-17].  
When HKI is cleaved proteolytically into two halves, the C-terminal half (mini-HKI) is 
active and inhibited potently by Glc-6-P and this inhibition is not subject to Pi-relief[8, 19].  
The N-half of HKI is inactive, but it still binds Glc-6-P tightly[7-8].  Mutational studies have 
shown that Glc-6-P is capable of inhibiting HKI potently when binding to either of the two 
binding sites on the enzyme[20-21].  Only mutations at both Glc-6-P binding sites eliminate 
the inhibition[21].  Data from equilibrium binding and kinetics experiments, however, 
indicate only one molecule of Glc-6-P binds to HKI with high-affinity, causing potent 
Glc-6-P inhibition[21-25]. 
Investigators have differed as to the Glc-6-P inhibition mechanism since the 1970s.  
According to Fromm, Glc-6-P inhibits the enzyme by binding to the C-terminal half, the 
6-phosphoryl group directly competing with the γ-phosphoryl site of ATP[23, 26].  Wilson 
assigned Glc-6-P inhibition to an allosteric site at the N-terminal half, on the basis of Glc-6-P 
protection against proteolysis[7, 27].  Both Fromm and Wilson agree, however, that Pi 
antagonizes Glc-6-P inhibition by binding to a high-affinity site at the N-terminal half[5, 18].  
Pi competes with Glc-6-P for the same phosphoryl binding site directly in the Wilson model, 
whereas Pi competes via an allosteric mechanism with Glc-6-P bound at the C-terminal half 
in the Fromm model[5, 18].  The existence of a single high-affinity site for Glc-6-P in 
equilibrium binding experiments can be reconciled with high affinity sites in each of the C- 
and N-terminal halves by a mechanism of anti-cooperativity in Glc-6-P binding[21].  The 
most recent variation (Chapters 3 & 4, this thesis) requires Glc to bind at the active site in 
order to induce potent inhibition at either the N- or C-terminal halves, with inhibitor binding 
being mutually antagonistic.  Pi relieves allosteric inhibition by the displacement of 
inhibitor from the N-terminal half; however, intrinsically weaker inhibition at the C-terminal 
half is not relieved by Pi.  Regardless of model, allosteric communications between N- and 
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C-terminal halves of HKI is an expectation. 
Presented here are studies that demonstrate an effect of the N-terminal half on the 
functional properties of the C-terminal half of HKI, that the molecular mechanism of 
inhibition for the truncated C-terminal half (mini HKI) differ significantly from that of 
wild-type HKI.  In addition, directed mutations at the N-terminal end of the transition helix 
and the flexible subdomain of the C-terminal half reveal significant effects at inhibitor 
binding pockets well removed from the sites of mutation.  The results are in agreement with 
the model proposed by Aleshin et al.[17]: rigid-body movement of the N-terminal domain 
induced by the binding of inhibitor stabilizes the flexible subdomain in a conformation 
unfavorable to the binding of ATP. 
Materials and methods 
Materials— A full-length cDNA of human hexokinase I, cloned into vector pET-11a was 
available from previous studies[19, 28-29].   Oligonucleotides came from IDT-DNA.  DNA 
sequencing was done at the Iowa State University DNA Synthesis and Sequencing Facility.  
Escherichia coli strain DH5a and BL21 were from Invitrogen.  DNaseI, 
phenylmethanesulfonyl fluoride (PMSF), leupeptin, bovine serum albumin (BSA), ATP, 
NADP, ampicillin, glucose 6-phosphate, mannose 6-phosphate and 2-deoxy-D-glucose 
6-phosphate were from Sigma.  1,5-anhydro-D-sorbitol was from Toronto Research 
Chemicals.  Isopropyl-D-thiogalactopyranoside (IPTG) was from Bio-World.  DEAE 
sepharose CL-6B and CHT ceramic hydroxyapatite (HA) Type II were from Bio-Rad.  
DEAE-5PW HPLC media was from Tosohaas.  Glucose-6-phosphate dehydrogenase 
(G6PDH) was from Roche. 
Construction, Expression and Purification of Wild-type and Mutant Hexokinase I— 
Oligonucleotide primers for directed mutations are as follows: 
5’-GGC-ACC-ATG-ATG-GCG-TGT-GGC-TAT-GAC-GAC-3’ for T216A, 
5’-C-CTG-ATC-ATC-GGC-GCG-GGC-ACC-AAT-GCT-TGC-3’ for T232A, 
5’-CGC-TTC-CTC-CTC-GCG-GAG-AGT-GGC-AGC-3’ for S445A; 
5’-CTC-CTC-TCG-GAG-GAT-GGC-AGC-GGC-AAG-G-3’ for S447D; 
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5’-C-CTC-TCG-GAG-AGT-GCG-AGC-GGC-AAG-G-3’ for G448A; 
5’-G-GAG-AGT-GGC-CCG-GGC-AAG-GGG-GCT-G-3’ for S449P; 
5’-G-CAG-ATA-GAG-GAG-ACC-GAT-GCT-CAT-TTC-CAC-3’ for L474D; 
5’-GAG-ACC-CTG-GCT-CAT-GCG-CAC-CTC-ACC-AAA-GAC3’ for F477A; 
5’-G-GAT-GAT-ATC-AGG-ATT-CAC-TAC-GAC-AGA-CTG-3’ for T723I; 
5’-CG-ATG-AAG-ACC-CGG-GGC-GCG-TTT-GAG-ACC-AAG -3’ for L781A; 
5’-GC-ATC-TTT-GAG-GCG-AAG-TTT-CTC-TCT-C-3’ for T784A; 
5’-GC-ATC-TTT-GAG-CTG-AAG-TTT-CTC-TCT-C-3’ for T784L; 
5’-GC-ATC-TTT-GAG-ACC-AAG-ATG-CTC-TCT-CAG-ATC-G-3’ for F786M; 
5’-GC-ATC-TTT-GAG-ACC-AAG-GAT-CTC-TCT-CAG-ATC-G-3’ for F786D; 
5’-GAG-AGT-GAC-CGA-GAA-GCA-CTG-CTC-CAG-GTC-3’ for L795E; 
5’-GT-GAC-CGA-TTA-GCA-ACC-CTC-CAG-GTC-CGG-GCT-ATC-3’ for L797T; 
5’-C-CGA-TTA-GCA-CTG-GAA-CAG-GTC-CGG-GCT-ATC-3’ for L798E; 
5’-CTC-CAG-GTC-CGG-GCT-GCG-CTC-CAG-CAG-CTA-GG-3’ for I803A; 
5’-GG-ACA-CTC-TAC-AAG-GCG-CAT-CCA-CAC-TTC-TCC-3’ for L867A; 
5’-GG-ACA-CTC-TAC-AAG-TAT-CAT-CCA-CAC-TTC-TCC-3’ for L867Y and 
5’-CTC-CTG-TCT-GAG-GAT-GCG-AGC-GGC-AAG-G-3’ for G896A, where in each of the 
preceding, the altered codon is underlined. 
A 200 ml culture of the transformed Escherichia coli BL21 was grown overnight at 
37 ºC in LB medium (33mg/L ampicillin) and then 1.5% cell were transferred to 9.6L LB 
medium (33mg/L ampicillin).  The culture was grown at 300 rpm and 37 ºC to A600=1.0.  
The temperature then was reduced to 16 ºC, isopropyl-β-D-thiogalactopyranoside (IPTG) was 
added to a final concentration of 0.5 mM and the culture was grown at 200 rpm for 20-22 hr. 
at 16 ºC.  The cells were re-suspended in 25 mM KPi (pH 7.5), 5 mM glucose, 3 mM MgCl2, 
1 mM dithiothreitol (DTT), 1 mM phenylmethanesulfonyl fluoride (PMSF), 50 µg/ml DNaseI 
and 5 µg/ml leupeptin.  The cells were broken by sonication and then centrifuged (33,000xg, 
1 hr.).  The supernatant fluid was adjusted to pH 7.5 and loaded onto a DEAE-anion 
exchange column, using 25 mM KPi, 5 mM glucose, 1 mM dithiothreitol DTT (pH 7.5), with 
a gradient of 0–400 mM NaCl.  The fractions containing HKI activity were pooled, 
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concentrated and dialyzed against 50 mM KPi (pH 7.0), 5 mM glucose, 1 mM dithiothreitol 
(DTT) and loaded onto a ceramics hydroxyapatite column with a gradient of 0.05–1 M KPi 
(pH 7.0).  HKI was collected and dialyzed against 25 mM KPi, 5 mM glucose, 1 mM 
dithiothreitol (DTT) (pH 7.5), and further purified by DEAE-5PW HPLC chromatography 
with a gradient of 0–500 mM NaCl.  The pure protein was identified by sodium 
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)[30].  Protein concentration 
was determined by the method of Bradford with BSA as a standard[31]. 
Hexokinase I Kinetics Studies— Hexokinase activity was determined by the 
glucose-6-phosphate dehydrogenase (G6PDH, E.C.1.1.1.49) coupled spectrometric assay[29].  
Commercial G6PDHas an ammonium sulfate precipitate was dialyzed against 80 mM Tris 
(pH 8.0) to remove sulfate, that mimics Pi in relief of 1,5-anhydroGlc-6-P inhibition.  
1,5-anhydroGlc-6-P is a surrogate for Glc-6-P in the kinetics of Glc-6-P inhibition.  The 
dicyclohexylamine salt of 1,5-anhydroGlc-6-P was prepared as described by Ferrari & 
Crane.[32] and it concentration determined by the method described by Drueckes et al.[33].  
The concentration of hexokinase in kinetics assay was 1.2–2.0 µg/ml.  The assay buffer for 
wild-type and mutant enzymes has 80 mM Tris, pH 8.0, 0.4 mM NADP, 3 mM MgCl2 and 2 
mM Glc.  For the determination of KmGlc, the assay buffer contained 80 mM Tris, pH 8.0, 
0.4 mM NADP, 3 mM MgCl2, 9 mM [ATP-Mg]2– with concentrations of Glc over the range 
of 1/5 KmGlc to 5 KmGlc.  For the determination of KmATP, the assay buffer contained 80 mM 
Tris, pH 8.0, 0.4 mM NADP, 3 mM MgCl2 and 2 mM Glc with concentrations of [ATP-Mg]2– 
ranging from 1/5 KmATP to 5 KmATP.  Determination of KI and KII employed a concentration 
of Glc of 2 mM, concentrations of 1,5-anhydroGlc-6-P from 0–400 µM and those of 
[ATP-Mg]2– from 1/2 KmATP to 4 KmATP.  Pi-relief of inhibition (%) is defined as 
100(A-B)/A, where A is the slope from (relative velocity of HKI)-1 versus inhibitor 
concentration in the absence of Pi, and B is the slope from plot of (relative velocity of HKI)-1 
versus inhibitor concentration in the presence of 6 mM Pi[21].  The relative velocity of HKI 
in the absence of inhibitor and Pi is unity[21].  The [ATP-Mg]2– concentration is fixed at 
KmATP in Pi-relief assays.  Determination of KPI and site dissociation constants is as 
described in Chapter 3 of this thesis.  Data-fitting was done with the computer program 
GraFit 7.0[34]. 
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Results 
Rationale for Directed Mutations— In the model of allostery proposed by Aleshin et al.[17], 
the binding of Glc-6-P leverages a rotation of the N-terminal half about the end of the 
transition helix, which in turn induces conformational change in the flexible subdomain of 
the C-terminal half (Figure 1).  The flexible subdomain can have two conformations, one of 
which prefers bound ATP and the other bound Glc-6-P.  In fact, glucokinase, which is 
insensitive to Glc-6-P inhibition, adopts an arrangement of residues (including the critical 
threonine) consistent with that observed for the ADP complex of HKI.  If the Aleshin 
mechanism is correct, then mutations to specific residues in the core of the flexible 
subdomain and near the N-terminus of the transition helix (pivot for the rotation of the 
N-terminal half) should greatly affect inhibition. 
Mutations in the vicinity of the pivot focus on the glucopyranose pocket of Glc-6-P, 
which includes a segment (loop 445–449) that exhibits conformational differences in crystal 
structures of Pi- and Glc-6-P-complexes of wild-type HKI[14, 18] (Figure 2).  Not only do 
main-chain angles of loop 445–449 differ, Ser499 hydrogen bonds with the 2-OH group of 
Glc-6-P, making a direct connection between inhibitor and the N-terminal end of the 
transition helix (Figure 3).  The mutation G448A is incompatible with observed main-chain 
angles and/or packing interactions observed in both the Pi- and Glc-6-P-complexes (Figure 4).  
S449P restrains the motion of the loop and disrupts hydrogen bonds between loop and 
inhibitor.  Thr216 forms a hydrogen bond with the carbonyl group of Gly448 in the Pi 
complex, but not in the Glc-6-P complex. 
The flexible subdomain combines a loop (residues 766–783) and two helices (α9, 
residues 784–791, and α10, residues 797–807)[14].  The base of ADP occupies a crevice 
between helix α9 and helix α11' (residues 862–868)[17].  Asp861 is important for catalysis 
and the inhibition at the C-terminal half (Chapter 2, this thesis), and Lys866 is important to 
inhibition (Chapter 3, this thesis).  Hydrogen bonds between the base of ADP and residues 
of helix α9 (Figure 5) indicate a direct role for the flexible subdomain in the recognition of 
ATP.  In the ADP complex structure, Thr784 from helix α9 forms a hydrogen bond with the 
backbone carbonyl group of Gly747[17].  The backbone carbonyl Gly747 also hydrogen 
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bonds with 2'-hydroxyl group of the adenine nucleotide[17].  Thr784 in the Glc-6-P complex, 
blocks the base binding pocket of ADP (Figure 5).  Leu867, from helix α11’, makes 
non-bonded contacts with the base of ADP[17] (Figure 5).  Electron density is present for two 
conformations of Phe786.  One conformer puts the side chain into the hydrophobic core of 
the flexible domain, whereas the other exposes the side chain to solvent.  Non-bonded 
contacts involving the side chains of Ile781 and Ile803 (Figure 5) also exhibit significant 
differences in the ADP and Glc-6-P-complexes of HKI.  The residues in the N-terminal half 
corresponding to Phe786 and Ile781 are Asp338 and Lys333, respectively.  Similarly, 
hydrophobic residues Leu795, Leu797 and Leu798 have residues with polar side chain in the 
N-terminal half (Figure 5). 
The last locus for sites of mutations (Leu474, Phe477 and T723) explored whether a 
point of articulation exists as the C-terminal end of the helix (Figure 3). 
Finally, in the instance of G448A, the effect on function was so significant, that the 
corresponding mutation to the C-terminal half (G896A) was simply done out of curiosity, and 
provided the best construct known in eliminating C-terminal half inhibition by 
1,5-anhydroGlc-6-P without greatly affecting catalytic activity. 
The type of mutation was often the substitution of alanine, but in several cases 
residue types observed in the N-terminal half were substituted for corresponding residues of 
the C-terminal half. 
 
Kinetics Results for Wild-type and Mutant Hexokinases— Wild-type and mutant hexokinases 
are at least 95% pure as determined by SDS-polyacrylamide gel electrophoresis (data not 
shown).  Shown in Table I are kinetic parameters for all mutant enzymes.  Mutant enzymes 
for which the analytical methods of Chapter 3 are possible (data available for Ki, Kii and KPI), 
have site dissociation constants and cooperativity parameters listed in Table II.  As the 
amount of tabular information is overwhelming, histograms of site dissociation constants and 
cooperativity parameters are available to allow quick visualization of mutations having 
significant effects on allosteric interactions (Figure 6). 
Mutations which have little effect on properties are S445A, S447D, L474D, F477A 
and T723I.  The list includes all the mutations at the C-terminal end of the transition helix.  
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T216A near the N-terminal pivot, and F786D, F786M and I803A in the flexible subdomain 
enhance site binding affinities for inhibitor at both the N- and C-terminal halves.  I781A has 
the most significant effect on inhibition for those enzyme forms amenable to the analysis of 
Chapter 3, causing 3-fold and 17-fold changes in site dissociation constants at the C- and 
N-terminal half, respectively.  Others mutant enzymes listed in Table II have been presented 
and discussed in Chapters 2 and 3 of this thesis. 
Mutant enzymes not listed in Table II are missing information, the mutant forms 
having been characterized prior to the development of analytical methods in Chapter 3 of this 
thesis.  If Kii is too high to measure, then Ki is a site-dissociation constant.  If KPI is known 
and Ki equals KPI, then no Pi-relief is observed and inhibition is due to the direct binding of 
1,5-anhydroGlc-6-P to the C-terminal half.  If KPI is extremely high, then Pi-relief is 
complete and inhibition is due to the binding of inhibitor to the N-terminal half.  Hence, 
G448A HKI has no inhibition from the N-terminal half and no Pi-relief, whereas G896A HKI 
has no inhibition from the C-terminal half and complete Pi-relief.  These two mutant forms 
of HKI represent opposite extremes in HKI inhibition (Figure 7).  The double mutation 
G896A/T232A eliminates measureable inhibition, as expected. 
Results of other mutations of residues in the flexible subdomain cause significant 
changes in properties of HKI.  T784A and L867A exhibit no inhibition, but the mutant 
enzymes have low activity.  L795E and L797T have no measurable Kii value.  Data are not 
available for these to mutant enzymes to unequivocally assign the mechanism of inhibition, 
but the low values for Pi-relief suggest inhibition by way of the C-terminal half. 
The situation for Phe786 is complicated.  F786D and F786M HKI exhibit enhanced 
inhibition as noted above; however F786D-mini HKI exhibits no measurable inhibition.  
Data for T232A/F786D HKI confirms inhibition comes from the C-terminal half. 
 
Kinetics of Wild-type and Mini Hexokinases with Different Substrates— As shown in Table 
III, both full-length and mini HKI use ATP, ITP, GTP, UTP and CTP as substrates; however, 
1,5-anhydroGlc-6-P does not inhibit catalysis of wild-type HKI supported by GTP, UTP or 
CTP, and exhibits a five-fold increase in IC50 in catalysis supported by ITP.  In contrast, 
1,5-anhydroGlc-6-P inhibits mini HKI potently regardless of the nucleoside triphosphate 
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used in support catalysis. 
 
Discussion 
HKI in most crystal structures is a dimer; whereas, in solution under conditions of assay (<1 
mg/ml protein concentration) it is a monomer[5, 14-16, 18, 36].  The lone example of a 
monomeric HKI in crystal structures is the triple mutant (E280A, R283A and G284Y), which 
eliminates subunit interactions of the crystalline dimer[17].  The triple mutant exhibits 
wild-type functional responses to 1,5anhydroGlc-6-P, Pi and substrates, and adopts a rod-like 
conformation of a single subunit in the crystallographic dimer[14-18].  Hence, HKI in solution 
should maintain a global conformation similar to that observed in crystallographic 
structures[36].  Interactions between the N- and C-terminal halves then occur only by way of 
the transition helix and a few polar contacts involving residues 242–251 of the N-terminal 
half and the flexible subdomain of the C-terminal half. 
Crystal structures reveal two binding sites for Glc-6-P, paired with binding sites for 
Glc. In solution one molecule of Glc-6-P binds to HKI with high affinity, and a second 
molecule of inhibitor binds with low-affinity[14-17, 21-25].  Fromm suggested that Glc-6-P 
potently inhibits the enzyme by binding to the C-terminal half, whereas Wilson assigned 
Glc-6-P inhibition to a site at the N-terminal half[7, 23, 26-27].  The Fromm and Wilson models 
agree, however, that Pi antagonizes Glc-6-P inhibition by binding to a high-affinity site at the 
N-terminal half[5, 18].  Pi replaces Glc-6-P directly in the Wilson model, whereas Pi competes 
via an allosteric mechanism with Glc-6-P bound at the C-terminal half in the Fromm model[5, 
18]
. 
Results from numerous investigations from the laboratories of Fromm and Wilson 
clearly indicate that each model individually cannot account for all observed phenomena.  
The Glc-6-P analog 1,5-anhydroGlc-6-P is a nonlinear competitive inhibitor of HKI with 
respect to ATP[20] and that Glc-6-P can bind to either N- or C-terminal halves causing potent 
inhibition[7-8, 19-21].  Moreover, several mutant forms of HKI (D84A, HKI+, HKI+-D84A, 
S88A, K418A, R801A, S415A, HKI-α+2) the sites of mutation all distant from the Pi 
binding site, exhibit reduced Pi-relief of 1,5-anhydroGlc-6-P inhibition and are inconsistent 
with the Wilson’s model [20, 25, 35, 37, 38], which make inhibitor and Pi binding inseparable.  
131 
Recent findings (Chapters 2, 3 and 4, this thesis) indicate inhibition arises by interactions of 
1,5-anhydroGlc-6-P at both N- and C-terminal halves of HKI, that binding affinity of the 
inhibitor is higher at the N- relative to the C-terminal half, that inhibitor binding sites interact 
antagonistically in the wild-type enzyme, that Pi displaces inhibitor from the N-terminal half, 
but not the C-terminal half, and that Glc must bind to the active site in order to engender 
potent product inhibition. 
In developing a model for allostery in HKI, one cannot rely on the properties of the 
truncated C-terminal half to represent the properties of the C-terminal half in the wild-type 
enzyme.  Properties of catalysis and inhibition of mini-HKI differ from those of wild-type 
HKI, and identical mutations in each system do not always cause identical changes in 
properties.  1,5-AnhydGlc-6-P inhibits catalysis regardless of the nucleoside triphosphate 
employed as a substrate of mini HKI (Table III).  On the other hand, 1,5-anhydroGlc-6-P 
potently inhibits wild-type HKI activity only when ATP is the substrate.  Mutations (T747A 
and L867A) eliminate or greatly reduce 1,5-anhydroGlc-6-P inhibition of wild-type HKI, but 
have little effect on 1,5-anhydroGlc-6-P inhibition of mini HKI (Table I).  In contrast 
F786D exhibits enhanced inhibition at both the N- and C-terminal domains in the full-length 
enzyme and no inhibition in mini HKI.  The conclusion is inescapable: the molecular 
mechanisms of inhibition for mini HKI and wild-type HKI differ. 
1,5-AnhydroGlc-6-P must bind directly to the active site of mini HKI, whereas 
inhibitor acts on wild-type HKI primarily through an allosteric mechanism (Chapters 2 and 3, 
this thesis).  In the direct binding mechanism, the 6-phosphoryl group of the inhibitor 
occupies the binding site for the α-phosphoryl group of adenine nucleotides[17].  If an 
alternative nucleotide binds productively to mini HKI, its phosphoryl group must overlap the 
binding pocket for inhibitor.  The situation differs markedly for wild-type HKI.  
1,5-AnhydroGlc-6-P closes the base binding pocket for the adenine nucleotide through an 
allosteric mechanism (to be described in detail below).  The triphosphoryl locus of the 
nucleotide binding pocket remains accessible, however, and as a consequence a range of 
nucleoside triphosphates can bind productively, albeit weakly, to phosphorylate Glc. 
An alternative binding mode for triphosphate nucleosides has indirect support from 
Toyoshima et al., who have observed different binding modes for ATP and TNP-ATP 
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(2'-(or-3')-O-(trinitrophenyl) adenosine 5'-triphosphate) to Ca2+-ATPase[39].  Although 
TNP-ADP binds with high affinity to wild-type HKI (Chapters 2 and 3, this thesis), steric 
collisions between the TNP moiety and residues 746–747 disallows the canonical binding 
mode (Figure 8).  TNP-ADP, however, can adopt an alternative binding mode analogous to 
that observed for Ca2+-ATPase.  In this alternative mode, the base moiety of the nucleotide 
does not occupy the base-binding pocket, but rather occupies the glucopyranosyl pocket for 
Glc-6-P.  Hence, a productive binding mode that sidesteps the proposed allosteric inhibition 
mechanism of wild-type HKI is plausible. 
Mapping locations of mutations (those presented here and in the literature) that 
significantly reduce Pi-relief, eliminate a measureable Kii and/or eliminate inhibition 
altogether results in Figure 9.  The locations of mutations are consistent with the model 
proposed by Aleshin et al.[17], namely mutations cluster in the region of the pivot and in the 
flexible subdomain.  The vast majority of mutant enzymes and the wild-type enzyme exhibit 
antagonistic coupling of inhibitor binding sites, but some mutant enzymes that have 
synergistic coupling.  Mutations that cause inhibition entirely through the N- or C-terminal 
half are known (G448A and G896A) and distinguishable from the mixed-inhibition 
mechanism of the wild-type enzyme. 
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Table I.  Kinetics parameters for mutant and wild-type HKI.# 
 
Group HKI 
Kcat KmGlc KmATP KIc KIIc KPIc Pi-Reliefd 
S-1 µM mM µM µM µM % 
 
Wild-type 92 ± 1 45 ± 3 1.03 ± 0.02 19 ± 2 a 240 ± 50 a 62 ± 2 85 
Mini-HKI 40 ± 1 30 ± 3 0.95 ± 0.05 12.5 ± 0.6 b N.A N.A N.R 
Transition 
helix N 
and the 
Glc-6-P 
pocket 
D413N 82 ± 1 57 ± 2 0.98 ±0.06 23 ± 4 80 ± 20 45 ± 2 80 
D861N 9.4 ± 0.1 37 ± 1 2.02 ± 0.09 30 ± 4 80 ± 20 98 ± 3 86 
D413N/D861N 10.0 ± 0.1 32 ± 2 1.59 ± 0.06 35 ± 5 110 ± 40 95 ± 4 78 
K418A 63 ± 1 88 ± 4 0.93 ± 0.05 44 ± 4 1100 ± 500 63 ± 7 44 
K866A 66 ± 2 63 ± 4 1.48 ± 0.09 70 ± 10 400 ± 300 369 ± 34 89 
K418A/K866A 71 ± 1 56 ± 2 1.1 ± 0.1 170 ± 20 1500 ± 700 460 ± 14 52 
mini-K866A 41 ± 1 43 ± 3 2.9 ± 0.2 60 ± 3 b N.A N.A N.R 
T216A 58 ± 1 70 ± 3 0.93 ± 0.03 8.1 ± 0.5 a 400 ± 90 a 36 ± 3 81 
T232A 60 ± 1 77 ± 3 0.73 ± 0.05 40 ± 1 N.A 60± 5 3 
S445A 69 ± 1 74 ± 3 0.69 ± 0.03 20 ± 2 a 290 ± 80 a 53 ± 1 76 
S447D 72 ± 1 113 ± 5 1.16 ± 0.03 23 ± 1 a 300 ± 60 a 57 ± 2 76 
S449P 84 ± 2 75 ± 2 0.88 ± 0.05 36 ± 2 b N.A 57 ± 4 48 
G448A 79 ± 1 107 ± 4 0.97 ± 0.06 64 ± 2 b N.A 61 ± 2 7 
G896A 86 ± 2 113 ± 2 0.45 ± 0.02 112 ± 6 b N.A 2300 ± 300 95 
T232A/G896A 68 ± 1 81 ± 2 0.30 ± 0.01 N.I N.A 1800 ± 300 N.A 
Mini-G896A 64 ± 1 74 ± 3 0.73 ± 0.05 400 ± 10 b N.A N.A N.R 
L867A 0.92 ± 0.08 55 ± 4 0.91 ± 0.05 N.I N.A N.A N.A 
L867Y 1.60 ± 0.03 28 ± 3 1.8 ± 0.1 N.I N.A N.A N.A 
Mini-L867A 0.72 ± 0.02 40 ± 3 0.64 ± 0.05 74 ± 5 b N.A N.A N.T 
Transition 
helix C 
L474D 70 ± 1 65 ± 3 1.23 ± 0.04 14.9 ± 0.9 a 110 ± 20 a 35 ± 2 76 
F477A 70 ± 1 80 ± 3 0.62 ± 0.03 22 ± 2 a 230 ± 60 a 93 ± 2 92 
T723I 66 ± 1 110 ± 4 0.84 ± 0.03 18 ± 1 a 150 ± 30 a 42 ± 3 80 
 
--To be continued 
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Table I.  Continued 
 
Group HKI 
Kcat KmGlc KmATP KIc KIIc KPIc Pi-Reliefd 
S-1 µM mM µM µM µM % 
 
Wild-type 92 ± 1 45 ± 3 1.03 ± 0.02 19 ± 2 a 240 ± 50 a 62 ± 2 85 
Mini-HKI 40 ± 1 30 ± 3 0.95 ± 0.05 12.5 ± 0.6 b N.A N.A N.R 
Flexible 
Subdomain 
I781A 163 ± 4 76 ± 2 1.23 ± 0.03 130 ± 10 a 1100 ± 300 a 169 ± 4 51.35 
Mini-I781A 55 ± 1 87 ± 4 1.3 ± 0.09 77 ± 3 b N.A N.A N.R 
T784A 1.35 ± 0.09 110 ± 20 0.90 ± 0.08 N.I N.A N.A N.A 
T784L 1.1 ± 0.1 28 ± 2 1.14 ± 0.07 N.I N.A N.A N.A 
Mini-T784A 0.90 ± 0.08 33 ± 1 1.2 ± 0.1 40 ± 2 b N.A N.A N.T 
F786M 42 ± 3 43 ± 5 1.08 ± 0.04 9 ± 1 a 80 ± 30 a 22.5 ± 0.3 81 
F786D 16.1 ± 0.2 31 ± 3 3.1 ± 0.1 7 ± 1 a 100 ± 30 a 14.9 ± 0.5 76 
T232A/F786D 17 ± 1 48 ± 2 3.1 ± 0.3 12.9 ± 0.5 b N.A 16.9 ± 0.2 10 
Mini-F786M 8.2 ± 0.3 19 ± 2 1.16 ± 0.05 6.5 ± 0.2 b N.A N.A N.R 
Mini-F786D 30.9 ± 0.4 142 ± 3 0.60 ± 0.04 N.I N.A N.A N.A 
L795E 121 ± 1 68 ± 5 0.35 ± 0.02 45 ± 3 N.A N.A 23 
L797T 12.2 ± 0.2 23 ± 1 2.24 ± 0.06 39 ± 3 N.A N.A 28 
L798E 74 ± 2 45 ± 2 0.90 ± 0.07 47 ± 3 220 ± 20 N.T 78 
I803A 34 ± 1 49 ± 1 2.7 ± 0.1 7.0 ± 0.7 a 50 ± 10 a 14.8 ± 0.3 80 
#Data for wild-type, D413N, D861N, D413N/D861N, K418A, K866A, K418A/K866A are reproduced from Chapter 3, this thesis. 
aData fit a non-linear competitive model.  
bData fit linear competitive model. 
cKI and KII are stoichiometric dissociation constants for 1,5-anhydroGlc-6-P from singly- and doubly-ligated enzymes and KPI is the 
stoichiometric dissociation constant for 1,5-anhydroGlc-6-P from the enzyme-Pi complex. 
dPi-relief of inhibition is defined as 100(A-B)/A, where A is the slope from plots of reciprocal relative velocity versus 
1,5-anhydroGlc-6-P concentration in the absence of Pi, and B is the slope from plot of reciprocal relative velocity versus inhibitor 
concentration in the presence of 6 mM Pi.  Relative velocity is the ratio of velocity at a specific concentration of inhibitor to the 
velocity in the absence of inhibitor.  The ATP concentration is fixed at KmATP for each enzyme. 
N.I., no inhibition observed up to 1 mM 1,5-anhydroGlc-6-P; N.T., not tested; N.R., no relief; N.A., not applicable. 
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Table II. Kinetics parameters and site affinity constants with respect to 
1,5-anhydroGlc-6-P for wild-type HKI and mutants# 
(all units except α are µM) 
#Results for wild-type, D413N, D861N, D413N/D861N, K418A, K866A, K418A/K866A are reproduced from 
Chapter 3, this thesis.  The following equations are used in the calculation of site dissociation constants: 
  	  
  ;  
    
  ;   	  ; 	   
 	  ;  	  
    
 
Group HKI KI KII α 
   	  	   	 
 Wild-type 20 240 0.37 30 62 77 163 
Glc-6-P  
Proximity 
T216A 8.1 400 0.12 10 36 90 310 
D413N 23 80 1.15 47 45 41 39 
D861N 30 80 1.77 43 98 24 56 
D413N/D861N 35 110 1.37 55 95 41 69 
K418A 44 1100 0.19 146 63 768 332 
K866A 70 400 1.14 86 369 76 324 
K418A/K866A 170 1500 0.49 270 460 554 946 
S445A 20 290 0.29 32 53 109 181 
S447D 23 300 0.32 39 57 121 179 
Hinge 
L474D 14.9 110 0.55 26 35 47 63 
F477A 22 230 0.53 29 93 54 176 
T723I 18 150 0.49 32 42 64 86 
Flexible 
Sub- 
domain 
I781A 130 1100 0.67 563 169 846 254 
F786D 7 100 0.28 13 14.9 47 53 
F786M 9 80 0.47 15 22.5 32 48 
I803A 7 50 0.56 13 14.8 24 26 
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Table III.  Kinetics parameters of full-length HKI and mini-HKI with common 
nucleoside triphosphates 
 
 
Nucleoside 
Triphosphate 
Full-length HKI Mini-HKI 
kcata  
(s-1) 
KmNTPa 
(mM) 
IC50 b 
(µM) 
kcata 
 (s-1) 
KmNTPa 
(mM) 
IC50 b 
(µM) 
ATP 91 ± 2 0.53 ± 0.04 20 ± 1 36.7 ± 0.5 0.47 ± 0.02 28 ± 1 
ITP 3.0 ± 0.2 2.9 ± 0.7 94 ± 4 1.83 ± 0,04 1.95 ± 0.09 38 ± 1 
GTP 4 ± 2 2.9 ± 0.5 ----c 1.66 ± 0.03 4.5 ± 2 12.8 ± 0.7 
UTP 3.8 ± 0.1 5.9 ± 0.4 ---- c 0.8 ± 0.1 7.8 ± 2 28.4 ± 0.3 
CTP 2.68 ± 0..06 3.3 ± 0.2 ---- c 1.14 ± 0.04 4.6 ± 0.2 6.2 ± 0.9 
 
aAssays were in 100 mM Tris, pH7.4, and 2 mM Glc, and Mg2+ 2 mM in excess of nucleotide.  The nucleoside 
triphosphates varied from 1/3 to 3 KmNTP . 
bIC50 means the concentration of 1,5-anhydroGlc-6-P that cause 50% inhibition with NTP concentrations fixed 
at KmNTP and glucose concentration fixed at 2 mM. 
cNo detectable inhibition up to 1 mM 1,5-anhydroGlc-6-P. 
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Figure 1. Allosteric states of the hexokinase I monomer. The conformation of monomeric hexokinase varies 
in response to ligation of its active site (C-terminal half) and its vestigial active site (N-terminal half). (a) In the 
presence of low concentrations of Glc-6-P, the allosteric interface between the N and the C-terminal halves 
maintains the flexible subdomain in an ATP-antagonistic state, in which Thr784 blocks the base-binding pocket 
for the nucleotide. (b) In the presence of elevated concentrations of Glc-6-P, the N and C-terminal halves are 
decoupled, with Glc-6-P bound directly to the active site, overlapping the ATP pocket. (c) Sufficient levels of 
Pi displace Glc-6-P from the N-terminal half and allow a rigid-body rotation of that half relative to the 
C-terminal half. The allosteric interface now stabilizes the ATP-compatible conformation of the flexible 
subdomain, removing Thr784 as a steric obstacle to ATP association. (d) ATP binds to the Pi-stabilized 
conformer of hexokinase. (Reprinted from Ref.17 with permission) 
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Figure 2.  Overview crystal structure of wild type HKI•Glc-6-P•Glc complex (Chapter 2, this thesis).  
Large domains (16-74, 210-447 for N-terminal half; 467-522, 658-895 for C-terminal half) are pink; small 
domains (75-209, 448-465 for N-terminal half; 523-657, 896-913 for C-terminal half) are yellow.  Glc-6-P and 
Glc are stick models.  The residues mutated in this report are colored blue.  (The illustration was generated 
with PyMOL). 
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Figure 3.  N- and C-terminal ends of the transition helix.  Structural details in the Glc-6-P pocket, 
N-terminal half (A) and the C-terminal end of the transition helix (B).  The structure is from Chapter 2, this 
thesis, wild-type HKI•Glc-6-P•Glc complex.  (The illustration was generated with PyMOL). 
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Figure 4.  Ramachandran Plot of Loop 445–449.  Main chain angles from the Glc-6-P•Glc complex 
(labeled magenta with chain A and B shown, from the HKI•Glc-6-P•Glc structure, Chapter 2, this thesis) and 
the HKI•Pi•Glc complex (labeled dark green, PDB: 1HKC). 
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Figure 5.  Structural details of the flexible subdomain.  A. hydrophobic pocket of F786 with the side chain 
buried in the core of the flexible subdomain.  From the HKI•Glc-6-P•Glc structure, Chapter 2, this thesis.  B. 
the interface between the N- and C-terminal halves.  Residues of the flexible subdomain are dark purple and 
others are light purple.  C. ADP binding pocket from structure 1DGK with C-terminal half (blue) 
superimposed to N-terminal half (light gray).  The side chains residues that involved in direct ADP binding or 
putatively contribute to ADP binding are labeled and the corresponding partners in N-half are marked in 
parenthesis.  The main chain residues involved in ADP binding are labeled only for C-half HKI.  D. Flexible 
subdomain from HKI•ADP•Glc (1DGK, blue) and HKI•Glc-6-P•Glc (pink) complexes superimposed based on 
C-terminal half large domain.  T784 from Glc-6-P are in two states.  The backbone of Gly is shown.  Names 
of mutated residues are bold fonts.  (The illustration was generated with PyMOL). 
142 
 
 
  
Figure 6.  Histogram 
of cooperativity 
parameter α and site 
affinity constants for 
wild-type HKI and 
mutants. 
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Figure 7.  Correlation between Pi-relief and (1-KI/KPI). 
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Figure 8.  Alternative binding for nucleotides.  A. ADP pocket of HKI structure from 1DGK.  B. possible 
TNP-ATP bound HKI structure from modeling.  TNP-ATP is shown as two derivatives, 
2'-(or-3')-O-(trinitrophenyl) adenosine 5'-triphosphate.  (The illustration was generated with PyMOL) C. 
Nucleoside triphosphates and derivatives.  (The illustration was generated with Bio-Draw). 
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Figure 9.  Residues involved in Glc-6-P allosteric inhibition.  Large domains (16-74, 210-447 for 
N-terminal half; 467-522, 658-895 for C-terminal half) are s pink and small domains (75-209, 448-465 for 
N-terminal half; 523-657, 896-913 for C-terminal half) are yellow.  Residues causing significant change in 
inhibition properties are blue.  Glc and Glc-6-P are stick models.  (The illustration was generated with 
PyMOL). 
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Chapter VI.  General Conclusion 
 
The work described in this thesis represents a significant advancement in our knowledge of 
the mechanism of allosteric regulation of human hexokinase Type I.  Chapter II presents a 
series of crystalline complexes and molecular dynamics simulations of recombinant human 
HKI with glucose 6-phosphate (Glc-6-P), 1,5-anhydro-D-glucose 6-phosphate 
(1,5-anhydroGlc-6-P), 2-deoxyglucose 6-phosphate (2-deoxyGlc-6-P) and mannose 
6-phosphate (Man-6-P).  For 2-deoxyGlc-6-P and Man-6-P, the C-terminal half tends 
toward an open conformation as MD simulations progress, consistent with early stages of 
ligand dissociation, whereas 1,5-anhydroGlc-6-P, adopts a stable, alternative binding mode in 
a slightly open conformation of the C-terminal half which differs from that of Glc-6-P.  This 
alternative binding mode might reflect synergistic binding of two molecules of 
1,5-anhydroGlc-6-P to sites with unequal constants of dissociation, as indicated by the 
kinetics data of D413N and/or D861N enzymes (D413 and D861 interact with 1-OH groups 
of Glc-6-P).  Simulations of the Glc-6-P complex of D413N HKI demonstrate a N-terminal 
half conformation similar to that of the 1,5-anhydroGlc-6-P complex of wild-type HKI.  The 
N-terminal half is open slightly relative to the N-terminal of wild-type HKI with bound 
Glc-6-P.  The data indicate differences in the response of HKI to Glc-6-P and 
1,5-anhydroGlc-6-P, suggesting an important role for the 1-OH group of the physiological 
inhibitor that has been overlooked.  Finally, the foundation is laid for a site-affinity model 
that is further developed in subsequent chapters. 
Chapter III presents crystalline complexes and molecular dynamics simulations of 
recombinant human HKI with glucose 1,6-bisphosphate (Glc-1,6-P2), as well as the kinetics 
studies of specific mutant forms of HKI with respect to Glc-1,6-P2.  1,5-AnhydroGlc-6-P is 
a nonlinear competitive inhibitor with respect to ATP, whereas Glc-1,6-P2 is a linear 
competitive inhibitor up to a concentration of 400 µM.  The crystal structure of HKI with 
Glc-1,6-P2 and molecular dynamics implicate Lys418 (N-terminal half) and Lys866 
(C-terminal half) in stabilizing hydrogen bond networks in inhibitor binding pockets.  The 
kinetics of inhibition of K418A and/or K866A mutants support the significant of these lysyl 
side chains in inhibition.  Pi-relief of inhibition is re-examined in the context of a new 
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kinetic model, which identifies a complex that allows both Pi and inhibitor to bind to the 
enzyme simultaneously.  Under experimental conditions of saturating Pi, the equilibrium 
constant for the dissociation of inhibitor from the enzyme•phosphate•inhibitor complex is 
taken as the dissociation of inhibitor from the C-terminal half, thus determining one of four 
site affinity constants.  One determined constant, along with other information, allows the 
complete numerical assignment of all site-affinity constants and a cooperativity parameter 
governing interactions between inhibitory sites.  The following conclusions arise from 
site-affinity values: Inhibitor binds to the N-terminal half with high affinity relative to the 
C-terminal half of HKI.  Pi affords relief of inhibition caused by inhibitor binding to the 
N-terminal half.  Binding sites for inhibitors at the N- and C-terminal halves are coupled 
antagonistically. 
Chapter IV is a study of glucose as (Glc) as a synergist and antagonist of HKI inhibition by 
1,5-anhydroGlc-6-P.  At submillimolar concentrations of Glc, the binding of Glc-6-P is 
synergistic with Glc; however when Glc concentration is high, the binding of 
1,5-anhydroGlc-6-P is undermined.  Effective inhibition of wild-type HKI requires two 
bound molecules of Glc, and that the binding of Glc to the active site is critical to potent 
inhibition by 1,5-anhydroGlc-6-P.  Glc binding to the active site controls the binding 
affinity of allosteric inhibitors at sites within the same half and in the opposite half of HKI. 
Chapter V presents the effects of directed mutations in regions putatively responsible for the 
allosteric inhibition of HKI, the N-terminal half pocket for Glc-6-P and the C-terminal half 
flexible subdomain.  Using the site affinity model developed in Chapters II and III, site 
affinity constants are determined for a significant sampling of mutant enzymes.  The effects 
of mutations are consistent with the proposed model of allosteric regulation due to Aleshin et 
al.  Allosteric inhibition involves a Glc-6-P induced rotation of the N-terminal half about 
the end of the transition helix connecting the N- and C-terminal halves of HKI.  Nonbonded 
contacts between the N-terminal half and the flexible subdomain of the C-terminal half 
undergo adjustments due to the rotation of the N-terminal half, the consequence of which is a 
state that blocks the base-binding pocket for ATP. 
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